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Abstract
A common reaction to xenobiotic exposure is the modulation of genes that mediate the 
response to such insult, including the drug metabolising enzymes and drug transporters. 
This transcriptional response is typically mediated by the nuclear receptor family of 
ligand activated transcription factors, and the translocation of these key regulators into 
the nucleus, whether before or after ligand binding, is a pre-requisite for their activity. 
The karyopherin a family of adapter proteins (6 in man) form a molecular bridge between 
nuclear cargoes and the nuclear import machinery. Previous work demonstrated that the 
rat karyopherin a genes are themselves responsive to a number of xenobiotics, including 
classical nuclear receptor ligands. The aim of this study was to delineate the molecular 
mechanism underlying transcriptional regulation of human karyopherin a2 (KPNA2) 
gene.
In silico analysis of the 2.6kb immediately upstream and including the first exon of 
human KPNA2 promoter revealed several putative transcription factor binding sites, most 
notably for the nuclear receptors vitamin D receptor (VDR), progesterone receptor (PR), 
retinoid related orphan receptor a (RORa), peroxisome proliferated activated receptor a 
(PPARa), glucocorticoid receptor a (GRa), pregnane X receptor (PXR) and hepatic 
nuclear factor 4 (PINF4) and the anti-oxidant response protein, Nrf2. Using a reporter 
gene assay in the human hepatoma cell line Huh7, preliminary experiments demonstrated 
that the KPNA2 gene was responsive to cognate ligands for many of these nuclear 
receptors, as well as oxidative stress-mediated activation of Nrf2.
In-depth analysis including promoter deletion, site directed mutagenesis and 
electrophoretic mobility shift assay were carried out to determine the molecular 
mechanism underlying these transcriptional effect. The down-regulation of human 
ICPNA2 expression by cyproterone acetate was mediated via GRa and not PXR whereas 
the down-regulation of human KPNA2 expression by Wy-14,643 was elicited not by its 
cognate nuclear receptor, PPARa but most likely via Nrf2 through the oxidative stress 
signaling pathway.
In conclusion, these findings provide a rational explanation for the mechanistic basis of 
human KPNA2 gene regulation by a number of endobiotics and xenobiotics, and 
postulate the importance of this phenomenon for optimizing cellular response to these 
stimuli.
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1.0 Introduction
Toxicology, derived from the Greek word toxicon (‘for the bow', since arrows were often 
poisoned, its meaning came to be associated with poison) and logos (gathering, studying 
and reason), has a vast array of definitions given by various people at various points in 
time. From Paracelsus, the father of modern toxicology who said, “Sola dosis facit 
venenum” (only dose determines the poison) to Klaassen and Amdur (Amdur et al. 
1993), who defined toxicology as the study of the adverse effects of chemicals on living 
organisms, the common theme of toxicology is the study of symptoms, mechanisms, 
treatments and detection of poisoning, especially the poisoning of people. The Society of 
Toxicology, (USA) further defines toxicology as the study of the adverse effects of 
chemical, physical or biological agents on living organisms and the ecosystem, including 
the prevention and amelioration of such adverse effects.
Toxicity is the adverse end product of a series of events that are triggered by exposure to 
chemical, physical and/or biological agents. Toxicity can manifest itself in various forms; 
from mild biochemical malfunctions to serious organ damage and even death. These 
events, which may be reversible or irreversible, are influenced by the absorption, 
distribution, metabolism and excretion (ADME) of these poisons, as well as the 
interactions of the toxin, or its metabolites, with cellular macromolecules. Toxicology 
integrates the study of all of these events at all levels of biological organisation, from 
molecules to complex ecosystems. The broad scope of toxicology, from the study of 
fundamental mechanisms to the measurement of exposure, including toxicity testing and 
risk analysis, requires an extensive interdisciplinary approach. Such an approach utilises 
the principles and methods of other disciplines, including molecular biology, 
pharmacology, chemistry (organic, inorganic, analytical and biochemical), physiology, 
medicine (human and veterinary), computer science and informatics, amongst others.
1.1 Mechanisms of homeostatic regulation of the human body in 
response to chemical insult
1.1.1 Introduction
The human body is a highly robust machine, allowing it to maintain functionality in a 
variety of environments, where it must steadily maintain and monitor concentrations of 
both endogenous and exogenous compounds. This homeostasis is vital both for normal 
cellular function and prevention of toxicity (Plant 2003). Here, mechanisms by which the 
body reacts to insult/exposure to chemical, physical or biological agents are discussed. 
Diverse mechanisms allow the body to mount a biochemical defence against the toxic 
insult, attempting to reduce damage to body systems through both chemical modification 
(detoxification) and rapid removal from the body (excretion). These processes are further 
consolidated by the underlying mechanisms at the molecular level (gene expression, 
transcription, drug metabolising enzymes, nuclear receptors and karyopherins). Together 
these procesess are involved in modifying the toxic compound, which need consideration 
in the research field to aid understanding of the mechanisms involved in the regulation of 
detoxification. The individual processes of ADME are discussed in more detail below.
1.1.2 Absorption
Bodily chemical exposure routes occur via ingestion, inhalation and dermal absorption 
under normal circumstances, and in addition, by direct injection in medical scenarios 
(Timbrell 2000). Before a substance can exert a pharmacological or toxicological effect 
in tissues, it has to enter the bloodstream, via any of these routes, and then cross a cell 
membrane to enter the cell (Plant 2003). Uptake into specific target organs or cells can be 
modified by the presence of some natural barriers, such as the blood-brain barrier (BBS).
Factors such as poor compound solubility, chemical instability in the stomach, and 
inability to permeate the intestinal wall can all reduce the extent to which a drug is 
absorbed after oral administration (Plant 2003; Rozman and Klaassen 2003). Absorption 
critically determines the compound's bioavailability, which is why some poorly absorbed 
drugs are administered intravenously or by inhalation (Timbrell 2000). The main barrier 
to drug absorption are the phospholipid bilayers that surround all cells; therefore, in 
theory, the more lipophillic a compound is, the more easily it can be absorbed and 
transported across lipid bilayers. However, other mechanisms such as active and 
facilitated transport and phagocytosis/pinocytosis (Timbrell 2000) also play a role in 
mitigating such influences. The lipid solubility of a chemical substance is usually 
represented by its partition coefficient (oil/water coefficient); the higher the partition 
coefficient, the more readily a substance is absorbed across the lipid bilayers and vice 
versa (Rozman and Klaassen 2003). Lipinski’s Rule of Five (not more than 5 hydrogen 
bond donors or 10 acceptors, molecular mass less than 500 Da, octanol-water partition 
co-efficient (Log P) less than 5 and number of rotatable bonds less than 10) is often used 
to evaluate the absorption potential of novel therapeutic compounds based on the 
principle that most therapeutic drugs are small and lipophilic (Lipinski et al. 2001).
1.1.3 Distribution
Once administered, compounds need to be carried to the site of action, most often via the 
bloodstream. After the chemical enters the blood, it is distributed rapidly throughout the 
body. The rate of distribution to each organ is related to the blood flow through that 
organ: In general the major body organs such as the liver, heart, lungs and kidney receive 
the majority of cardiac output, resulting in good distribution to these tissues, followed by 
tissues such as muscle and skin. Tendons, teeth and ligaments have poor blood flow and 
hence it is extremely difficult to achieve therapeutic doses in these tissues through the 
systemic circulation without causing toxicity in better perfused organs (Plant 2003). 
Despite the general belief that compounds are able to passively diffuse into the cells, the 
importance of membrane transporters, which are localised on the surface of the cells, are 
now thought to be equally important (Ayrton and Morgan 2001). The expression of
specific influx and efflux transporters could potentially impact compound disposition 
within the cells in on which they are expressed (Plant 2003). Another factor that affects 
distribution of compounds is plasma protein binding; binding of compounds to plasma 
proteins such as albumin limits their distribution, as only free drug is able to diffuse or be 
transported across membranes (Rang et al. 1999).
The BBB, though not an absolute barrier to the passage of toxic substances into the 
central nervous system (CNS) is less permeable compared to most other areas of the 
body. One reason for this is that the CNS capillary endothelial cells are tightly adherent, 
leaving very few or no pores between cells for paracellular diffusion of compounds. The 
CNS capillaries are, to an extent, surrounded by astrocytes, which provides an additional 
defence to the barrier, thus limiting the permeability of compounds. The protein 
concentration of the interstitial fluid of the CNS is much lower than other body fluids and 
hence limits the movement of water insoluble compounds that are bound to proteins. In 
addition, the brain capillary endothelial cells contain multiple ATP-dependent multi-drug 
resistant (MDR) proteins that expel compounds back to the circulatoiy system (Rozman 
and Klaassen 2003). For these reasons, the degree of compound ionisation and lipid 
solubility are vital determinants of the rate of its entry into the CNS; ionisation 
diminishes the rate whereas increased lipophilicity increases it (Rozman and Klaassen 
2003).
1.1.4 Metabolism
After a compound has been absorbed into a biological system and distributed, it may 
undergo metabolism (also known as biotransformation). The purpose of metabolism is to 
produce products that are more water soluble, thus facilitating excretion and elimination 
of the products (Timbrell 2000; Rozman and Klaassen 2003). Drug metabolism involves 
two processes: Phase I (functionalization) and phase II (conjugation) reactions, as shown 
in Table l.I. During these reactions, polar bodies are either introduced or unmasked, 
which results in increased polarisation of the original compounds (Gibson and Skett 
2001). Drug metabolism reactions are catalysed by the drug metabolising enzymes
(DMEs), a divergent group of proteins that are responsible for metabolising a vast array 
of xenobiotic compounds including drugs, environmental pollutants, and endogenous 
compounds (Nelson 2003). In general DMEs provide protection against harmful exposure 
to xenobiotics as well as endobiotics (Xu et al. 2005).
REACTION ENZYME LOCALISATION
Phase I
Hydrolysis Esterase 
Peptidase 
Epoxide hydrolase
Microsonies, cytosol, lysosomes, blood 
Blood, lysosomes 
Microsomes, cytosol
Reduction Azo- and nitro- reduction 
Carbonyl reduction 
Disulfide reduction 
Sulfoxide reduction 
Quinone reduction 
Reductive dehalogenation
Microflora, microsomes, cytosol 
Cytosol, microsomes, blood 
Cytosol 
Cytosol
Cytosol, microsomes 
Microsomes
Oxidation Alcohol dehydrogenase 
Aldehyde dehydrogenase 
Aldehyde oxidase 
Xanthine oxidase 
Monoamine oxidase 
Diamine oxidase 
Prostaglandin H synthase 
F lav i n-monooxygenase 
Cytochrome P450
Cytosol
Mitochondria, cytosol
Cytosol
Cytosol
Mitochondria
Cytosol
Microsomes
Microsomes
Microsomes
Phase II
ENZYME LOCALISATION
Glucoronide conjugation Microsomes
Sulfate conjugation Cytosol
Gluthathione conjugation Cytosol, microsomes
Amino acid conjugation Mitochondria, microsomes
Acétylation Mitochondria, cytosol
Méthylation Cytosol, microsomes, blood
Table 1.1.General pathways of xenobiotic metabolism and their m ajor subcellular locations (Adapted 
from (Parkinson 2003)
1.1.4.1 Phase I
Phase I reactions may occur by oxidation, reduction, hydrolysis, hydration, isomérisation 
and dethioacetylation reactions (Gibson and Skett 2001). If the metabolites of phase I 
reactions are sufficiently polar, they may be readily excreted at this point. However, 
many phase I products are not eliminated rapidly and undergo a subsequent reaction 
(Phase II) in which an endogenous substrate combines with the newly 
incorporated/unmasked functional group to form a highly polar conjugate (Gibson and 
Skett 2001).
The oxidative reactions are the most pre-eminent phase I reactions, with the majority 
being catalysed by the cytochrome P450 enzymes located on the smooth endoplasmic 
reticulum of the cell. Cytochrome P450 oxidase (commonly abbreviated as GYP) is a 
generic term for a large number of related, but distinct, oxidative enzyme. These have 
thought to have evolved over 3.5 billion years ago and have been identified in all 
kingdoms of life (Danielson 2002). The CYPs are found abundantly in the liver, kidney, 
gastrointestinal tract and lung (Gonzalez and Nebert 1990; Nebert et al. 1991; Meyer 
1996). Their name refers to "pigment at 450 nm", so named for the characteristic Soret 
peak formed by absorbance of light at wavelengths near 450 nm when the heme iron is 
reduced (with sodium dithionite) and complexed to carbon monoxide. More than 11,500 
distinct GYP sequences are known and officially named (P450 Nomenclature 
Committee), whilst the Human Genome Project has confirmed 57 full genes and more 
than 59 pseudogenes coding for the various CYPs expressed within humans. The 
enzymes are divided among 18 families and further classified into 43 subfamilies (Nelson
2003). Proteins from the same family are defined as greater than 40% identical at the, 
while those in the same subfamily are greater than 70% identical amino acid level 
(Gibson and Skett 2001).
The liver has the highest concentration of this enzyme group although it can be found in 
many other tissues, most notably the intestine (Gibson and Skett 2001). The majority of 
drug metabolism is carried out by a few members of the GYPl, GYP2, and GYP3
families and occurs primarily in the liver (Table 1.2). Among the CYP subfamilies, 
CYP2C and CYP3A are the most abundant types in humans and together account for the 
metabolism of approximately 80% of drugs that undergo oxidation reactions. Within the 
CYP2C family, CYP2C8, CYP2C9 and CYP2C19 contribute to 20% of the total CYP 
content (Shimada et al. 1994). Interestingly, whereas CYP2B6 and CYP2D6 only make 
up a fraction of the total CYP content (less than 1.5%), they metabolise up to 30% of 
drugs (Shimada et al. 1994). The CYP3A4 has the capability to metabolise a vast number 
of structurally distinct chemicals including approximately 60% of therapeutic drugs 
(Barwick et al. 1996).
CYP Percentage of total CYP expression (%)
3A4/5/7 30
2C8/9/18 20
1A2 15
2E1 10
2A6 5
2D6 5
2C9 5
lA l small*
2B6 small*
Table 1.2; Human liver cytochrome P450s (Gibson and Skett 2001)
* are present in only small amounts in human liver and therefore not assigned a percentage expression.
1.1.4.2 Phase II
Phase II reactions are known as conjugation reactions and are usually detoxifying in 
nature, involving the interactions of the polar functional groups of phase I metabolites. 
The conjugated group renders the foreign molecule more water soluble and so more 
readily cleared from the body and less likely to exert a toxic effect (Plant 2003). The 
reactions involved in phase II are sulphation, glucuronidation, gluthathione conjugation, 
acétylation, méthylation and fatty acid and amino acid conjugation (Gibson and Skett 
2001). These reactions can then be further divided according to the chemical energetics
inherent within the conjugate. Type 1 reactions involve high energy conjugates as the 
conjugated molecules contain reactive groups and will react with relatively unreactive 
groups such as the hydroxyl group introduced by phase I reactions. Conversely, type 2 
reactions utilise low energy conjugates with limited chemical reactivity and these tend to 
conjugate to molecules with high chemical reactivity (Plant 2003). Sulphation and 
glucuronidation are considered type 1 reactions, while gluthathione conjugation is a type 
2 reaction (Plant 2003).
1.1.5 Excretion
Numerous hydrophilic (i.e. more polar) compounds and their metabolites are removed 
from the body via the process of excretion. The elimination of these substances from the 
body is clearly an important determinant of their biological effect; rapid elimination will 
reduce the likelihood of toxicity occurring and reduce the duration of the biological 
effect. The main routes of excretion are the kidneys, the hepatobiliary system, the 
gastrointestinal tract and the lungs. To lesser extent, secretion into the milk, sweat and 
other fluids are also excretory routes from the body (Timbrell 2000; Rozman and 
Klaassen 2003; Pleuvry 2005).
1.1.5.1 Urinary excretion
Relatively small, water soluble molecules of molecular weight <20 IcDa are excreted into 
the urine from the bloodstream (Rang et al. 1999; Rozman and Klaassen 2003). Urinary 
excretion involves one of three mechanisms: Glomerular filtration; diffusion from the 
bloodstream into tubules (i.e. tubular secretion); and tubular reabsorption (Inui et al. 
2000; Timbrell 2000). The secretion and reabsorption processes in the renal tubules are 
mediated by carrier systems or transporters. Within the kidney, nephrons, comprised of 
the proximal and distal tubules, cany out the specialised directional transport processes 
that mediate the secretion or reabsorption of various solutes. Figure 1.1 depicts the 
various families of transporters expressed in the kidney. The family of organic cation 
transporters (OCTs), organic-anion transporters (OATs), organic-anion transporting
polypeptides (OATPs) and multiresistant drug protein (MRP) 1 and 6 are shown to be 
expressed in the basolateral membrane of the renal epithelial cells. Members of the 
peptide transporters (PEPT), P-glycoprotein/Multidrug-resistant protein (PgP/MDRl), 
MRP2 and 4 and OCTN2 are however located at the luminal (apical) membrane (Rozman 
and Klaassen 2003). These transporters play pivotal roles in regulating the excretion and 
reabsorption of exogenous and endogenous organic anions, cations, nucleosides and 
peptides that include a vast array of drugs and their metabolites (Wu et al. 1998; Zhang et 
al. 1998; Inui et al. 2000; Ayrton and Morgan 2001; Scherrmann 2009). The PEPTs were 
shown to be responsible for the tubular reabsorption of peptide-like drugs such as beta- 
lactam antibiotics (Ganapathy et al. 1995).
Extracellular fluid
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Figure 1.1: Schematic diagram showing the localisation of uptake and efflux transporter families in 
the kidney’s proximal tubule. The families of transporters are organie cation transporters (OCTs), 
organic-anion transporters (OATs), organic-anion transporting polypeptides (OATPs), multiresistant drug 
protein (MRP), P-glycoprotein/multidrug-resistant protein (PgP/MDRl) and peptide transpoters (PEPT), 
Carnitine/Organic cation transporter 2 (OCTN2). Figure adapted from (Rozman and Klaassen 2003).
1.1.5.2 Hepatobiliary excretion
For large polar compounds with molecular weight >300 Da, biliary excretion is the 
predominant route of excretion, although some smaller, polar molecules are also 
eliminated via this route. Since some drugs and their metabolites are excreted into the 
bile where are transported across the biliary epithelium against their concentration 
gradient, active secretory transport systems are required. There are three specific 
transport systems: One for neutral compounds, one for anions, and one for cations 
(Timbrell 2000). Since biliary excretion depends heavily on active transport, as with renal 
excretion, this system may be saturated, leading to increased concentrations of 
compounds in the liver and the potential for toxicity. Drugs may also come into contact 
with the gut microflora, which may metabolise the drug and convert it into a more 
lipophillic substrate that can be reabsorbed from the gut into the blood supply and so 
return to the liver. This process is known as enterohepatic recirculation and can increases 
duration that a drug remains in the body by up to two-fold. This process can therefore 
lengthen the period of drug action, which is especially important for drugs that undergo a 
high rate of first-pass metabolism (Rang et al. 1999; Timbrell 2000; Chan et al. 2004). 
Metabolism by gut microflora can also cause toxicity in situations were a compound is 
modified to a more toxic metabolite.
There are many transporters localised in a polarised fashion on hepatic parenchymal 
cells, whose role it is to transport foreign compounds from the blood into liver and from 
the liver into bile canaliculi (Figure 1.2). The transporters located on the sinusoidal side 
of the parenchymal cells include the sodium-dependent taurocholate peptide (NCTP), 
liver specific transporter (LST), OATP 1 and 2, and OCT 1. NCTP transports bile acids 
such as taurocholate into the liver, whereas the other transporters import xenobiotics. 
Once in the liver, the bile acids are transported out into the bile canaliculi by the bile salt 
excretory protein (BSEP) and MDRl and MRP2 act to move xenobiotics into the bile. 
Xenobiotics destined to the transported back into the bloodstream rather than excreted are 
under the control of MRP3 and 6 (Rozman and Klaassen 2003; Chan et al. 2004). When a 
xenobiotic has arrived in the liver hepatocyte it has two fates; it can be transported into 
the blood or bile unchanged, or it may be biotransformed by phase I and II drug-
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metabolising enzymes to a more hydrophilic substrate and then transported into blood or 
bile (Rozman and Klaassen 2003).
LST
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Apical Space
Figure 1.2: Schematic diagram of the liver transporters. The transporters are sodium-dependent 
taurocholate peptide (NCTP), liver specific transporter (LST), organic-anion transporting polypeptides 
(OATP), organic cation transporters (OCT), multiresistant drug protein (MRP), multidrug-resistant protein 
(MDR) and bile salt excretory protein (BSEP). Figure adapted from (Rozman and Klaassen 2003).
1 1
1.2 The coordinate regulation of the ADME genes
1.2.1 Nuclear receptors
Since Phase I and Phase II metabolic processes are clearly pivotal in controlling the fate 
of both xenobiotics and endogenous compounds, their levels must be controlled in such 
manner that their activities are tightly regulated to prevent undesirable alterations within 
cells. The induction or down-regulation of various enzymes and transporters involved in 
the phase I and II xenobiotic metabolising systems is mediated by a group of transcription 
factors known as ligand-activated transcription factors or nuclear receptors (NRs) 
(Nakata et al. 2006). Cells respond to extracellular signals through two general signalling 
pathways, which are dependent on the properties of the ligand (Mangelsdorf and Evans 
1995; Rosen et al. 1995). While growth factors, hydrophilic ligands and neurotransmitters 
bind to cell membrane receptors, triggering a cascade of secondary messengers within the 
cell resulting in the activation of transcription factors, other small hydrophobic molecules 
and metabolic intermediates enter or are generated within the target cells and bind to 
members of the NR superfamily of ligand-activated transcription factors (Laudet and 
Gronemeyer 2002).
To date, 69 NRs have been identified (Table 1.3; (Laudet et al. 1999; Burris and McCabe
2001) and out of these, 48 NRs and 3 pseudogenes members are found in humans (Figure 
1.3; (Laudet et al. 1999; Robinson-Rechavi et al. 2001; Ruau et al. 2004; Zhang et al.
2004). In other species, 47 and 49 NRs have been identified in rats and mice respectively 
(Zhang et al. 2004); 21 in the fruit fly {Drosophila melanogaster; (Rubin et al. 2000) and 
mosquito {Anopheles gambiae, (Holt et al. 2002; Bertrand et al. 2004); 17 in the sea 
squirt {Ciona intestinalis; Dehal, 2002; Yagi, 2003, 70 in fugu; Bertrand, 2004 and 66 in 
tetraodon; Bertrand, 2004). In contrast, the nematodes Caenorhabditis elegans and 
Caenorhabditis briggsae have undergone expansions of this gene family and have >270 
and >250 predicted members respectively (Sluder and Maina 2001; Stein et al. 2003).
1 2
GROUP DESIGNATION COMMON NAME
Subfamily 1
A N RIAI TRa, c-erbA-1, THRA
NR1A2 TRp, c-erbA-1, THRB
B N RIBI RARa
NR1B2 RARP, I-IAP
NR1B3 RARy, RARD
C NRICI PPARa
NR1C2 PPARp, NUC-1, PPAR6, FFAR
NR1C3 PPARy
D NRIDI REVERBa EAR-1, EAR-IA
NR1D2 REVERBp EAR-lp, BD73, RVR, HZF2
NR1D3 E75
E N RIEI E78, DR-78
F NRIFI RORa, RZRa
NR1F2 RARp, RZRp
NR1F3 RORy, TOR
NR1F4 HR-3, DHR-3, MHR-3, GHR-3, CNR-3, CHR-3
G N RIGI CNR-I4
H NRIHI ECR
NR1H2 UR, 0R-1,NER-1, RIP-15, LXRP
NR1H3 RLD-1, LXR, LXRa
NR1H4 FXR, RIP-14, HRR-1
I N RIII VDR
NR1I2 ONR-1, PXR, SXR, BXR
NR1I3 MB-67, CAR-1, CARa
NR1I4 CAR-2, CARp
J NRIJI DHR-96
K N RIK I NHR-1
Subfamily 2
A NR2A1 FINF-4
NR2A2 HNF-4G
NR2A3 HNF-4B
NR2A4 DHNF-4, HNF-4D
B NR2B1 RXRA
NR2B2 RXRB, H-2RIIBP, RCoR-1
NR2B3 RXRG
NR2B4 USP, Ultraspiracle, 2C1, CF-1
C NR2C1 TR2, TR2-11
NR2C2 TR4,TAK-1
D NR2D1 DHR-78
E NR2E1 TEL, TLX, XTLL
NR2E2 TEL, Tailles
F NR2F1 COUP-TFl, COUP-TFA, EAR-3, SVP-44
NR2F2 COUP-TFII, COUP-TFB, ARP-1, SVP-40
NR2F3 SVP, COUP-TF
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F (Cont) NR2F4
NR2F5
NR2F6
COUP-TFIII, COUP-TFG
SVP-46
EAR-2
Subfamily 3
A NR3A1 ERa
NR3A2 ER(3
B NR3B1 ERRl, ERRa
NR3B2 ERR2, ERRP
C NR3C1 GR
NR3C2 MR
NR3C3 PR
NR3C4 AR
Subfamily 4
A NR4A1 NGFI-B, TRS, N 10, NUR-77, NAK-1
NR4A2 NURR-1, NOT, RNR-1, HZF-3, TINOR
NR4A3 NOR-1, MINOR
NR4A4 DHR-38, NGFl-B, CNR-8, C48D5
Subfamily 5
A NR5A1 SFl, ELP, FTZ-F 1, AD4BP
NR5A2 LRH-1, xFFlrA, xFFlrB, FFLR, PHR, FTP
NR5A3 FTZ-F 1
Subfamily 6
A NR6A1 GCNF, RTR
Subfamily 0
A NROAl KNl, Knirps
NR0A2 KNRL, Knirps related
NR0A3 EGON, Embiyonic gonad, EAGLE
NR0A4 0DR7
NR0A5 Tri thorax
B NROBl DAX-1, AHCH
NR0B2 SHP
Table 1.3: Nuclear receptor nomenclature. TR, Thyroid hormone receptor; RAR, Retinoic acid receptor; 
PPAR, Peroxisome pro I i ferator-activated receptor; RAR, RAR-related orphan receptor; LXR, Liver X 
receptor; FXR, Farnesoid X receptor; VDR, Vitamin D receptor; PXR, Pregnane X receptor; SXR, Steroid 
and xenobiotic receptor; BXR, benzoate X receptor; CAR, Constitutive androstane receptor; HNF, 
Hepatocyte nuclear factor; RXR, Retinoid X receptor; TR, Testicular receptor; TLX/Tailless, Human 
homologue of the Drosophila tailless gene; COUP, Chicken ovalbumin upstream promoter-transcription 
factor; SVP, Seven-up; EAR, V-erbA-related gene; ER, Estrogen receptor; ERR, Estrogen-related receptor; 
GR, Glucocorticoid receptor; MR, Mineralocorticoid receptor; PR, Progesterone receptor; AR, Androgen 
receptor; NGFIB, Nerve growth factor IB; NURR, Nuclear receptor related; NOR, Neuron-derived orphan 
receptor; SF, Steroidogenic factor; LRH, Liver receptor homolog; FTZ-F, Fushl tarazu factor; G CNF, 
Germ cell nuclear factor; DAX, Dosage-sensitive sex reversal; AHCH, adrenal hypoplasia critical region 
on chromosome X; SHP, Small heterodimer partner; ECR, Ecdysone receptor; UR, Ubiquitous receptor; 
HAP, Hepatoma; AD4BP, Adrenal 4 binding protein; RTR, Retinoid receptor-related testis-associated 
receptor; ARP, Apolipoprotein AI regulatory protein 1; FTP, Fetoprotein transcription factor; RVR, Rev- 
erbA-related receptor; RZR, Retinoid Z receptor. (Adapted from Burris and McCabe, 2001; Laudet and 
Auwerx, 1999).
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NRs can be classified into groups depending on i) their subcellular localisation in the 
absence of ligands and ii) their mechanistic properties. Subcellular location is further 
divided into to categories; those located in the cytoplasm (Type I) or those in the nuclear 
compartment (Type II). Mechanistic properties are classified into 4 types (Types I-IV); 
Type I members bind to a ligand in the cytoplasm, resulting in dissociation from the heat 
shock proteins and formation of a homodimer. This complex then translocates into the 
nucleus, although the exact order of these latter two steps is controversial. Examples of 
Type I members includes the estrogen receptor-like subfamily such as ER, GR, MR, AR 
and PR. Type II NRs (e.g. subfamily of thyroid hormone receptor-like such as PPAR, 
VDR, PXR, CAR and FXR) are those receptors that reside in the nucleus regardless of 
their ligand binding status and form heterodimers (usually with retinoid X 
receptor,RXR). In the absence of ligand, these receptors are associated with corepressor 
proteins and upon addition of ligand, the corepressor complex dissociates and 
coactivators are recruited to activate transcription of target genes. Type III NRs (e.g.the 
retinoid X receptor-like subfamily), are similar to Type I NRs, except that they bind to 
direct repeat instead of inverted repeat sequences. Type IV NRs bind to DNA either as 
monomers or dimers, but only a single DNA binding domain of the receptor binds to a 
single half site response element. Most of the NR subfamilies fall into this group (Novae 
and Heinzel 2004), or are identified based on their dimérisation and DNA binding 
properties (Germain, 2006).
This classification system was also proposed by Mangelsdorf and Evans (Mangelsdorf 
and Evans 1995), who proposed four categories of NRs as illustrated in Figure 1.3. Class 
I (Steroid Receptors) include the known steroid hormone receptors that function as 
homodimers, binding to half-site response element inverted repeats. Class II (RXR 
heterodimers) exist as heterodimers with the RXR receptor and bind to direct repeats, 
although some bind to symmetrical repeats and function in a ligand-dependent manner. 
With the exception of the steroid receptors, all other known ligand-dependent receptors 
are classified into Class III (Dimeric orphan receptors) or Class IV (Monomeric or 
tethered orphan receptors). These receptors function as homodimers binding to direct 
repeats or to extended core sites as monomers, respectively (Figure 1.3). Most orphan
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receptors fall into Class 111 or IV, and can be defined as a receptor for which no 
endogenous ligand has (yet) been identified; once an endogenous ligand is identified, 
these receptors are referred to as ‘adopted’ receptors (Mangelsdorf and Evans, 1995).
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Figure 1.3: Classification of nuclear receptors according to their ligand binding, DNA binding and 
dimérisation properties. Nuclear receptors ean be divided into 4 groups according to their ligand and 
DNA binding properties and their unique dimérisation complex; steroid receptors (Class 1), RXR 
heterodimers (Class II), homodimeric orphan receptors (Class III) and Monomeric orphan receptors (Class 
IV). Taken from Mangelsdorf and Evans 1995.
1.2.2 Structure and function of nuclear receptors
NRs share common structural features (Figure 1.4), which include a central DNA binding 
domain (DBD) and a ligand binding domain (LBD) located in the C-terminal half of the 
receptor (Bourguet et al. 2000). These receptors contain variable N-terminal and C- 
terminal domains, as well as a variable length hinge region between the DBD and LBD. 
NRs share more sequence similarity in their DBDs than in their corresponding LBDs 
(Wurtz et al. 1996; Giguere 1999; Germain et al. 2006).
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Figure 1.4: Schematic of the structural domains of a nuclear receptor. Nuclear 
receptors are composed of six domains consisting of N-terminal region of A/B region that 
includes the ligand-independent transactivation domain (AF-I), a DNA binding domain 
(C) and a ligand-binding domain (LBD) (E), which are separated by a flexible hinge 
region (D) and a C- terminal (F) domain that may be absent in certain nuclear receptors, 
that consist of activation factor 2 (AF-2).
One of the most important feature of NRs is the DNA binding domain (DBD, Region C); 
this confers sequence specific DNA recognition to a region of DNA known as the 
hormone response element (Mangelsdorf and Evans 1995; Germain et al. 2006). This 
response element consists of hexameric DNA core motif, 5’ (A/G)GGTCA 3’, separated 
by 1-8 nucleotides. As illustrated in figure 1.5, the repeat can be arranged as a direct 
repeat (DR), an inverted repeat (IR) or an everted repeat (ER).
(A/G)GGTCA X (A/G)GGTCA Direct Repeat (DR)
 ►  ►
(A/G)GGTCA X (A/G)CTGGA Inverted Repeat (IR)
 ► <----------
(AZG)CTGGA X (AZG)GGTCA Everted Repeat (ER)<   ►
Figure 1.5: The nuclear receptor response element in the DNA binding domain. The hexameric 
nuclear receptor binding sequence (A/G)GGTCA spaced by X nucleotide(s). The repeat can be arranged as 
a direct repeat (DR), an everted repeat (ER) or an inverted repeat (IR)._________________________________
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The DBD mainly consists of two zinc-finger motifs, the C-terminal motif (Cys-X5-Cys- 
X9-Cys-X2-Cys) and the N-terminal motif (Cys-X2-Cys-X13-Cys-X2-Cys), in which the 
4 cysteine residues chelate one ion (Laiidet and Gronemeyer 2002). The first motif 
contains a P-box that directs the specificity of DNA binding, while the second motif 
contains a D-box, which weakly facilitates protein dimérisation via the DBD when 
presented with a suitable DNA sequence (Nikolenko and Krasnov 2007). In addition, 
interactions with the DNA backbone and residues flanking the core recognition sequence 
are determined by the T- and A-box sequence elements outside of the zinc-fingers 
(Laudet and Gronemeyer 2002). The binding of NRs to DNA can occur in monomeric, 
homodimeric or heterodimeric conformations (Glass 1994). Orphan receptors such as 
nerve growth factor IB (NGF-IB) or Rev-erb are examples of monomers, that bind to an 
extended hexameric motif (Laudet and Gronemeyer 2002), while steroid and some non­
steroid receptors bind as symmetrical homodimers. Non-steroidal NRs, such as TR, RAR, 
PPAR and VDR, are examples of heterodimers that form complexes with RXRa (Renaud 
and Moras 2000).
The ligand binding domain (LBD; Region E) is the main domain that has a role in protein 
dimérisation (Glass 1994) and occasionally has a repression function (Tsai and O'Malley 
1994; Moras and Gronemeyer 1998). This domain also contains the ligand binding 
pocket (Renaud and Moras 2000). A common feature of all NRs is an antiparallel tri­
layered a-helical sandwich (helices H4, H5, H8, H9 and H ll are sandwiched between 
HI, H2 and H3 on one side, and H6, H7 and HIO on the other). In addition to the a- 
helices, there is also a P-hairpin and varying length loop (Laudet and Gronemeyer 2002). 
When a ligand binds to the LBD, helix HI 1 moves to become contiguous with helix HIO, 
and this results in the movement of helix FI 12 and the leashing of the co-loop. The co-loop 
flips over helix H6, carrying the N-terminal of helix H3. This causes helix H12 to seal 
the ligand binding pocket and stabilises the complex, thus activating transcription 
(Chambon 1996). The H12 helix also plays an equally vital role in recruiting 
coactivators. When an agonist is bound to the NR, helix H12 is positioned such that a 
coactivator can bind to the LBD surface (Heery et al. 1997). In the event that an 
antagonist is bound to the NR, helix H12 is sterically positioned by the antagonist side
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chain to occupy the same response element as coactivators, thus hindering their binding 
(Brzozowski et al. 1997; Shiau et al. 2002).
Several NRs can also repress transcription, either when the agonist is absent or when 
enhanced by certain antagonists, which is a function attributable to corepressor 
recruitment (Laudet and Gronemeyer 2002). Binding of corepressors can also take place 
on the surface of the non-liganded LBD and is mediated by a short signature motif called 
the CoRNR (corner) box. This box is similar to the NR box; the coactivator signature 
motif responsible for interactions with NRs (Hu and Lazar 1999), suggesting that 
recognition of liganded and un-liganded NRs by coactivators or corepressors is as result 
of the subtle differences between these two boxes (Hu and Lazar 1999).
From Figure 1.4, it can also be seen that in addition to the ligand- and DNA-binding 
domains, NRs contain another 4 domains or regions. The DBD and LBD are linked 
together by a flexible hinge region (Region D) that allows the domains to adopt different 
configurations. These configurations facilitate the vast array of response element and 
different dimérisation combinations required. In addition, region D contains the nuclear 
localisation signal (NLS; (Gronemeyer and Laudet 1995), either as a complete unit, or as 
a fragment. The NLS plays a vital role in the nucleocytoplasmic shuttling for the majority 
of NRs into the nucleus (except corticoid receptors that reside in the cytoplasm) when 
they are activated by their cognate ligands i (Guiochon-Mantel et al. 1994; Baumann et 
al. 1999). The NLS is recognised by a group of transport factors known as 
importins/kai-yopherins, which consist of the kaiyopherin a/p complex (Conti et al. 1998; 
Leung et al. 2003). The karypherins will be considered in further detail in section 1.3.3
The A/B region is among the least conserved domains of the NR, which varies in length 
among NRs from less than 50 to 500 amino acids (Robinson-Rechavi et al. 2003). For 
example, the VDR has a very short A/B domain of 21 amino acids long (Laudet and 
Gronemeyer 2002) whereas GR has a 185 amino acid long domain (Kassel and Herrlich 
2007). The A/B region also has one or more constitutionally active transcriptional 
activator (AF-1) (Mangelsdorf and Evans 1995) and several autonomous activation
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domains (Robinson-Rechavi et al. 2003). The differences between NRs isoforms are due 
to variation in this region. The A/B region may also undergo post-translational events 
such as phosphorylation, which further modifies structure and function (Shao and Lazar 
1999).
Lastly, the least evolutionary conserved domain of NR is the F domain, with some NRs 
not even possessing an F region. Although not much is known of the function of the F 
region, some studies suggest that it may have a role in regulating E domain coactivator 
recruitment and directing its specificity (Sladek et al. 1999). Studies carried out by 
Montanto et al., (1995) and Nichols and colleagues (1998) have shown that the F domain 
may play an important role in regulating the NR transcriptional molecular mechanism, as 
it may affect antagonist action ((Montano et al. 1995); (Nichols et al. 1998)
1.2.3 Nuclear receptor modes of action
The three most common modes of action for nuclear NRs and how they can positively or 
negatively regulate the expression of target genes are: repression, derepression and 
transcription activation. Repression is a common feature of ligand-free NRs, which 
recruit a corepressor complex with histone deacetylase activity (HDAC) resulting in the 
repression of target gene expression. Derepression occurs following ligand binding, 
causing the dissociation of the HDAC complex and recruitment of the first coactivator 
complex with histone acetyltransferase (HAT) activity, which results in chromatin 
decondensation. This first coactivator complex is an integral part but is not sufficient for 
the complete activation of target genes. Transcriptional activation is the final step 
required to complete the activation of a specific target gene; this involves the dissociation 
of the HAT complexes and the assembly of a second coactivator complex 
(TRAP/DRIP/ARC). This complex is able to establish contact with basal transcription 
factors and thus enables the complete transcriptional activation of target genes (Laudet 
and Gronemeyer 2002; Robinson-Rechavi et al. 2003).
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1.2.3.1 Transcriptional coregulators of nuclear receptors
The role of coregulators is important in mediating the transcriptional activity and 
hormonal signalling of NRs. The coregulators can be divided into 2 groups: coactivators, 
which activate transcription, and corepressors that suppress transcription (McKenna et al. 
1999). One of the main functions of ligand bound NRs is to increase the promoter 
availablitiy of a specific target gene for general transcriptional machineiy. However, it is 
important to note that some NRs can interact directly with components of the general 
transcription apparatus; for example, RAR interacts with TFIIH. NR coactivators can be 
divided into 4 groups; Group 1 includes the ATP-dependent chromatin remodelling 
factors such as SWI/SNF, TIFla, NSD-1 (NR binding SET domain containing protein 1) 
and others (McKenna and O'Malley 2002). Group 2 consist of acetyltransferases of the 
SRC (steroid receptor coactivator) family and CBP/p300. The TRAP ((thyroid receptor- 
associated proteins)/DRIP (vitamin D receptor-interacting proteins) proteins are part of 
Group 3 NR coactivators. Group 4 consist of other coactivators such as E3 ubiquitin 
ligases, positive cofactors (PCs), HMGs and so on.
In terms of a corepressor role on the transcription of target genes, these are generally 
mediated by ATP-dependent chromatin remodelling (NURD corepressor), histone 
deacetylation (HDAC-1/HDAC-2 corepressors), or direct interactions with the general 
transcription apparatus to destabilise the preinitiation complex, as well as stimulating 
phosphorylation, ubiquitination, and degradation of proteins (McKenna and O'Malley
2002). Both coactivators and corepressors interact with NRs via a conserved short motif 
represented by the amino acid sequence LxxLL (Heery et al. 2001), which is known as 
the NR box or an ID (receptor-interacting domain, (McKenna and O'Malley 2002). Not 
all NR coregulators solely recognise the NR box; for example, the androgen receptor 
recognises the LxxLL motif, but can also interact with FxxLF, FxxLW, WxxLF, 
WxxVW, FxxFF, and FxxYF motifs (Hur et al. 2004).
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1.2.3.2 Agonist / antagonist properties of nuclear receptors
Several studies have shown the importance of the ligand-induced conformational change 
between the ligand bound LBD (holo-LBD) and LBD without ligand (apo-LBD). These 
studies highlight the crucial role of helix H12 and its interaction in the control of agonist / 
antagonist properties of NRs (Bourguet et al. 1995; Gronemeyer and Laudet 1995; Shiau 
et al. 2002). NRs can either act as agonist-induced factors that enhance the transcription 
of target genes, or as antagonist-induced factors that completely or partially reduce the 
transcription of target genes. The difference between agonist and antagonist properties is 
that while agonists work by inducing a conformation of the receptor that favours 
coactivator binding, antagonist ligands sterically prevent the alignment of helix H12 into 
the holo position, thus repressing transcriptional activation (Bourguet et al. 2000). In this 
section, the antagonism properties will be further discussed.
There are two mechanisms by which antagonism can occur. Firstly, a shift towards the 
amino terminus of the LBD in combination with a 120° clockwise rotation, would result 
in helix H I2 being packed on a groove, formed by the carboxy terminal region of H3 and 
H4, which corresponds to the coactivator NR box. Due to helix H12 repositioning, the 
interaction surface for coactivators, for which helix H12 forms a crucial part, is not 
formed and this prevents the transcription of a target gene (Bourguet et al. 2000; 
Gronemeyer et al. 2004). Secondly, AF-2 antagonist molecules share a common, bulky 
side-chain and due to this property, helix H I2 is unable to adopt the holo conformation as 
the antagonist extension points towards helix H I2 and exits the binding pocket between 
H3 and H ll. This structural hindrance prevents H12 from taking the active conformation 
(Bourguet et al. 2000; Gronemeyer et al. 2004). In the antagonist conformation, 
lengthening of the LI 1-12 loop that results from the unwinding of the C-terminal of helix 
H ll,  allows helix H12 to assume a second low energy position by binding to the 
coactivator recognition pocket, thus blocking the coactivator function (Laudet and 
Gronemeyer 2002). The antagonist unwinding process is due to the different ligand- 
receptor interactions at the level of H ll and the surrounding regions (Figure 1.6; Laudet 
and Gronemeyer, 2002; Bourguet, 1995).
2 2
Aside from complete antagonism of AF-2 function, there is also the potential for AF-2 
partial agonist-antagonism (Bourguet et al. 2000). For example, oleic acids are mixed or 
partial AF-2 agonist-antagonist ligands for RARa; despite showing a weak but clear 
transcriptional AF-2 activity, these ligands cause H12 to adopt an antagonistic 
conformation (Bourguet et al. 2000). This may be explained by the fact that oleic acid 
displays some, but not all, features of pure AF-2 agonists and antagonists. The difference 
between pure and partial antagonism is the impact on the steric properties of NR 
conformation. Since oleic acid lacks a bulky side-chain, it does not block the active 
conformation of helix H I2 (similar to an agonist), yet it is able to stimulate the 
unwinding of H ll,  allowing the positioning of H12 in the antagonist groove (Figure 1.6; 
(Bourguet et al. 2000). By contrast, the PPARa mixed agonist-antagonist, GW0072 has a 
different partial agonist-antagonist mechanism from oleic acid. In this case, the partial 
activity of GW0072 is attributed to the LBD holo conformation not being fully stabilised, 
with the helix H12 position probably depending on the intracellular concentration of 
coactivators and corepressors (Mangelsdorf and Evans 1995). Thus, these ligands might 
either act as AF-2 agonists or antagonists depending on cellular environment (Bourguet et 
al. 1995).
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Figure 1.6: A structural view on how the binding of various ligands can induce different nuclear 
receptor conformations, thereby modulating their transcriptional activity. Agonist ligands (left) 
induce a conformation of nuclear receptor ligand-binding domains (LBDs) in which the hoio-position of 
helix H12 is firmly stabilised (note that the black lines between the ligand and H12 indicate that the overall 
holo-LBD conformation is strongly stabilised by the ligand, which does not necessarily have to directly 
interact with H 12). This active conformation provides a surface to which co-activators can bind via their 
nuclear receptor boxes that contain LxxLL motifs. By contrast, antagonists with bulky substitutions (centre 
panel) prevent the proper positioning o f H 12 in its agonistic site and therefore destabilise the interaction 
surface. 1 he antagonist-induced unwinding of the C-terminal part of helix HI 1 allows helix HI 2 to bind to 
the static part of the co-activator binding site. In the presence of partial AF-2 agonists-antagonists (right), 
the holo-form is poorly stabilized (black lines). However, the agonist position of H12 is not precluded by a 
steric hindrance of the ligand and the active conformation might, at least transiently, be adopted. 
Consequently, the biological activity of such ligands might be highly dependent on the cellular 
concentration of co-activators and co-repressors. Ago, agonist; Ant, antagonist (Bourguet et al. 1995).
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1.2.4 Nuclear receptor cross-talk
In order to maintain the most efficient response to any given stimulus, and to provide a 
safety net in the event of the cognate receptors being deficient, it is vital that the NRs 
interact with each other (cross-talk; Plant and Aouabdi, 2009). This cross-talk may occur 
at the level of sharing heterodimer partners, coregulators, ligands, DNA binding 
elements, signal transduction pathways, other signalling pathways or even other 
biological processes (Laudet and Gronemeyer 2002; Plant and Aouabdi 2009). A well 
known cross-talk between NRs are the interactions between PXR and CAR (Maglich et 
al. 2002). The CAR has been shown to regulate at least 69 target genes, whereas at least 
40 target genes are under the regulation of PXR, with many of the genes being co­
regulated by both NRs (Maglich et al. 2002; Ueda et al. 2002). To further add to the 
complexity of the mechanism of NR cross-talk, recent studies have shown that PXR and 
CAR cross-talk with HNF4a to synergistically activate the human CYP2C9 gene (Chen 
et al. 2005), while PXR and HNF4a collaborate in the activation of CYP3A4 gene 
expression (Li and Chiang 2006). Another example of cross-talk occurs between PXR 
and GR. In this scenario, glucocorticoids act as high affinity ligands for GR, but low 
affinity ligands for PXR, with the cross-talk being caused through concentration- 
dependent activation. At low concentrations of glucocorticoids, GR is activated by 
ligand, which increases the expression of PXR, CAR and RARa, amongst other GR- 
target genes (Pascussi et al. 2000; Pascussi et al. 2000; Falkner et al. 2001; Pascussi et al.
2003). In the presence of high concentrations of glucocorticoids, PXR will be also be 
significantly activated, resulting in an increase of PXR-target gene expression (Falkner et 
al. 2001; Pascussi et al. 2003). Such cross-talk probably acts to balance the action of 
glucocorticoids, through the differential activation of GR-dependent (physiological) 
responses and PXR-dependent (metabolic) responses.
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1.2.5 Summary on nuclear receptors
Understanding NR regulation will shed light on how a NR works and further, how they 
could be manipulated pharamacologically. Major emphasis has been given to the PXR 
regulation of drug metabolizing enzymes and transporters (Handschin and Meyer 2005; 
Tirona and Kim 2005). Specifically, emphasis has been placed on molecular modelling of 
receptor-1 igand interactions (Lewis et al. 1987), molecular mechanisms of induction (Ogg 
et al. 1999; El-Sankary et al. 2000; El-Sankary et al. 2002; Gibson et al. 2002), potency 
and efficacy of receptor ligands (El-Sankary et al. 2001), relative receptor expression 
(Swales et al. 2003), promoter mutations (Hamzeiy et al. 2002), auxiliary transcription 
factors and chromatin confirmation (Bombail et al. 2004; Phillips et al. 2005), 
toxicological relevance (Plant and Gibson 2003) and NR interactions networks (Plant 
2004). However, in order to regulate transcription, a key process in all events is the 
translocation of NRs into the nucleus where they bind to specific response elements of 
DNA and eventually modulate the transcription of target genes. The subcellular 
localisation of NRs in the absence of ligand varies, and is one distinguishing feature of 
the different classes. Whereas GR and AR are localized in the cytoplasm in the absence 
of ligand, the mineralocorticoid receptor (MR) is evenly distributed in both nucleus and 
cytoplasm; upon ligand binding all three receptors are localised into the nucleus (Kumar 
et al. 2006). By contrast, ER and PR are localized in the nucleus in both the presence and 
absence of ligand. The cellular distribution of non-steroid binding NRs also differs; TR, 
RXR, RAR, PPARa and LXR are localized in the nucleus both in the absence and 
presence of ligand (Zelko et al. 2001; Maruvada et al. 2003; Dong et al. 2004) whereas 
CAR is retained in the cytoplasm by forming a complex with CAR cytoplasmic retention 
protein (CCRP) and heat shock protein 90 (HSP90) and only translocates to nucleus upon 
agonist activation (Yoshinari et al. 2003; Hosseinpour et al. 2006). NRs also undergo 
nuclear export (DePranco 2002; Shank and Paschal 2005) and it seems likely that 
nucleocytoplasmic shuttling plays an important role in NR function (Kolodkin, 2010). 
The regulation of NR localisation, in particular the role of the nuclear import machinery 
in defining function has received relatively little attention compared to other aspects of 
NR function and is an area that requires further attention.
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1.3 Nuclear translocation
1.3.1 The nucleus and nuclear pore complex
The foremost feature that characterises eukaryotes from prokaryotes is the presence of a 
nucleus, which contains a highly specialised and organised internal scaffolding called the 
nuclear matrix. This spatial separation of the nuclear compartment from the cytoplasmic 
compartment by the nuclear envelope allows gene expression to be regulated by 
mechanisms that are exclusive to eukaiyotes (Davis 1995), including the access of 
proteins to the genetic material. The nuclear envelope is composed of three domains; the 
outer membrane that is continuous with the endoplasmic reticulum, an inner membrane 
that abuts the nuclear lamina on the inner surface of the nucleus, and the perinuclear 
space that separates them. For passage into the nucleus, a molecule must pass through 
both membranes. This is achieved by the presence of nuclear pores, which are created by 
fusion of these two domains at a region known as the pore membrane (Rout and 
Aitchison 2001).
The nuclear envelope is penetrated at the pore membrane by nuclear pore complexes 
(NPCs); large proteinaceous assemblies that allow exchange of molecules between the 
two compartments. Molecules can traverse the nuclear pore complex by one of two 
different mechanisms depending on their size. Small molecules can freely migrate 
between the cytoplasm and nucleus through the NPC by passive diffusion, while 
macromolecules migrate through the pore by an active process. In the latter, appropriate 
molecules are recognised and selectively transported by carrier proteins in a carrier- 
determined direction. Nucleocytoplasmic transport comprises a multitude of substrates, 
as not only must all nuclear proteins, such as histones and NRs be imported from the 
cytoplasm, but also transfer RNA (tRNA), ribosomal RNA (rRNA), and messenger RNA 
(mRNA) that are synthesized by transcription in the nucleus and need to be exported to 
the cytoplasm, where they function in translation. Macromolecules harbour specific 
signals that allow them to cross the NPC transport machinery, and by doing so, the cell
27
ensures that only selected molecules are permitted into the nucleus (Rout and Aitchison 
2001).
1.3.1.1 Nuclear pore complex architecture
As described above, the NPC provides the exclusive avenue for macromolecules (size 
>40 kDa and a diameter as large as 23 nm) to migrate between the nucleus and cytoplasm 
(Davis 1995). The vertebrate NPC has a size of approximately 124 MDa, is composed of 
an estimated at least forty different proteins and perforates the entire nucleus envelope 
(Reichelt et al. 1990; Davis 1995; Cohen et al. 2005). The pore has a total diameter of 25 
nm with a 9 nm aqueous channel in the centre (Paine et al. 1975). The total number of 
NPCs per nucleus varies widely between organisms, cell type and growth conditions, but 
mammalian cells typically contain 3000 to 5000 NPCs (Maul 1977). A single NPC 
allows a mass flow of about 100 MDa/second and rates of approximately 1000 
translocation events per second (Ribbeck and Gorlich 2001).
The NPC consists of four basic structures: First, at the waist of the NPC is a spoke-ring 
assembly anchored within the pore membrane that forms the central framework. Here, the 
lipid bilayers of the inner and outer nuclear envelope are fused. Second, there is a central 
plug that lies within the aqueous channel formed by the spoke-ring assembly. On one side 
of the rings, filaments proti ude outwards forming the third structure, while on the other 
side of the ring, a nuclear basket that lies within the nucleus represents the fourth 
structure (Figure 1.7; Davis, 1995). These structures are described in more detail in the 
following sections and are shown in Figure 1.7.
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Figure 1.7: Structure of the nuclear pore complex. Each NPC is a large proteinaceous assembly 
embedded in the pore membrane domain of the nuclear envelope, where the inner and outer nuclear 
membranes fuse. The NPC contains eight spokes, projecting radially from the wall of the pore membrane 
and surrounding a central tube called the central transporter. Each spoke is composed of numerous struts 
and attached to its neighbors by four coaxial rings: an outer spoke-ring in the lumen of the NE adjacent to 
the pore membrane, a nucleoplasmic ring, a cytoplasmic ring, and an inner spoke-ring surrounding the 
central transporter. A considerable portion of each spoke traverses the pore membrane and resides in the 
NE lumen. Together these structures comprise the central core. Peripheral elements project from this core 
toward the nucleoplasm and cytoplasm. These include: numerous proximal filaments on both faces of the 
cylindrical central core, whose presence (though not directly imaged) is inferred from the large number of 
symmetrically disposed filamentous nucleoporins; eight cytoplasmic filaments, attached at the cytoplasmic 
ring; and nuclear filaments originating at the nuclear ring and conjoining distally to form the nuclear 
basket, which connects with elements of the nucleoskeleton (not shown). Taken from Rout and Aitchison, 
200 1 .
The spoke-ring assembly consists of nuclear and cytoplasmic rings that are 
interconnected by two sets of eight spokes, and this forms a waist at the pore membrane 
(Davis 1995). The spokes project outwards to the centre of the pore where they fuse at 
the ends to form an inner annulus, which surrounds a channel of 40 nm (Davis 1995). 
Each spoke unit is made up of four morphologically distinctive subunits; ring, annular, 
columnar and lumenal (Hinshaw et al. 1992), with the unit repeated eight times around 
the perimeter of the pore and in mirror image across the nucleocytoplasmic plane. The 
annular subunits are in diagonally-opposite orientations, thus connecting the top of one 
spoke to the bottom of the adjacent spoke (Hinshaw et al. 1992; Davis 1995). The column 
subunit forms the arm of the spoke and attaches the annular subunit and lumenal subunit 
to the rings (Davis 1995), the majority of which lies in the lumenal space of the nuclear 
envelope. The resulting interaction anchors the spoke ring complex to the pore membrane
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(Davis 1995). In addition to the large central channel, there are also smaller channels that 
allow the passage of smaller substrates via passive diffusion (Davis 1995).
The central plug is regarded as an aqueous conduit able to accommodate substrates as 
large as 23 nm (Dworetzky and Feldherr 1988). The plug is a cylindrical transporter 
closed at each end and tapered inwardly at the pore waist in an hourglass configuration 
(Akey and Goldfarb 1989; Davis 1995). It ponsists of two distinct configurations with 
respect to the central transporter; one at the rim and the other over the centre (Akey and 
Goldfarb 1989). The occluded ends of the transporter could thus reflect substrates docked 
over a central transport channel (Akey and Radermacher 1993). The transporter channel 
must be able to expand significantly to accommodate large substrates, as the internal 
diameter is only approxmately 10 nm (Akey and Radermacher 1993). It is important to 
note that the variable presence and inconsistent shape of the central plug may suggest that 
it is not a true NPC structure. This fact is further confirmed by the observation that NPCs 
with a nuclear basket do not possess an occlusion of the central channel: This suggests 
that these two structures may be the one and the same (Davis 1995).
The peripheral components of the nuclear pore complex consist of the filaments and the 
nuclear basket. From the studies of the NPCs of Xenopiis oocytes, it has been shown that 
there are eight short cylindrical filaments that extend into the cytoplasm from the regions 
between each ring subunit (Goldberg and Allen 1993). The filaments serve as a docking 
site for incoming protein molecules and they also play an important role in connecting the 
NPC to cytoskeleton elements (Davis 1995). On the nuclear side of NPC, the nuclear 
basket extends 50-1 OOnm out from the nuclear ring and terminates at a distal annulus 
(Goldberg and Allen 1993). This structure is different from the filaments and thus shows 
that the NPC is asymmetrical in shape. From the studies of newt {Tviturus) oocytes, the 
nuclear basket appears to have a regular hexagonal meshwork of 8-10 filaments in which 
the distal annuli of the basket appear to be embedded (Goldberg and Allen 1993).
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1.3.1.2 Nuclear pore complex composition
With the assumption that the NPC is made up completely of protein, a study carried out 
in 1990 using a quantitative scanning transmission electron microscope suggested that the 
NPC is composed of at least 100 different types of polypeptides laiown as nucleoporins 
(Nups; (Reichelt et al. 1990), which range in size from 50-360kDa (Rout and Aitchison 
2001), Each NPC is composed of approximately 30 different nucleoporins (Reichelt et al. 
1990), that form a stationary phase for nucleocytoplasmic exchange, while soluble 
transport factors and their cargoes form the mobile phase (Rout and Aitchison 2001). All 
nucleoporins are present within the NPC in multiple copies, usually 1, 2 or 4 copies per 
spoke (thus having a total of 8, 16 or 32 copies per NPC as there are eight spokes), and 
are localised to both nuclear and cytoplasmic sides of the nuclear envelope (Stoffler et al. 
1999; Rout et al. 2000). Movement across the NPC requires direct interaction between 
nucleoporin domains that harbour multiple phenylalanine-glycine (PG) dipeptide repeats, 
usually GLEG or FxFG (where x is any residue) separated by polar spacer sequences of 
varying length (Gorsch et al. 1995; Rout and Aitchison 2001). These repeats are 
characteristic of many nucleoporins (Cook et al. 2007) as they interact with the nuclear 
transport machinery, with the interaction aiding in the nucleocytoplasmic shuttling of 
cargoes (Rout et al. 2000; Rout and Aitchison 2001).
The NPC is attached to the nuclear envelope at the pore membrane domain via integral 
proteins, collectively known as poms (pore membrane proteins). Poms play an important 
role in NPC assembly, by initiating and stabilising the formation of the pore membrane 
domain and serving as a membrane anchor site for the ever growing NPC (Rout and 
Aitchison 2001). However, currently little is known of the function of each pom and only 
two genes encoding integral proteins of the pore membrane have been identified so far in 
vertebrates (Cohen et al. 2005). Poml21 encodes a wheat germ agglutinin (WGA) 
binding protein localised at the pore membrane domain (Hallberg et al. 1993). It contains 
six XFXFG repeats that are posttranscriptionally modified by O-linked GIcNAc {O- 
linked N-acetylglucosamine) and plays a vital role in providing stability to the NPC 
assembly throughout interphase of the cell cycle (Bodoor et al. 1999). Nuclear pore
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glycoprotein 210 (Gp210) is a major constituent of the lumenal ring and is a major 
protein in metazoan NPCs (Rout and Aitchison 2001). It is also the only pore membrane 
gene that is evolutionary conserved, thus indicating its importance in NPC formation and 
function (Cohen et al. 2005). The Gp210 is recruited late during NPC assembly and is 
hyperphosphorylated during early mitosis, to initiate the disassembly of the NPC and 
nuclear envelope (Bodoor et al. 1999; Cohen et al. 2005).
1.3.2 Nuclear transport cargoes and signals
The rapid and efficient nucleocytoplasmic transport of thousands of proteins and RNAs is 
also a very specific process; only those proteins destined to function in the nucleus are 
imported, and the requirement for specific export is equally stringent. This specificity is 
largely determined by the presence of particular signals, the nuclear localisation signal 
(NLS) for nuclear import or the nuclear export signal (NES) for export, within the amino 
acid sequence of the cargo protein (Fried and Kutay 2003).
The first study conducted to characterise the NLS was carried out on simian virus 40 
(SV40) Large T antigen (Kalderon et al. 1984), which identified the sequence, 
PIŒIGRKV, as being crucial for transport of this protein. This monopartite motif is 
characterised by a single cluster of basic amino acids, with a consensus sequence of 
KXKRK (Kalderon et al. 1984) that has been defined in other proteins which utilise this 
type of signal. A similar basic NLS, a bipartite signal in which two clusters of basic 
amino acids separated by an intervening stretch of 5 to 20 amino acids (consensus 
KRnKKKK), was first characterised from the Xenopus nucleoplasmin protein 
(IGRPAATKKAGAQAIOCKICLD (Robbins et al. 1991). These so-called classical NLSs 
therefore consist of one or two clusters of basic amino acids separated by a linker 
(Gorlich and Kutay 1999) and it was first thought that import of most nuclear proteins is 
mediated by the classical NLS (Pemberton and Paschal 2005). Many cargo proteins do 
indeed contain such signals, for example the NLS of the core histones (Mosammaparast 
et al. 2001; Mosammaparast et al. 2002) and ribosomal proteins (Jakel and Gorlich 1998) 
have this structure. However, other studies revealed NLSs with other characteristics: the
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M9 (heterogenous nuclear RNP A l protein, which is one of the major pre-mRNA/mRNA 
binding proteins in eukaryotic cells) NLS consists of a large domain of 38 amino acids 
that is glycine rich and deficient in basic amino acids (Pollard et al. 1996).
On the other hand, cargoes that are destined to be exported out of the nucleus bear the 
nuclear export signal. The most well characterised NES is the hydrophobic NES, which is 
a loosely conserved motif containing three to four hydrophobic residues, most commonly 
leucine (Fischer et al. 1995). More than seventy five proteins containing this NES have 
been recognised (la Cour et al. 2003) and include many transcription factors and cell- 
cycle regulators. The protein kinase A inhibitor and the viral HIV Rev protein also 
contain the NES (Fischer et al. 1995; Wen et al. 1995). As with nuclear import, there are 
cargoes that utilise different signals, for example the M9 NLS of hnRNP Al (described 
above) can fiinction as both a nuclear import signal and a NES (Siomi et al. 1997). Major 
targets for nuclear export are the mature mRNAs that need to be exported to the 
cytoplasm for translation. In this case, the NES is not located within the cargo itself (i.e. 
the mRNA) but instead resides within proteins such as the hnRNPs, which clothe the 
mature message (Michael et al. 1995; Michael et al. 1997; Luo and Reed 1999) and the 
process itself is mediated by a specific export complex (Erkmann and Kutay 2004).
Regulation of NLS can occur by several mechanisms including modification or signal 
masking (Kaffman and O'Shea 1999) or via the phosphorylation of an amino acid located 
proximal to the classical NLS. These alterations result in decreased binding to the nuclear 
transport machinery (Harreman et al. 2004). Likewise, the NES can also be regulated by 
modifications (Stommel et al. 1999; Alt et al. 2000). The regulatory points enable the cell 
to not only determine which proteins should be transported in and out of the nucleus, but 
also under which conditions such transport should occur. It is important to note the 
presence of other types of NLS such as proline-tyrosine NLS (PY-NLS), non-classical 
importin a NLs amongst others (McLane, 2009).
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1.3.3 The nuclear transport machinery
The efficient passage of molecules larger than 50 kDa or 6-nm through the NPC requires 
several conserved protein factors, collectively known as the kaiyopherin p family (Table 
1.4; Gasiorowski and Dean, 2003; Pemberton and Paschal, 2005). In general, 
kaiyopherins mediate either nuclear import (importins) or nuclear export (exportins), and 
karyopherins may interact directly with the NLS (or NES) of their cargo, or may require 
another protein to act as an adapter. The best known of the adapter proteins are members 
of the evolutionarily conserved kaiyopherin a family (also known as importin a) 
(Goldfarb et al. 2004; Pemberton and Paschal 2005). These proteins are able to bind to 
both the NLS and to one particular karyopherin p. In the case of nuclear import, the 
complex formed between the NLS-bearing cargo and the import karyopherin is then 
translocated into the nucleus through the NPC (Pemberton and Paschal 2005) where it 
dissociates to release the cargo. Conversely, cargo that is destined to be exported out of 
the nucleus and contains a NES will be recognised by export karyopherins in the nucleus 
and dissociation of the complex takes place in the cytoplasm.
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Karyopherin Examples of interactions with class of molecules/ function
Import
a 1 Imports ‘classical’ NLS (PKKKRKV) containing proteins
a 2 Imports transcription factors and many viral proteins
a 3 Imports DNA binding proteins, recognizes classical NLS with additional flanking amino acids
a 5 Imports activated STATl, a transcription factor
a 7 Expression strongly up regulated in diabetic rat kidney
p i Imports karyopherin a homologues with karyopherin p binding domains
P 2 Import o f hnRNPAl, histones, ribosomal proteins
P 3 (RanBP5, Pselp) Import o f ribosomal proteins
P 4 (Kapl23) Import o f ribosomal proteins
Nmd5p (Kapl 19p) Imports MARK, TFIIS
Snurportin 1 m3G-cap receptor, import o f snRNPs
K apll4p Imports TATA-binding protein
Importin 4 Import o f histones, ribosomal proteins
Importin 5 Import of histones, ribosomal proteins
Importin 7 (RanBP?) Forms heterodimers with p 1, import of histone HI, Import of HIV RTC, Glucocorticoid receptor, ribosomal proteins
Importin 8 (RanBPS) Signal recognition particle (SRP) import, Import o f RNA binding proteins.
Importin 9 Import o f histones, ribosomal proteins
Importin 11 Import o f UbcM2, rpL12
Transportin SRI Import of SR proteins
Transportin SR2 Import o f SR proteins
Export
Crml Export o f proteins containing leucine based NES sequences
CAS Exports karyopherin a
Exportin-t (LosIp) tRNA export
Exportin 4 Export of eIF-5A
Exportin 5 Export of microRNA precursors
Exportin 6 Export o f Profilin, actin
Exportin 7 Export o f p50Rho-GAP, 14-3-38
Import/Export
Importin 13 Rbni8, Ubc9, Pax6 (import) elF-lA (export)
Transportin (P 2) Import/export proteins containing the M9 sequence
MsnSp (Kapl42p) Import/export of cell cycle control proteins
MtiTOp (K ap llip ) Polyadenylated RNA export, imports mRNA binding proteins
Table 1.4: List of importins and molecules they import or export. (Adapted from Pemberton and 
Pascal, 2005; Gasiorowski and Dean, 2003).
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1.3.3.1 The nuclear transport cycle
The key players in the classical NLS-dependent nuclear import pathway are, karyopherin 
P and the NLS-receptor karyopherin a (Adam and Adam 1994; Gôrlich et a l  1995), 
constituents of the RanGTPase system, which regulates binding and dissociation as 
described below (Melchior et a l  1993) and nuclear transport factor 2 (NTF2; (Paschal 
and Gerace 1995).
As described above, proteins in the cytoplasm that contain the classical NLS are bound 
by kaiyopherin a, which recognizes this highly basic ‘PKKKRKV’ string of amino acids 
(Nadler et al. 1997). Karyopherin a acts as an adaptor molecule, binding both the NLS of 
the cargo protein and karyopherin p (Figure 1.8A), although as previously mentioned, in 
some cases, kaiyopherin p may interact directly with the NLS (including the classical 
NLS) independent of karyopherin a, using similar NLS recognition motifs. These 
a/p/NLS or p/NLS multiprotein complexes localise to the nuclear envelope as 
karyopherin p binds to filaments that protrude from the NPC into the cytoplasm (Figure 
1.8A(Gorlich et a l 1995; Moroianu et al. 1995; Gorlich and Kutay 1999).
The association of cargo with kaiyopherin p (in complex with karyopherin a) is then 
followed by the association of this complex with another soluble protein involved in the 
import process; Ran. Ran is a small nucleotide binding protein, which when in the 
cytoplasm is present in its GDP bound form (RanGDP). The total complex is 
translocated through the pore with the help of a third soluble protein, NTF2, which assists 
in mediating translocation of the Ran-containing complex through the pore, although it 
does not form an integral part of the import complex (Ribbeck et al. 1998). Once inside 
the nucleus, the guanine nucleotide exchange factor RCCl (also known as RanGEF) 
replaces the Ran-bound GDP with GTP, causing the import cargo to dissociate from the 
karyopherin/Ran complex (Figure 1.8B and C). This mechanism is unusual in that it does 
not involve a kinase reaction, but rather occurs by exchanging the entire nucleotide 
(Bischoff and Ponstingl 1991).
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Figure 1.8: Mechanism of nuclear transport. A) Cargo with an NLS in the cytoplasm interacts with 
karyopherin (importin) (3 via the karyopherin (importin) a adaptor. B) a/p/NLS multiprotein complexes 
translocate through a NPC and C) are dissociated by nuclear RanGTP. D) Karyopherin p is exported to the 
cytoplasm in association with the Ran GTP, while karyopherin a is exported in association with RanGTP 
by CAS. Ultimately, GTP is hydrolysed by cytoplasmic RanGAP resulting in the disassociation of 
karyopherin a and karyopherin p from the RanGTP and releasing the karyopherins for another nuclear 
protein import cycle
Following karyopherin a/p/cargo complex dissociation after Ran guanine nucleotide 
exchange factor (RCCl), karyopherin p remains associated with RanGTP and is 
exported. The nuclear export receptor, cellular apoptosis susceptibility (CAS), another 
karyopherin P homologue, binds karyopherin a. This CAS-karyopherin a complex is also 
exported along with RanGTP (Izaurralde et al. 1997); the binding of CAS to karyopherin 
a also promotes the release of the NLS-cargo, helping to prevent futile transport cycles
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(Kutay et al. 1997). Following export to the cytoplasm, the RanGTP undergoes 
nucleotide hydrolysis. This can occur anywhere in the cell, but it is strictly controlled by 
several proteins surrounding the NPC. Ran-bhiding protein 2 (RanBP2) is found in the 
cytoplasmic face of the NPC and acts as a scaffold where import and export complexes 
assemble and disassemble. RanBP2 is known to bind proteins such as Ran-GTPase- 
activating protein 1 (RanGAP 1 (Matunis et al. 1998), which triggers GTP hydrolysis of 
RanGTP. Following the conversion of RanGTP to RanGDP a new RaiiGDP/karyopherin 
a/ karyopherin p/NLS complex can form and undergo trans location into the nucleus 
(Lounsbury and Macara 1997).
Conversely, exportins or nuclear export receptors, bind their substrates preferentially in 
the nucleus forming a trimeric complex with RanGTP (Kutay et al. 1997; Arts et al. 
1998). The trimeric complex is then transferred to the cytoplasm where it is 
disassembled, triggered by GTP hydrolysis. The substrate-free and Ran-free exportin can 
then re-enter the nucleus, bind and export the next cargo molecule. As described earlier, 
many of the nuclear export signals are characterized by a leucine rich string of amino 
acids that are recognized by Crml, the exportin protein or simply known as exportin. The 
first two proteins in which NESs were identified are the HIV-1 Rev protein and the 
polypeptide cAMP-dependent protein kinase inhibitor (PKl). Rev uses the NES sequence 
(LPPLERLTLD) to bind to the Crml (Fischer et al. 1995) and the entire complex, 
together with the RanGTP is exported out of the nucleus. RanGTP appears to promote the 
interaction between exportin (Crml) and NES-containing cargo proteins (unlike the 
import situation).
Since regulator of chromosome condensation 1 (RCCl) is restricted to the nucleoplasm 
and RanGAP 1 is found mainly in the cytoplasm, a RanGTP gradient exists across the 
nuclear envelope with a high RaiiGTP/RanGDP ratio in the nucleus; this acts to drive 
protein trafficking back and forth across the NPC. Usually, nuclear import of karyopherin 
P requires RanGDP whereas export requires RanGTP.
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1.3.3.2 Karyopherin p: structure and role in nuclear transport
The kaiyopherin p family of proteins have three primaiy functions embedded within their 
role in nuclear transport: the ability to bind to (multiple) cargo proteins (including 
karyopherin a), the ability to interact with the nuclear pore complex to bring about 
translocation, and the ability to interact with Ran (GTP or GDP) in order to bring about 
complex assembly and disassembly (Kaffman et al. 1998; Fried and Kutay 2003; 
Pemberton and Paschal 2005). Elucidation of the structure of karyopherin pi bound to its 
cargo (Matsuura and Stewart 2004; Petosa et al. 2004) along with structures of 
karyopherin p2-Ran (Chook and Blobel 1999; Vetter et al. 1999) and a fragment of the 
exportin Crml have suggested that each karyopherin is typically composed of 20 HEAT 
(Huntington, elongation factor 3, ‘A’ subunit of protein phosphotase 2A and TORI) 
repeats, and approximately 40 amino acid repeats composed of two antiparallel helices 
connected by a short turn (Matsuura and Stewart 2004; Petosa et al. 2004). The super 
helix formed by the HEAT repeats provides an extensive interaction surface in the form 
of N-terminal and C-terminal arches and further proves that several cargoes are 
recognised by each karyopherin and that the karyopherins have multiple binding sites 
(Chook and Blobel 2001; Conti 2002). In addition, the ability of karyopherins to adopt 
different conformations according to their cargoes (Cingolani et al. 1999; Fukuhara et al.
2004) aids in recognition of various cargoes by a single karyopherin. This interaction was 
demonstrated elegantly by Fukuhara and colleagues, by studying the overall shape of 
several members of karyopherin family using small angle X-ray scattering. Structural 
analysis affirms considerable variability in conformation between individual 
karyopherins bound to different cargoes/substrates and between different karyopherins 
(Fukuhara et al. 2004).
The binding of karyopherins with the Ran system has also been elucidated by 
crystallographic studies (Chook and Blobel 1999; Vetter et al. 1999). These studies have 
shown that a karyopherin involved in either nuclear import or export has different affinity 
towards RanGTP. Nuclear import karyopherins have a relatively high affinity for 
RanGTP and the binding of RanGTP leads to the dissociation of their import cargoes,
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whereas export karyopherins that form a trimeric complex of RanGTP and cargo have a 
relatively low affinity for Ran in the absence of cargo (Fried and Kutay 2003). Studies on 
an N-terminal fragment of karyopherin pi-RanGTP and karyopherin p2-RanGTP show 
similarities in their Ran binding, where Ran contacts the concave surface of the N- 
terminal arch (Chook and Blobel 1999; Vetter et al. 1999). Ran may also come into 
contact with the acidic loop found between two FIEAT repeats in the centre of the protein 
in the C-terminal. This could suggest that the loop would also contact the cargo and may 
explain how RanGTP binding results in cargo dissociation (Chook and Blobel 2001).
When travelling through the NPC, all p type karyopherins bind briefly to nucleoporins, 
specifically the FG nucleoporins that provide the NPC binding sites for the karyopherin 
(Suntharalingam and Wente 2003). The binding of an N-terminal fragment of 
karyopherin pi to the yeast FG repeat nucleoporins shows that the interactions are 
primarily hydrophobic and are mediated by the amino acid phenylalanine. In karyopherin 
pi, two hydrophobic pockets are formed by the side chain of residues between HEAT 
repeats 5 and 6, and 6 and 7, into which, phenylalanines are inserted into the FG repeats 
(Bayliss et al. 2000). In addition, a nucleoporin binding site has been identified in the C- 
terminal of karyopherin pi (Bednenko et al. 2003). In the same way that binding 
affinities vary between karyopherins and RanGTP, it is important to note that different 
karyopherins have a range of binding affinities towards nucleoporins (Suntharalingam 
and Wente 2003), which may suggest that the transport of individual karyopherins could 
be regulated by preferential use of different binding sites. It has also been shown that the 
affinity of karyopherins could be affected by the asymmetrically located nucleoporins 
within the NPC; importins often show high affinity to the nucleoplasmin face of NPC, 
while exportins seem to prefer the cytoplasmic face of NPC (Ben-Efraim and Gerace 
2001; Pemberton and Paschal 2005).
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1.3.3.3 Karyopherin a structure and its role in nuclear transport
The most understood function of karyopherin a is to serve as an adapter that links 
classical NLS-containing proteins to importin p, which, in turn, facilitates translocation 
into the nucleus (Goldfarb et al. 2004). To achieve this function, karyopherin a is 
composed of a flexible N-terminal importin-P-binding (IBB) domain and a highly 
structured cylindrical superhelix domain comprised of ten tandem armadillo (ARM) 
repeats (Figure 1.9). These structures were first identified in the gene product of 
Drosophila melanogaster segment polarity gene armadillo, and its human orthologue, p- 
catenin (Peifer et al. 1994), along with the exportin cellular apoptosis susceptibility 
domain (CAS), which binds to the tenth ARM repeat (Conti et al. 1998; Conti and 
Kuriyan 2000; Goldfarb et al. 2004).
N terminal
Auto-inhibition
NLS-cargo
binding CAS binding
C terminal
importing 
binding domain (IBB)
10 ARM repeats
Figure 1.9: Schematic of the structural domain of karyopherin a. Different funetions and binding 
partners are indicated. Karyopherin a consist of the importin binding domain located at the N-terminal and 
the highly structured 10 tandem armadillo (ARM) repeats that function as the binding site for cargoes 
containing the NLS. The 10*’’ ARM repeat serves as the cellular apoptosis susceptibility (CAS) binding site 
and a small hydrophilic C-terminal domain of unknown function. (Adapted from Goldfarb et al., 2004).
Each individual ARM repeat contains approximately 40-45 amino acids that form three 
helices; HI, H2 and H3 (Chook and Blobel 2001). Successive ARM repeats are linked by 
a spacing of approximately 9 Â and a rotation of approximately 30°. These repeated units 
generate a cylindrical superhelical structure that is 100 Â in length and 30 Â in diameter. 
A continuous shallow groove lined by H3 helices follows the superhelical axis of the 
domain (Chook and Blobel 2001). Studies in Saccharomyces cerevisiae and Mus
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musciiltis karyopherin as bound to NLS peptides (Conti et ai. 1998; Conti and Kuriyan 
2000; Fontes et al. 2000) revealed the presence of two NLS-binding sites on karyopherin 
a, consisting of ARM repeats 2-4 and 7-9. Monopartite NLSs bind only to ARM repeats 
2-4, whereas bipartite NLSs bind to both (Conti and Kuriyan 2000; Kosugi et al. 2009). 
Crystal structure analyses of kaiyopherin a with several classical NLSs have shown that 
an NLS is recognised through interaction based on both hydrophobicity and charge 
(Conti et al. 1998; Conti and Kuriyan 2000; Fontes et al. 2000). Repeats 2-5 can be 
superimposed onto HEAT repeats 9-12 of karyopherin (3, suggesting that HEAT and 
ARM repeat proteins are evolutionarily related (Conti and Kuriyan 2000).
The IBB domain is a flexible region upstream of the ARM repeats. The IBB domain has 
two roles; firstly, it can bind in trans to karyopherin (31 to target the trimeric complex 
through the NPC, (Gorlich et al. 1996) and secondly, it contains an autoinhibitory 
sequence that mimics an NLS and regulates the binding of NLS-cargo complexes to the 
ARM domain of karyopherin a  (Moroianu et al. 1996). This autoinhibitory sequence 
(Figure 1.9) interacts in cis with the NLS-binding pocket when karyopherin a is not 
bound to karyopherin (3 (Kobe 1999). However, this interaction is low affinity, as 
karyopherin a still can bind though the NLS-cargo in the absence of karyopherin (3 
(Goldfarb et al. 2004). The IBB domain therefore acts as a competitive inhibitor to 
regulate binding of NLS cargoes to the binding groove through these cis and trans 
interactions and, when displaced, enables the binding of the NLS to the nascent targeting 
complex (Goldfarb et al. 2004). As previously described, when RanGTP binds to 
karyopherin p it causes the dissociation of the karyopherin a/p complex. The 
autoinhibitoiy domain within the IBB, along with CAS, also have a role in releasing the 
NLS-cargo from the complex (Gilchrist and Rexach 2003).
Karyopherin a genes can be classified into one of three conserved subfamilies (a l, a2 
and a3; (Kohler et al. 1997; Plant et al. 2006; Mason et al. 2009). To date, six 
karyopherin a encoding genes have been identified in man (Plant, 2006; Cortes, 1994; 
Cuomo, 1994; Kohler, 1997; Nachuiy, 1998; Kohler, 1999). In the literature, these are 
alternatively refered to as karyopherin a and importin a, however it should be noted that
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in humans, the numbering of individual members of the family differs according to 
defined nomenclature (see Table 1.6 for a summary). In the rat, chicken, zebrafish and 
pufferfish there are also 6 karyopherin a genes (Plant et al. 2006), and their numbering 
matches that used in the (official) karyopherin a gene naming system in humans. In 
comparison to rats, there are only 5 karyopherin a genes in mice, and in the 
pseudotetraploids Xenopus laevis, there are 5 pairs of genes. Non-vertebrates such as 
Drosophila and Ciona have 3 karyopherin a genes corresponding to one from each 
subfamily (Mason et al. 2002; Plant et al. 2006), whereas Saccharomyces cereviseae has 
only a single karyopherin a homologue (Yano et al. 1992). In humans, the karyopherin 
a I subfamily consists of karyopherin al, 5 and 6 genes, with only karyopherin a2 in the 
a2 subfamily. Lastly, the karyopherin a3 subfamily consists of karyopherin a3 and 
karyopherin a4 genes. A possible evolutionaiy tree for the karyopherin a family was 
presented by Plant et al. (2006) and is shown in Figure l.IO.
K aryopherin Im portin O ther names Accession No.
Karyopherin a l 
(KPNAl)
Importin a5 IP0A5, NPI-1, RCH2, SRPl NM002264
Karyopherin a2 
(KPNA2)
Importin a l IPOAl, QIP2, RCHI, SRPlalpha NM002266
Karyopherin o3 
(KPNA3)
Importin a4 RP11-432M24.3, IPOA4, SRPl, 
SRPl gamma, SRP4, hSRPI
NM002267
Karyopherin a4 
(KPNA4)
Importin a3 1POA3, MGC12217, MGC26703, 
Q IPl, SRP3
NM002268
Karyopherin a5 
(KPNA5)
Importin a6 IP0A6, SRP6 NM002269
Karyopherin a6 
(KPNA6)
Importin a7 RP4-622L5.1, FLJ11249, IP0A7, 
KPNA7, MGC17918
NM012316
Table 1.5; List of hum an karyopherin a  genes and their orthologs.
Source: National Centre for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/)
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Figure 1.10: Schematic phylogenetic representation of karyopherin a genes across organisms and the 
subfamily group in which they belong (Adapted from Plant et al., 2006).
Kaiyopherin alphas are widely distributed across tissues, but may also illustrate tissue 
specificity in their levels of expression. For example, human KPNA2 and KPN A4 are 
most highly expressed in testis, ovaries and lungs whereas KPNA3 is expressed in all the 
above tissues and is expressed at very low levels in the liver. There is no KPNAl 
expression in the brain and KPNA5 is only expressed in testis. Finally, KPNA6 is 
expressed in a wide range of tissues (Kohler et al. 1997; Kohler et al. 1999). Studies of 
karyopherin a expression in the rat show similar wide expression patterns with variation 
in levels between tissues (Plant et al. 2006). While KPNA2 is highly expressed in most 
tissues, as in humans, KPNA5 expression is much lower and restricted to specific tissues, 
including the testis. Certain tissues, including the testis, thymus and spleen, show high
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overall levels of karyopherin a expression, whereas in others, including the liver, levels 
are much lower. This may make the latter tissues more vulnerable to induced alterations 
in karyopherin a levels.
The consequences of variation in expression levels of particular karyopherin as remains 
to be proven, but it may impact on the efficiency of the trans location of specific nuclear 
proteins, since evidence suggests that the karyopherin as exhibit cargo selectivity (Kohler 
et al. 1999). The signal transducers and activators of transcription (STAT) family of 
proteins are involved in regulating cellular growth and proliferation in response to growth 
factors and cytokines. Of these, STATl is specifically imported by the karyopherin a l 
(KPNAl) isoform (Sekimoto and Yoneda 1998; McBride et al. 2002) and STAT3 has 
been shown to bind to both KPNAl and KPNA6 (Ushijima et al. 2005; Ma and Cao 
2006). RAG-1 is required for V(D)J (Variable-Diversity-Joining region) recombination 
of the T-cell receptor and B-cell immunoglobulins. RAG-1 protein is bound by both 
KPNAl and KPNA2 (Cortes et al. 1994; Cuomo et al. 1994), as is lymphoid enhancer- 
binding factor 1 (LEF-1), another protein that has important regulatory roles in B and T- 
cell development (Prieve et al. 1998).
Components of the nuclear import machinery themselves are also recognized by specific 
karyopherin as. For example, the RaiiGEF RCCl is specifically imported by KPNA4 
under normal cellular conditions, however, KPNA3 is able to transport RCCl at much 
lower efficiency (Kohler et al. 1999; Talcott and Moore 2000). It has been shown that 
some biological processes are affected by alterations in karyopherin a levels. 
Proliferation of HeLa cells, for instance was strongly inhibited by the down-regulation of 
karyopherins a4, a l ,  a6 and (31, although down-regulation of 1CPNA2 and KPNA3 had 
little effect (Quensel et al. 2004). However, despite these and other studies, it is not yet 
clear what impact the variations in karyopherin a  levels observed in tissues have on the 
subcellular localization of specific cargoes or on cellular function.
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1.3.3.4 Karyopherin a2
Karyopherin a l  is the most widely studied amongst the karyopherin a family. Though 
there is abundance in literatures regarding the genomic structure (Conti et al. 1998; Dorr 
et al. 2001), role and biological impact of KPNA2, there were no association in regards to 
nuclear receptors. Recent KPNA2 search on PubMed and Google scholar databases 
retrieved 156 and 625 articles respectively in comparison to 4952 and 64,500 articles 
respectively on multidrug resistance protein 1 (MDRl). This shows that there is still 
room for further expanding our understanding of this important protein.
The human KPNA2 has a size of 11,123 bases, 529 amino acids and 57862 Da and is 
located at chromosome 17q24.2 (GeneCards Gene Database; http://www.genecards.org). 
The binding affinity of KPNA2 protein to importin p is 10nm±18% (Kohler et al. 1999). 
It is expressed in a wide range of organs and most interestingly, is overexpressed in 
certain type of cancers as shown in Figure 1.11 and Table 1.6.
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Figure 1.11: KPNA2 expression level in human: Duplicate measurements were obtained for twelve 
normal human tissues (out of 28 tissues shown) hybridized against Affymetrix GeneChips HG- 
U95A-E (Weizmann Institute; GeneNote data) and for 22 normal human tissues hybridized against 
HG-U133A (Genome Institute o f the Novartis Research Foundation; GNF data). Taken from 
GeneNote (http://bioinfo2.vveizmann.ac.il/cgi-bin/genenote/home_page.pl).
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Cancer KPNA2 Level References
Flepatocellular carcinoma Overexpressed (Yoshitake et al. 2011)
Prostate carcinoma Overexpressed (Moifezavi et al. 2011)
Non-muscle-invasive bladder cancer Overexpressed (Jensen et al. 2011)
Non-small cell lung cancer Overexpressed (Wang et al. 2011)
Ovarian cancer Overexpressed (Zheng et al. 2010)
Breast cancer Overexpressed (Dahl et al. 2006; Dankof 
et al. 2007; Gluz et al. 
2008)
Esophageal squamous cell carcinoma Overexpressed (Sakai et al. 2010)
Cervical cancer Overexpressed (Van der Watt et al. 2009)
Ductal carcinoma in situ Overexpressed (Dankof et al. 2007)
Cutaneous Melanoma Overexpressed (Winnepenninckx et al. 
2006)
Table 1.6: List of cancers associated with KPNA2.
Apart from cancers, KPNA2 is also shown to be associated with several other diseases 
such as severe acute respiratory syndrome (SARS) where the SARS coronavirus 0RF6 
protein is localised in the endoplasmic reticulum/Golgi membrane where it binds and 
disrupts nuclear import machinery complexes by tethering KPNA2 and KPNAl to the 
membrane. This causes the retention of STATl in the cytoplasm which leads to the 
expression of STATl-activated genes that establish an antiviral state being blocked 
(Frieman et al. 2007). The nuclear translocation of the viral protein R of the HIV typel is 
promoted by KPNA2 and is crucial for the replication of the virus (Kamata et al. 2005; 
Nitahara-Kasahara et al. 2007). The KPNA2 also contributes to the nuclear localisation 
and tumour suppression function of the Nijmegen breakage syndrome 1 (NSBl) complex 
which is associated with cancer predisposition, growth retardation amongst others (Tseng 
et al. 2005; Teng et al. 2006). The nuclear entry of E6 oncoprotein of high-risk human 
papillomavirus type 16 ocuurs via several pathways including the classical KPNA2 
shuttling (Le Roux and Moroianu 2003). Nuclear transport of the virus plO of Borna 
disease, a infectious neurological disease occurs via KPNA2 transport machinery (Wolff 
et al. 2002). In regards to Alzheimer’s disease, KPNA2 is accumulated in the Hirano’s 
bodies in hippocampal neurons that hinders normal nucleo-cytoplasminc shuttling (Lee et 
al. 2006). The protein that is responsible for the replication and thereafter viral infection 
of dengue is the dengue virus nonstructural protein 5 and KPNA2 plays an integral part in
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the nuclear localisation of this protein (Pryor et al. 2007). This may also encompass 
significant importance to other members of the flaviviruses in which dengue belongs such 
as West Nile viruses and yellow fever (Pryor et al. 2007).
There are many chemicals that are reported to be able to interact or are associated with 
KPNA2 as shown in Table 1.6. These chemicals are either responsible for increasing or 
decreasing the KPNA2 mRNA expression level.
Chemicals Expression level of 
KPNA2 mRNA
Species References
4,4'-methylene dianiline Increased Mns mnsculns (Kwon et al. 
2008)
4-hydroxytamoxifen Decreased Homo sapiens (Scafoglio et al. 
2006)
Dextroamphetamine Increased Mus miiscidiis (Sokolov et al. 
2003)
Arsenite Decreased Mus musculus (Yu et al. 2008)
Benzo(a)pyrene Increased Mus musculus (Verhofstad et 
al. 2010)
Benzo[a]pyrene diol 
epoxide
Decreased Homo sapiens (Dreij et al. 
2010)
Bisphenol A Increased Homo sapiens (Buterin et al. 
2006)
Bortezomib Increased Homo sapiens (Abeltino et al. 
2011)
Cadmium Chloride Decreased Danio rerio (Yang et al. 
2007)
CD 437 Decreased Homo sapiens (Garattini et al. 
2004)
Cyclosporine Increased Homo sapiens (Jennen et al. 
2010)
Cyproterone acetate Decreased Rattus norvégiens (Plant et al. 
2006)
Estradiol Increased Homo sapiens (Buterin et al. 
2006; Scafoglio 
et al. 2006)
Fliiorouracil Decreased Homo sapiens (Le Fevre et al. 
2007)
Genistein Increased Homo sapiens (Buterin et al. 
2006)
Hydroxyurea Decreased Homo sapiens (Le Fevre et al. 
2007)
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Lycopene Increased Homo sapiens (Chalabi et al. 
2006)
Methylcholanthrene Increased Mus musculus (Rohrbeck et al. 
2010)
Nitrosomethylbenzylamine Increased Rattus norvegicus (Reen et al. 
2007)
Pirinixic acid Increased Rattus norvegicus (Plant et al. 
2006)
Raloxifene Decreased Homo sapiens (Scafoglio et al. 
2006)
Resveratrol Decreased Homo sapiens (Jones et al. 
2005)
ST1926 Decreased Homo sapiens (Garattini et al. 
2004)
Table 1,7: List of chemicals that alters KPNA2 niRNA expression level in different species.
1.3.4 Pharmacological aspects of nuclear import and export
1.3.4.1 Nuclear transport of nuclear receptors
It is important to understand the regulation of NRs and eventually gene expression 
changes by nuclear transport. NRs have been implicated in a host of physiological 
processes including development, proliferation and differentiation, and also in the context 
of human diseases (Shank and Paschal 2005). As described previously, the subcellular 
localisation of the NRs is an important aspect of their function since active NRs need to 
access DNA to activate transcription. The classes of NR differ in their unliganded 
localisation, with type I being primarily cytosolic whereas type II show predominantly 
nuclear localisation in the absence of ligand. Upon ligand binding, NRs redistribute to the 
nucleus in order to regulate target gene transcription. It seems likely that most, if not all, 
NRS exhibit some degree of nucleocytoplasmic shuttling, which may contribute to their 
functions (DeFranco 2002; Shank and Paschal 2005).
The most studied NR in terms of nucleocytoplasmic shuttling is the glucocorticoid 
receptor (GR), one of the type I receptors. GR has two nuclear localisation signals; NLS-
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1 is a basic bipartite motif that overlaps approximately 27 amino acids with the DBD- 
hinge region (Madan and DeFranco 1993), while the less efficacious NLS-2 overlaps 
with the LBD, incorporating approximately 200 amino acids of GR’s LBD (Savory et al. 
1999). NLS-1, being the strongest signal, is responsible for relatively rapid nuclear 
import (Scherrer et al. 1993; Hache et al. 1999; Pemberton and Paschal 2005). In 
addition, NLS-1 dependent import is regulated by binding of both agonists and 
antagonists, and high concentrations of GR can also mediate ligand-independent 
translocation (Pemberton and Paschal 2005). In comparison, NLS-2 mediated nuclear 
import is much slower compared to that of NLS-1 and is purely agonist-specific 
(Pemberton and Paschal 2005).
The nuclear import receptors mainly responsible for the nuclear import of GR are the 
karyopherin a-importin (31 heterodimer, which can bind to NLS-1 (Pemberton and 
Paschal 2005), importin 8, which binds to NLS-2, and importin 7 (a member of the (3 
kaiyopherin family), which recognises both (Pemberton and Paschal 2005). Surprisingly, 
the interaction of karyopherin a-importin (31 heterodimer, importin 7 or importin 8 with 
GR is ligand-independent (Freedman and Yamamoto 2004). This may suggest that the 
popular model explaining the dissociation of GR with chaperones such as heat shock 
protein 90 (hsp90) upon ligand binding is incorrect (Freedman and Yamamoto 2004; 
Pemberton and Paschal 2005). Ligand binding may instead regulate a critical chaperone- 
dependent step that occurs after the recognition of NLS by the nuclear import machinery 
(Freedman and Yamamoto 2004).
Studies on nuclear export of NRs are still in their infancy and remain enigmatic. 
However, data suggest that nuclear export may either be Crml-dependent or Crml- 
independent, depending on cellular conditions (Pemberton and Paschal 2005; Kumar et 
al. 2006). Possible mechanisms explaining these theories encompass the fact that NRs 
lack a hydrophobic NES. It is postulated that other proteins such as p i60 coactivators or 
members of the 14-3-3 family that bind NRs contain the export signal and thereby 
function as adapters for Crml dependent export (Amazit et al. 2003; Kino et al. 2003).
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Ligand binding and NR dimérisation may also influence whether nuclear export is Crml- 
dependent or -independent (Prufer and Barsony 2002).
It is also important to acknowledge the contribution of signal transduction pathways to 
NR localisation. For example, nuclear import of GR can be triggered by shear-stress 
activation of mitogen-activated protein (MA)P and phosphatidylinositol-3 (PI-3) kinases 
(Ji et al. 2003). MAP kinases are also shown to implicate nuclear export of GR, ER and 
PR (Shank and Paschal 2005).
1.3.4.2 Pharmacological regulation of nuclear transport
Understanding the importance of nuclear import and export in pharmacological and 
pathophysiological terms may provide important information to enable the design and 
targeting of drugs that would affect the nuclear import and export of proteins. Altering 
the functioning of these proteins would simultaneously help to elucidate further roles and 
mechanisms of action. To date, there are several drugs that target this process, including 
those that inhibit the nuclear export of NF-icB (nuclear factor kappa-1 ight-chain-enhancer 
of activated B cells); nuclear localisation of nuclear factor of activated T-cells (NF-AT); 
and the nucleocytoplasmic shuttling of human immunodeficiency virus (HIV)-l 
(Gasiorowski and Dean, 2003).
The most obvious target to use when attempting to inhibit nuclear import or export is the 
NPC itself, although complete inhibition of nuclear transport would result and would 
limit cell viability. Within the NPC, it would make sense to target the FG and FxFG 
repeats as they are the most common characteristic of nucleoporins and the components 
that provide the interaction with karyopherins passing through the NPC. Monoclonal 
antibodies including mAb4I4 and RL2 have been shown to block trans location through 
the NPC (Snow et al. 1987). These antibodies elicit their effects by preventing the 
association of cargoes with the rim of the NPC, resulting in the impairment of nuclear 
transport (Gasiorowski and Dean 2003). Another common feature of several nucleoporins 
is O-linked GlcNAc. Wheat germ agglutinin is a lectin that binds to N-acetylglucosamine
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and when added to cells, results in inhibition of nuclear import by associating with the 
moiety and physically blocking the channel (Finlay et al. 1987).
The NF-icB is a protein complex that controls transcription of DNA and is involved in 
cellular responses to stimuli such as stress, cytokines, free radicals, UV irradiation, and 
bacterial and viral antigens (Gilmore 2006). NF-kB contributes to a complex signal 
transduction pathway that results in the stimulation of apoptotic and immune response 
genes (Gasiorowski and Dean 2003). Acétylation of NF-kB in the nucleus by nuclear 
protein histone deacetylase 3 (HDAC3) prevents it from associating with its inhibitor 
(IkB) and being exported out of the nucleus (Gasiorowski and Dean 2003). Trichostatin 
A (TSA) is a Streptomyces bacterial product that acts as a cell cycle (Yoshida and Beppu 
1988) and histone deacetylase inhibitor (Yoshida et al. 1990). TSA has been used as an 
anti-cancer drug with the assumption that HDAC inhibition would lead to permanent 
histone acétylation, thus maintaining the transcription of anti-cancer genes (Zhang, 2006; 
Kim, 2003). TSA has indeed been shown to block the nuclear export of NF-icB 
(Gasiorowski and Dean 2003), and thus may well extend the pro-apoptotic stimulus from 
this protein. In keeping with this finding, TSA has been shown to block cell proliferation 
and trigger apoptosis in hepatoma cells (Herold et al. 2002). A synthetic derivative of 
TSA, 4(dimethylamino)-V-[7-(hydroxyamino)-7-oxoheptyl]-benzamide, has also shown 
promise as a multiple anti-cancer drug (Remiszewski et al. 2002).
Nuclear factor of activated T-cells (NFAT) are a family of transcription factors shown to 
be important in immune response. Immunosupressor drugs such as cyclosporin A and 
FK56 bind to cyclophilin and prevent calcineurin from dephosphoiylating NFATs. The 
phosphate keeps the NLS of the NFATs well hidden from nuclear import machinery, 
preventing nuclear localisation and thus leading to immunosuppression (Liu et al. 1991; 
Griffith et al. 1995). However, these drugs illustrate a potential problem with targeting 
nuclear import as they have side effects associated with the blockade of calcineurin 
import, which is important in regulating other signaling pathways. Second generation 
drugs, such as low molecular weight synthetic pyrazole compounds (3,5- 
bistrifluoromethyl pyrazoles) solve this problem and can be administrated at lower doses
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without the side effects caused by blockade of the calcineurin cascade (Trevillyan et al. 
2001).
Most anti-HIV therapies were developed to inhibit viral entry, viral genome replication 
and viral specific proteolysis. For example, leptomycin B (LMB) is a Streptomyces 
product that is an effective inhibitor Rev-Crml-dependent nuclear export. However, as 
discussed above, complete blockade of nuclear-cytoplasmic shuttling is liable to produce 
significant side effects and in this particular case, inhibition of all all Crml-mediated 
export would prove to be fatal (Wolff et al. 1997). Studies have shown that arylene bis 
(methylketone) compounds disrupt formation of the preintegration complex (PIC), which 
is required for the productive infection of nondividing cells and leads to failure of nuclear 
import (Dubrovsky et al. 1995). Another arylene bis compound, CNI-H0294, suppresses 
HIV-1 replication (Flaffar et al. 1998) and could be used in conjunction with other anti 
HIV drugs in cocktail therapy (Gasiorowski and Dean 2003). Table 1.5 provides list of 
drugs that affect nuclear import (Gasiorowski and Dean 2003).
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Drug/ agent Target Nuclear import / export effect
Wheat germ aggulatinin V-Acetylglucosamine 
moieties on nucleoporins
Binds to sugar and blocks import of 
proteins through the NPC
Anti-FG repeat antibodies Nucleoporins Blocks importins from docking to NPC
Dimethylfumarate NF-kB Retains NF-kB in cytoplasm even after 
TNF-a signal
Cyclosporin A Cyclophilin Cyclophilin-cyclosporin complex binds 
calcineurin and inhibits dephosphorylation 
of NFAT/ maintains cytosolic localization 
of N F AT/immunosuppressant
FK506 FKBP12* FICBPI2-FK506 complex binds 
calcinuerin to inhibit dephosphorylation of 
NFAT/immunosuppressant
3,5-Bistrifluoromethyl
pyrazoles
NF-AT pathway Blocks NF-AT nuclear import without 
inhibiting calcinuerin activity
Leptomycin B Crml Non-specifically inhibits all Crml 
mediated nuclear export
Arylene bis (methylketone) 
compounds
HIV-1 reverse 
transcriptase
Associates with RT component o f PIC, 
blocks nuclear import o f viral genome
HIV-1 monoclonal antibodies HIV-1 envelope proteins Bind virus before cellular entry, block 
nuclear import o f genome
Transfected importin |3 binding 
domain (IBB)
Importin p Conserved domain from importin alpha 
family acts as a dominant negative 
competitive inhibitor o f importin a/|3- 
mediated import
Table 1.8: Drugs or agents that affect nuclear import
* FKBP12 is notable in humans for binding the immunosuppressant molecule tacrolimus (originally 
designated FK506). (Gasiorowski, 2003)
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1.4 Hypothesis, aims and objectives
It is clear that the nuclear translocation of NRs is an important component of their 
function, impacting on their liganded and in some cases unliganded activities. However, 
the precise role of specific components of the nuclear transport machinery in this process 
has yet to be elucidated. Similarly, although several studies have reported the tissue and 
cell-type specific expression pattern of the karyopherins in mammals (Nachury et al. 
1998; Kohler et al. 2002; Plant et al. 2006) there is currently little information regarding 
the transcriptional control of their gene expression. To date, the only studies have been 
carried out on the karyopherin a  family, which are known to respond to a number of 
xenobiotics including liver growth agents (Plant et al. 2006) as well as to exogenous 
agents that induce cell differentiation (Kohler et al. 2002). Since several of these 
compounds are known ligands for NRs, this suggests that these transcription factors may 
play a role in regulating the levels of the proteins that control their own subcellular 
localisation.
This research was initiated to explore this area, and in particular to characterize the role 
of NR’s on the regulation of the KPNA2 gene, the most highly and widely expressed 
member of the karyopherin a gene family.
Hypothesis
NRs play a role in the regulation of karyopherin a at the transcriptional level, which in 
turn alters the capacity of that karyopherin a to transport molecules across the nuclear 
envelope.
Aims
To examine the molecular mechanisms of NR-dependent transcriptional regulation of 
human KPNA2.
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Objectives
1. To identify the proximal regulatory region of human KPNA2 and putative nuclear 
factor binding sites using in silico analysis.
2. To clone the human KPNA2 promoter region into the secretory alkaline phosphatase 
(SEAP) reporter vector and confirm its activity in transfected human liver cells.
3. To determine the functionality of predicted NR binding sites by:-
a) Assessing the impact of their cognate ligands on human KPNA2 expression 
using the SEAP reporter gene assay.
b) Determining the affect of deleting and mutating putative NR binding sites.
c) Assessing NR-DNA interactions in vivo using the electromobility shift assay.
4. To assess the impact of altering KPNA2 levels on the subcellular localisation of 
specific cargos using a combination of RNA interference (RNAi), over-expression and 
fluorescence microscopy.
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2.0 Materials and Methods
2.1 Materials
2.1.1 General chemicals and materials
Table 2.1 shows the list of all the chemicals and materials used and their suppliers. 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (Dorset, UK) 
and were of molecular biology standard.
Item Supplier
Polymerase chain reaction (PCR) and Sub-cloning
PrimeSTAR™ HS DNA Polymerase Cambrex (Nottingham, UK)
Restriction enzymes, DNase I and buffers Promega (Southampton, UK), New 
England Biolabs (Hertfordshire, UK)
Agarose Fisher (Loughborough, UK)
DNA MightyMix (T4 Ligase) TaKaRa Bio Inc. (Otsu, Japan)
DH5a E.coli competent bacteria cells Produced in house (Jenny Spinks, 
University of Surrey)
Bacterial agar, Tryptone, Yeast extract Oxoid Ltd (Basingstoke, UK)
DNA oligomers for PCR Eurofins MWG Opérons (Ebersberg, 
Germany)
DNA purification (gel extraction, reaction 
cleanup, midi- and maxi-preparation)
Qiagen (Crawley, UK)
pCR®-Blunt II-Topo® and Zero Blunt® 
TOPO® PCR cloning kit
Invitrogen (Paisley, UK)
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Cell Culture
Dulbecco’s modified eagle medium 
(DMEM, 4.5 g/L glucose, L- glutamine and 
without sodium pyruvate), Trypsin-EDTA, 
Penicillin-streptomycin, Foetal bovine 
serum. Non-essential amino acids.
Invitrogen GIBCO (Paisley, UK)
FuGENE 6 and Lactate Dehydrogenase 
(LDH) kit
Roche (Lewes, UK)
Phospha-Light™ Secreted Alkaline 
Phosphatase Reporter Gene Assay System
Applied Biosystems (Foster City, LA, 
USA)
96 well Optiplates Perkin Elmer (Buckinghamshire, UK)
Cell culture flasks with vented lids 
(Nunclon)
Nalgene Nunc International (Roskilde, 
Denmark)
Electrophoretic Mobility S [lift Assay (EMSA) Analysis
LightShift Chemiluminescent EMSA Kit Pierce (Rockford, IL, USA)
Bis-acrylamide stock solution 2% w/v VWR (Lutterworth, UK)
Acrylamide stock solution 40% w/v VWR (Lutterworth, UK)
DNA oligomers and Biotin 3' end-labelled 
DNA target
Eurofins MWG Opérons (Ebersberg, 
Germany)
Positively charged nylon membrane Pierce (Rockford, IL, USA)
X-ray film Kodak (Rochester, NY, USA)
Electrophoresis and transfer apparatus Bio-Rad Laboratories, (Hertfordshire, UK)
Table 2-1 Suppliers of specialist materials used iii this work
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2.1.2 Plasmids
The plasmid maps used in this project are shown in the appendix. The pSEAP2-Basic 
reporter vector plasmid was purchased from Clontech (Mountain View, CA, USA). The 
Pregnane X receptor (PXR) plasmid was a kind gift from Dr. Steven Kliewer 
(GlaxoSmithKline, Research Triangle Park, NC, USA) whereas, peroxisome proliferator 
activated receptor alpha (PPARa) and the glucocorticoid receptor alpha (GRa) were 
courtesy of Dr. J. Tugwood (AstraZeneca, Macclesfield, UK).
2.2. Methods 
2.2.1 In silico Analysis
In silico analysis was undertaken to determine the position of the human KPNA2 
promoter and thereafter, identity transcription factor binding sites so that cognate ligands 
could be determined for each of them.
2.2.1.1 Determination of human KPNA2 promoter position
The human (NM 002266), rat (NM 053483), and cow (NM 001034449) gene sequence of 
karyopherin «2 was obtained from the National Centre of Biotechnology Information 
(NCBI) Genbank database website (http://www.ncbi.nlm.nih.sov/index.shtml) and a 
sequence of 20kb upstream of and including the first exon was determined for each 
species. The 20kb sequence was then compared between these three species to search for 
homology using VISTA Software (http://senome.lbl.sov/vista/index.shtml).
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2.2.1.2 Determination of transcription factor binding sites in the human 
KPNA2 promoter
In silico analysis of the putative human KPNA2 promoter sequence using Mat Inspector 
('www.genomatix.de: Cartharius, 2005) was undertaken to determine putative 
transcription binding sites. Thereafter, the cognate ligands for each putative transcription 
factor were identified through literature searching.
2.2.2 Polymerase chain reaction (PCR)
Once the position of the putative human KPNA2 promoter had been identified, PCR was 
carried out to amplify the region of interest from human genomic DNA. This was 
achieved using unique primers so that the target sequence could be cloned into an 
expression vector.
2.2.2.1 Primer design
The human KPNA2 promoter sequence was imported into Vector NTI 4.0 (Invitrogen, 
Paisley, UK). The parameters for primer design were set at 40-60% GC content, a T,n of 
50°C to 60°C and a length of 20 to 25 nucleotides. Two sets of primers were designed for 
a nested PCR reaction (Table 2.2). In the second set of primers, a double mismatch 
mutation was added to produce an Acc65 I restriction site (GGTACC) into the forward 
primer (-2459F) and a Hind III restriction site (AAGCTT) into the reverse primer (-77R). 
The primers used are shown in Table 2.1. Upon receipt, lyophilised primers were 
resuspended in O.IX Tris-EDTA (TE; 1 niM Tris pH 8, 0.1 mM EDTA) buffer to a stock 
concentration of 100 pmol/pl and stored at -20°C.
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Position (human 
KPNA2 sequence; 
bases)
Forward /Reverse Predicted Tm (“C) Sequence
-2686 Forward 62.4 5’ GGAGTTTCGCTCTTGTTGTCCAG 3’
+162 Reverse 61.4 5’ CAGCCGCCTGGTCAATGAAC 3’
-2459 Forward 65.8 5’ GTGGTCTGGGTACCTCAGCCT 3’
-77 Reverse 62.1 5’ CGTTCAAAGCTTCCACCTCGAC 3’
Table 2.2: Primer pairs and sequences used for amplifying the human KFNA2 promoter region.
Letters in underlined, bold type indicate restriction sites generated (GGTACC is an Acc65  I restriction site 
and AAGCTT is a H ind  III restriction site) in the sequence.
2.2.2.2 Performing the polymerase chain reaction
PCR was carried out to isolate and exponentially amplify the human KPNA2 promoter 
sequence using a high fidelity polymerase called Prime STAR (Cambrex, Wokingham, 
UK) to reduce the number of mutations caused by PCR. Volumes used for a typical 50 pi 
PCR are shown in table 2.3.
Reagents Volume (pi) (Total = 50 pi) Working Concentration
Prime STAR buffer (5x) 10 Ix
dNTPs (2.5 mM each) 4 200 pM
Primers (10 pmol/pl each) 1.25 (1:1 primer pair mix) 0.25 pM each
Human genomic DNA (stock o f 25 ng/pl) 4 2 ng/pi
Prime STAR Polymerase (2.5 U/pl) 0.5 1.25 U
Water (MilliQ) 30.25 Make up to 50 pi
Table 2.3: Volumes used in PCR using Prime STAR polymerase
The PCR reactions were carried out in a PTC-200 Gradient Thermal Cycler (MJ 
Research, Waltham, MA, USA). Reactions were heated to 94°C for 1 minute (pre-cycle) 
followed by 10 cycles at 98°C for 10 seconds, 60°C for 5 seconds, 68°C for 3 minutes. 25 
cycles as above were carried out, in addition to 10 seconds per cycle in the elongation 
phase and finally 68°C for 5 minutes. Nested PCR is a modification of the basic PCR 
technique, in that two sets of primers (instead of one pair) are used in two sequential
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rounds of amplifications to produce very specific fragment. The intention of using the 
nested PCR method is to reduce the contaminations in the end-product due to non­
specific primer binding to incorrect regions of the DNA (Figure 2.1).
Target DNA
[Template
-2686 F > First PCR
Template from 
first PCR
I I 
-2459 F -77 RI I
1^651  ^ y Second PCR________________Second PCR
final product 
H/ndiii containing the 
target DNA
First set of primers 
I I Second set of primers
Figure 2.1: Schematic diagram of a nested PCR process
Firstly, human genomic DNA was used as a template and was hybridised to the first set of primers shown 
in green (-2686 F and +162 R). The produet generated from the first PCR was subjected to a seeond PCR. 
using a second set of primers in yellow (-2459 F and -77 R) containing Acc65 I and Hind  III restriction 
sites respectively. The second set o f primers was ‘nested’ within the first PCR product to produce a highly 
specific end product containing the target DNA sequenee. This process reduces non-specific amplification 
and ensures no contaminations in the end-product.
2.2.2.3 DNA agarose gel electrophoresis
PCR end products were analysed by agarose gel electrophoresis. A 1% agarose gel (w/v) 
made in IX TAE (0.04 M Tris acetate pH 8, 0.01 M EDTA) containing 0.5 pg/ml 
ethidium bromide, was used to separate 2 pi reaction products. Products were mixed with 
3 pi of 5X Orange G loading dye (0.25% Orange G, 50% glycerol) and 7 pi of IX TE to
62
increase the volume so that samples were easy to manipulate. Electrophoresis was 
carried out at 4-5 V/cm until % of the gel length or until sufficient separation was 
achieved. The bands were visualised under UV light using the Gene Genius Bio Imaging 
System camera and software (GeneSnap, Syngene, Frederick, USA) and images were 
taken. The products were compared to appropriate molecular weight markers.
2.2.3 DNA cloning techniques
2.2.3.1 Restriction endonuclease digestion
The purified PCR product along with the pSEAP2-Basic reporter vector was subjected to 
restriction endonuclease (RE) digestion with the RE sites (Acc65 I and Hind III) mutated 
in the primers to produce compatible ends for ligation. Restriction digest reaction 
mixtures were prepared according to Table 2.4 and were incubated at 37°C overnight.
Reagent
PCR product pSEAP2-Basic 
reporter vector
Volume (pi) Volume (pi)
Buffer (lOX) 4 2
Acc651 (10 U/pl)» 2 0.7
77W m i(10U /p l)» 2 0.7
DNA lO(lOpg) 0.5 (1 pg)
Sterile water (MilliQ) 22 16.1
Total volume 40 20
Table 2.4: Restriction digests of nested PCR product and pSEAP2-Basic.
* Total amount o f enzymes were not more than Vio of the final volume.
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2.2.3.2 Déphosphorylation of vector using alkaline phosphatase
The linearised pSEAP2-Basic reporter vector was subjected to 5’ dephosphorylation 
using alkaline phosphatase. This prevents re-circularisation and re-ligation of linearised 
reporter vector. Briefly, 2 pi of alkaline phosphatase buffer (lOX) and 1 unit of alkaline 
phosphatase were added to the pSEAP2-Basic digest, which was incubated at 37°C for 30 
minutes. More alkaline phosphatase (1 unit) was added and the incubation repeated.
2.2.3.2 Purification of DNA from enzymatic reactions
Polymerase chain reaction products and DNA fragments generated by restriction 
digestion were purified by one of three methods, as described below.
2.2.3.2.1 Clean-up of digested PCR product and pSEAP2-Basic reporter 
vector
The digested PCR product and linearised pSEAP2-Basic reporter vector were purified 
from enzymatic reactions using the MinEliite Reaction Cleanup Kit (Qiagen), according 
to the manufacturer’s instructions, or by phenol:chloroform extraction and ethanol 
precipitation (section 2.2.3.3.3). The kit is designed to purify DNA from all enzymatic 
reactions. Briefly, 300 pi of buffer ERC was added to the enzymatic reaction and mixed. 
The mixture was placed in a column with a built-in silica membrane that binds DNA and 
the column was spun at 13,000 rpm for 1 minute. Excess salts were removed by adding 
750 pi of buffer PE and centrifuging for 1 minute at 13,000 rpm. Finally, the DNA was 
eluted with 10 pi EB buffer.
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2.2.3.2.2 DNA purification from agarose gels
The DNA band corresponding to the correct size was gel-purified using the MinElute® 
Gel Extraction Kit (Qiagen, Crawley, UK) according to manufacturer’s instructions. The 
reaction containing the DNA of interest (PCR or restriction digest) was mixed with an 
appropriate volume of 5X Orange G loading dye and separated on a 1% agarose gel 
containing 10 pg/ml ciystal violet (w/v) in IX TAE. The desired band was excised using 
a sterile scalpel and heated to 50°C in buffer QG (solubilisation buffer) to dissolve the 
gel. QG buffer contains guanidine thiocyanate, a powerful protein dénaturant. The 
solution was then passed through an affinity column containing a silica membrane for 
binding of DNA in high-salt buffer. Traces of agarose were removed by washing with 
buffer QG and by centrifugation. Removal of salts was carried out by washing the 
column with buffer PE containing 96-100% ethanol, and purified DNA was eluted from 
the silica membrane under basic conditions using a low salt buffer (10 pi of Buffer EB; 
10 mM Tris-Cl, pH 8.5).
2.2.3.2.3 Phenol; chloroform extraction and ethanol precipitation
Phenol : chloroform extraction is a method used to remove proteins, enzymes, buffers and 
other contaminants from DNA, which is then precipitated with ethanol. The volume of 
DNA solution (e.g. PCR product or restriction digest) was brought up to 100 pi with IX 
TE buffer. An equal volume of phenolxhloroform (1:1 v/v, pH 7.5) was added and 
vortexed until a white solution was obtained. The sample was then centrifuged at 13,000 
rpm for 5 minutes in a microfuge. The upper aqueous phase, containing the nucleic acids, 
was removed from the interface and organic phases and three volumes of ice-cold 100% 
ethanol, 0.1 volumes 3 M sodium acetate (NaOAc; pH 5.2) and 1 pi of tRNA (10 mg/ml) 
were added to the aqueous layer. This was centrifuged for 15 minutes at 13000 rpm 
before the supernatant was removed. The resultant pellet was washed with 200 pi of 70% 
ethanol. Following the second centrifugation at 13,000 rpm for 5 minutes, the supernatant 
was removed and the pellet was left to air dry at room temperature for 10 minutes before 
being resuspended in 10 m M  Tris, pH  8. Extraction products were examined by
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visualization on a 1 % agarose gel containing ethidium bromide as described in section 
2.2.2.3. The DNA was stored at -20°C until further use.
2.2.3.3 Ligation
The purified PCR insert after RE digestion was cloned into the pSEAP2-Basic reporter 
vector. Prior to ligation, an equal volume of the insert and vector solutions were separated 
on a 1% agarose gel with ethidium bromide (section 2.2.2.3) to assess the relative 
intensity of each product to determine the suitable ratio for ligation. Approximately 25 ng 
of linearised and dephosphorylated pSEAP2-Basic vector was mixed with an 8-fold 
molar excess of the KPNA2 promoter fragment and an equal volume of DNA Ligation 
Mighty Mix (TaKaRa Bio Inc, Otsu, Japan). A vector control was included where sterile 
water replaced the insert volume. The samples were incubated at 16°C for 1 hour before 
being stored at -20°C.
2.2.3.4 Transformation of bacteria
The ligated plasmid was transformed into a competent E.coli strain, DH5a. These 
bacterial cells contain a recAl mutation that reduces the occurrence of unwanted 
recombinations of cloned DNA. In addition, it also contains an endAl mutation that 
eliminates non-specific digestion by endonucleases. Due to these properties, the 
competent DH5a strain is a suitable candidate for transformation of plasmid DNA, 
Competent DH5a cells were stored in 50 pi aliquots at -80°C and defrosted on ice. Four 
microlitres (not more than 1/10 of total volume of cells) of ligation product was added to 
an aliquot of competent E. coli DH5a cells, incubated on ice for 30 minutes and heat 
shocked at 42°C for 45 seconds. Five hundred microlitres of LB broth (0.17 M NaCl, 
0.5% yeast extract and 1% tryptone) was added and incubated for 1 hour at 37°C in a 
shaker at 200 rpm. The cells were spun at 7000 rpm for 2 minutes and 400 pi of LB 
broth was removed and the pellet was resuspended in the remaining 100 pi of medium. 
This suspension was spread on an LB agar (LB broth plus 1.5% bacto-agar) plate
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containing ampicillin (50 |ig/ml) and grown overnight at 37°C. Following incubation, 
single colonies were selected and grown separately in 5 ml LB broth supplemented with 
50 pg/ml ampicillin, at 37°C overnight with shaking.
2.2.3.5 Rapid selection of recombinant plasmids
Prior to mini-preparation, the overnight cultures were screened for presence of insert. 
Screening was achieved by adding 60 p,l of culture medium to 60 pi phenolxhloroform 
(1:1, pH 7.5) and 10 pi of 5X Orange G loading dye. Samples were vortexed vigorously 
and centrifuged for 5 minutes at 13,000 rpm to separate the phase containing plasmids 
and all bacterial nucleic acids (top layer) from the bottom layer containing proteins. 
Twenty microlitres of the top layer was run on a 1% agarose gel with ethidium bromide 
along with uncut parent vector (without inserted DNA) as a control, and a molecular 
weight marker.
2.2.3.6 Mini-preparation of plasmid DNA
Plasmid DNA confirmed to contain an insert was isolated from the bacterial culture using 
an alkaline lysis method. Briefly, cells were centrifuged into a pellet and resuspended in 
100 pi of 50 niM Tris-HCl, pH8; 10 mM EDTA and 100 pg/ml RNase A, and then lysed 
under alkaline conditions (200 pi of 200 mM NaOH, 1% SDS (w/v)). The cell debris was 
then precipitated using 150 pi of 3.0 M potassium acetate, pH 5.5 and the supernatant 
was retrieved. Ethanol (800 pi) was then used to precipitate the DNA from the 
supernatant and the supernatant was removed. The DNA was rinsed with 70% ethanol 
and resuspended in Ix TE buffer. Restriction digestion was used to verify the correct 
DNA fragment had been ligated into the vector (Section 2.2.3.1 and 2.2.2.3).
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2.2.3.T Endotoxin-free preparation of plasmid DNA
The purpose of endotoxin-free preparation is to produce large quantities of highly pure 
DNA that is suitable for transfection into mammalian cell lines. Isolation of DNA from 
bacteria can result in endotoxin (e.g. lipopolysacharride) contamination, which 
significantly reduces transfection efficiency in sensitive eukaryotic cells such as Huh? 
cells. Endotoxin-free DNA preparation includes a step that minimises endotoxin 
contamination, thus increasing transfection efficiency. A single bacterial colony (or 50 pi 
of a 5 ml overnight culture) was used to inoculate 100-250 ml LB broth containing 50 
pg/ml ampicillin. This culture was incubated at 37°C overnight with shaking (-300 rpm). 
Plasmids were then isolated using the Qiagen endotoxin-free midi- or maxi-preparation 
kit (100 ml or 250 ml culture respectively). This method is based on a modified alkaline 
lysis procedure, followed by binding of plasmid DNA to an anion-exchange resin.
The culture was centrifuged at 6000 xg for 15 minutes at 4°C to harvest the bacterial 
cells. For a midi-preparation, the bacterial pellet was resuspended in 5 ml of Buffer PI 
(with RNase A) and vortexed until no cell clumps remained. Five millilitres of buffer P2 
(lysis buffer; sodium dodecyl sulphate and sodium hydroxide) was added and mixed 
gently but thoroughly by inverting 6 times and the mixture was incubated at room 
temperature for 2-5 minutes. Chilled buffer P3 was added to the lysate and mixed 
immediately but gently by inverting 6 times. The mixture was poured immediately into 
the barrel of the QIAfilter cartridge and incubated at room temperature for 10 minutes. 
Then, the cell lysate was filtered into a 50 ml tube and 1/10 volume of endotoxin removal 
buffer ER was added to the filtered lysate, inverted 10 times and incubated on ice for 1 
hour. A QIAGEN-tip 100 was equilibrated by applying buffer QBT and the lysate was 
applied and allowed to enter the resin in the column by gravity flow. The column was 
washed twice with 12 ml buffer QC (medium-salt wash) to remove all contaminants, 
carbohydrates and impurities from the plasmid preparations. The plasmid DNA was 
eluted from the resin with 5 ml of buffer QN, and precipitated and desalted by adding 0.7 
volumes of room temperature isopropanol. The mixture was mixed and centrifuged at 
13,000 rpm for 15 minutes at 4®C. The supernatant was decanted carefully without
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disturbing the pellet and the pellet was washed with 3 ml of endotoxin-free room 
temperature 70% ethanol, and centrifuged at 13,000 rpm for 5 minutes. Lastly, the pellet 
was air dried for 10 minutes and redissolved in a suitable volume of endotoxin-free IX 
TE buffer.
2.2.3.S Measurement of DNA concentration and purity
Plasmid DNA concentration was measured using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Montchanin, USA.) The ratio of 
absorbance at 260/280 nm was the primary measure of purity. A 260/280 ratio of 1.8-2.0 
and 260/230 ratio of -2.0 was accepted as pure for DNA solutions (Nanodrop ND-1000 
Spectrophotometer V3.0.1 User Manual). Final, the integrity of the plasmid DNA was 
confirmed by restriction digestion: 1 pg of DNA was digested in a 15 pi volume as 
outlined in section 2.2.3.1 and the resulting fragments were separated by gel 
electrophoresis and compared to the predicted digestion pattern generated in Vector NTI 
4.0.
2.2.3.9 DNA sequencing
The fidelity of all constructs used in this study was confirmed with sequencing, by 
sending plasmid DNA to GATC Biotech (Konstanz, Germany). Three sets of primers 
were used for the sequencing reactions for each plasmid (Table 2.5). Sequence identity to 
the target sequence was compared and confirmed using the basic local alignment search 
tool (BLAST) algorithm ( www .neb i.nlm. nih. gov/BL A ST : (Altschul et al. 1990).
Primers Sequence (5’ - 3 ’)
SEA? 5’ CTAGCAAAATAGGCTGTCCC
SEA P3’ CCTCGGCTGCCTCGCGGTTCC
SOObp TFSS forward CAAAAGAAATGTGTATCGGATCTCC
Table 2.5: Primers used for sequencing.
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2.2.3.10 Promoter deletions series
To identity regions for transcription factor binding within the human KPNA2 promoter, a 
series of deletion fragments of the promoter were generated and cloned into pSEAP2- 
Basic vector as described for the original full length clone. As shown in figure 2.2, the 
aim of these deletions was to produce a series of fragments of the human KPNA2 
promoter in which each nuclear receptor binding site was sequentially removed. To 
achieve these fragments, primers were designed between each NR binding site and the 
next. For all the fragments, the antisense primer containing the restriction site for Hind III 
(AAGCTT) was the same primer used in the previous PGR reaction (-77R primer; section 
2.2.2). Each sense primer was unique, but all contained an Acc65 I restriction site. For 
the antioxidant response element (ARE) deletion fragment (fragment 7, AARE), a 
different antisense primer was used since the AARE sense and -77R anti sense primers 
were incompatible. The list of primers used for this deletion series is shown in table 2.6. 
For the generation of fragment 6 (APPAR and HNF4), the presence of an endogenous 
M u  I restriction site in the appropriate location enabled this clone to be generated 
without PGR.
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PXR/PPAR a
PR RORa GR HNF4/PPA R a ARE HNF4
VDR,-2.6kb
-1.67kbAVDR
-1.55kbAPR
-1 48kbARO R a
-1.32kbAPXR and PPARa
-0.98kbAGR
-0.88kbA HN F4 and PPARa
SEAP I-0.48kbAARE
Figure 2.2 Sequential deletion series of the human KPNA2 promoter
Fragment Forward/Reverse Primer Sequence (S’ to 3’)
AVDR Forward GGATCTGGTACCTGCAAACCTTC
APR Forward GCTGCITTGGTACCTCCAACCAG
ARORa Forward CTGCCCCGGTACCATTCTCAG
APXR and PPARa Forward GGCATTGGTACCTGCAAAAATGG
AGR Forward CTTAGGAGAGGTACCGTGAAACAGAG
-77R antisense Reverse CGTTCAA AG CTTCC ACCTCG AC
AARE Forward GCTGCAGGTACCACACGGTCTTTG
ARE antisense Reverse CAAGCCAAAGATCTGGAAGTTGCCC
Table 2.6: Primers sequences for promoter deletion series
Letters in bold and underlined indicate restriction sites generated (GGTACC is an Acc65 I restriction site, 
AAGCTT is a H ind III restriction site and AGATCT is a Bg/ II restriction site)
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2.2.3.11 Site directed mutagenesis
Site directed mutagenesis is a powerful method most commonly used in molecular 
biology and biochemistry to study protein function, gene expression and vector 
modification (Hemsley et al. 1989). The aim of carrying out site directed mutagenesis in 
this study was to introduce specific mutations at the putative NR binding sites through 
PCR, thus ablating the binding site without destroying or altering the rest of the human 
KPNA2 promoter. Therefore, this method is more precise than promoter deletions, 
enabling more specific and defined effects to be observed.
Two sets of primers were designed for each mutation: for each set, one primer was 
designed within the promoter region and the other within the pSEAP2-Basic reporter 
region (see table 2.6 and 2.7 for list of primer sequences). The first set of primers was 
designed to amplify the fragment downstream and including the binding site of interest 
on the human KPNA2 promoter. The second set of primers was designed to amplify the 
region upstream and including this site (Figure 2.3). Therefore, the sense primer of the 
downstream fragment is designed to overlap with the antisense primer of the upstream 
fragment. Crucially, these two primers are design to mutate the putative transcription 
factor binding site by converting it to the same unique restriction site. Therefore, once 
both fragments are amplified, they can be digested with the restriction enzyme and 
ligated so that resulting fragment contains the mutated sequence introduced by the 
restriction site (Figure 2.3). This fragment was used as a template for the second round of 
PCR to amplify the desired mutant KPNA2 promoter, which was then digested with 
Acc651 and Hind III and cloned into the pSEAP2-Basic reporter vector.
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Vector region hKPNA2 promoter Vector region
1 .
Restriction enzyme siteluuuuuu 2.i PCR
I Digest and Ligate
PCR using it as a template
Clone into pSEAP2-Basic reporter vector
Figure 2.3 General schematic for generation of site directed mutagenesis constructs
Two overlapping complementary primers (1 and 2) were designed into which nucleotide mismatches were 
introduced to simultaneously mutate the transcription factor binding site of interest and introduce a unique 
restriction site. Using appropriate primers designed against the flanking vector DNA, these two fragments 
were amplified and following restriction digestion, were ligated. The ligation product served as a template 
for a second round of PCR using nested primers designed within the vector region. The resulting promoter 
fragment was then cloned into the pSEAP2-Basic reporter vector.
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Construct Fragment Primer Sequence (5’ to 3 ’)
SDM PXR
1 CCTTTACTCGAGCTGGCTTTACGATGAATGGGTTTGTTTGCCGGATCAAGAGCTACCAAC
2 GCCAGCCCAAGCTACCATGATAAGTAAGGTAAAGCCAGCTCGAGTAAAGGGTTGG
SDM GR
1 GTAATCTTTTCTCGAGCAAAAAAATTGCTTCCAATGATGAGCACTTTTAAAGTTCTG
2 GAGA ACTT TAAAAGTGCTCATCATTGGGCAATTTTTTTGCTCGAGAAAAGATTAC
SDM PPARal
1 CCCTTTACTCGAGCTGGCTTTACGGATGATGCCCAGGGAGAGCTGTAG
2 GCCAGCCCAAGCTACCATGATAAGTAAGGTAAAGCCAGCTCGAGTAAAGGGTTG
SDM PPARa2
1 GGAAAACTCGAGTGATTCTGAAACGACAGTAAGAGAATTATGCAGTGCTG
2 GGCGTCAATACGGGATAATACGAATCACTCGAGTTTTCCTCTG
SDM ARE
1 GAATGCGGAACCGGTGGGAAATTTAAATCGGGTTTGTTTGCCGGATCAAGAGCTACCAAC
2 CGCTGTTGAGATCCAGTTCGATGTAACCCACGATTTAAATTTCCCACCGGTTCCGCATTCC
Nested
amplfication
Nested For GCCAGCCCAAGCTACCATGATAAGTAAG
Nested Rev GATGATGCCCAGGGAGAGCTGTAG
Table 2.7: Primers sequences for site directed mutagenesis mutants
Letters in underlined, bold text indicate restriction sites generated (CTCGAG is a Xho 1 restriction site, 
ACCGGT is an Age 1 restriction site).
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2.2.4 Cell based techniques
2.2.4.1 Huh? cell culture conditions
The human hepatoma (Huh?) cell line is a differentiated immortalised cell line from 
human hepatoma tissue (a kind gift from Dr Steve Hood, GlaxoSmithKline, Ware, UK; 
(Nakabayashi et al. 1982). Huh? cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; 4.5 g/L glucose, with L- glutamine, without sodium pyruvate and with 
phenol red) supplemented with 10% foetal bovine serum (FBS), 1% (v/v) non-essential 
amino acids (NEAA) and penicillin/streptomycin (10 U/ml penicillin and 10 pg/ml 
streptomycin) in 75cm^ flasks with vented lids. Cells were incubated at 37^C in the 
presence of 5% CO2. Cells were only used until passage 2 0 , as cells are liable to de­
differentiate and change phenotype if passaged excessively (Phillips, 2004).
When Huh? cells reached 80% confluency, they were subcultured by tiypsinisation. 
Complete medium was removed by aspiration and cells were washed with 10 ml sterile 
phosphate buffered saline (PBS) before the addition of 3 ml IX PBS-trypsin-EDTA 
(PET). The flask was gently rocked to ensure even coverage with the protease. 
Approximately 2ml of PET was aspirated and the flask was incubated at 37®C for 5 
minutes or until cells had detached (as verified by microscopy). Cells were detached by 
gently tapping the side of the flask and 9ml complete medium was added to inactivate the 
pro tease. Cell suspensions were mixed by pipetting and split at a ratio of between 4:1 and 
6:1 into new 75cm^ vented cell culture flasks containing 15 ml complete medium. 
Medium was refreshed every 2 to 3 days with 15 ml of complete medium until cells 
reached approximately 80% confluence.
2.2.4.2 Storage and recovery of Huh? cells in liquid nitrogen
In order to maintain a constant stock of cells and for long term storage, cells were stored 
in liquid nitrogen. When Huh? cells reached 90% confluency, they were washed with 
PBS, trypsiiiised and transferred to a sterile 50ml tube. The mixture was centrifuged for 5
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minutes at 1300 xg. The supernatant was aspirated without disturbing the pellet. The 
pellet was then resuspended in 90% FBS and 10% DMSO to a final concentration of 
-1x10^ cells/ml and aliquoted into cryovials. The cryovials were then incubated on ice 
for 30 minutes and slowly frozen at -80°C overnight before storing in liquid nitrogen. For 
recovery, cryovials were thawed at 37°C for 5 minutes and cells were transferred into a 
50 ml tube containing 20 ml of warm complete medium. The cells were pelleted by 
centrifugation at 1300 xg for 5 minutes. The pellet was then resuspended in 10 ml of 
warm complete medium and finally transferred to a 25 cm  ^vented tissue culture flask and 
incubated at 37°C with 5% CO2. Complete medium was replaced after 24 hours to 
remove any non-adherent cells and final traces of DMSO.
2.2.4.3 Cell counting
Once cells had reached approximately 90% confluency in tissue culture flasks, they were 
washed and trypsiiiised as described in section 2.2.4.1 and resuspended in 10 ml complete 
medium. Cells were then counted using an improved neubauer haemocytometer. The 
haemocytometer was covered with a glass slip and ~ 8  pi of cell suspension were applied 
at the edge of the cover slip until the surface was covered completely by capillary flow. 
Huh7 cells were counted manually and an average of two squares was taken. The value 
was then multiplied by 10"^  and the concentration was adjusted to IxlO^cells/ml.
2.2.5 Transient transfection of Huh? cells
Once DNA had been cloned into the secretory alkaline phosphatase (SEAP) reporter 
vector, the constuct was transfected into Huh7 cells. Active promoters were then analysed 
by measuring SEAP activity.
2.2.5.1 Plasmids
The plasmids used for transfection included the pSEAP2-Basic reporter acting as a 
negative control, in addition to all the human KPNA2 promoter clones generated as
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described above. Expression plasmids for ligand activated NRs (VDR- PBF6A^5-VDR, 
PXR- pSG5-PXR, GRa- pSG5-GRa, and PPARa- pCR3-PPARa) were used for co­
transfection assays.
2.2.5.2 Transfection
Huh? cells (passage <20 and 80%-90% confluent) were washed and trypsiiiised as 
described in section 2.2.4.1 and were plated at a concentration of 2 x 10"^  cells/well (200 
pi) in a 96-well plate. Cells were incubated in a humidified chamber at 37°C with 5% 
CO2 for 24 hours to allow attachment.
After 24 hours, when cells were at 80% confluence, DNA transfection into cells took 
place using FuGene 6  transfection reagent (Roche Diagnostics Ltd., Lewes, UK). 
FuGene 6  is a multi-component lipid-based transfection reagent that complexes with 
plasmid DNA and enables it to enter into cells (Feigner et al. 1987), In order for the lipid- 
DNA complex to interact with, and pass through the negatively charged cell membrane, a 
net positive charge must exist in the lipid-DNA complex. Therefore the positive charge 
contributed by the cationic lipid must exceed the negative charge of the DNA. A charge 
ratio of 3:1 FuGene: DNA was previously found to be optimal (El-Sankary et al. 2001; 
Aouabdi et al. 2006), so appropriate volumes were added to serum free medium 
according to the FuGene protocol (25 ng/well of DNA). Briefly, 25 ng/well of the 
pSEAP plasmid (pSEAP2-Basic or KPNA2 promoter clone) was mixed with 25 ng/well 
of expression plasmids for ligand activated NRs. A master mix containing 0.15 pl/well of 
FuGene 6  in 10 pl/well serum free media was incubated for 2 minutes at room 
temperature before being added to the DNA. The transfection solution was then 
incubated at room temperature for 30 minutes. Medium was aspirated from the each well 
and replaced with complete medium ( 1 0 0  pi per well) to which had been added the 
FuGene: DNA complex. The plate was incubated at 37°C with 5% CO2 in a humidified 
chamber for 24 hours.
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2.2.S.3 Treatment of Huh? cells with xenobiotics
At 24 hours post-transfection, the medium was removed and replaced with medium 
containing either the xenobiotics, oxidative stress inducers, or the 0 .1% vehicle control. 
Xenobiotic stock solutions were made at lOOOX their maximum working concentration in 
vehicle solution and were then diluted in stripped serum medium to their working 
concentrations, such that for all doses, the vehicle concentration was 0.1%. Cells were 
incubated with the xenobiotic for 48 hours at 37°C with 5% CO2. Medium from before 
and after the exposure to xenobiotics were stored at -20°C for later SEAP analysis. Post­
dose medium was also analysed for indications of cell death by measuring the release of 
lactate dehydrogenase (LDH) from cells.
2.2,6 Cell assays
Since transcription of the SEAP reporter gene is under the control of the inserted 
promoter, by measuring SEAP activity it was possible to infer KPNA2 promoter activity. 
Expressed SEAP protein contains a secretory tag, and hence the tag can be quantified 
when secreted from cells into the medium. Dephosphoiylation of a substrate by SEAP 
generated emitted light that can be measured at 477 nm and is directly proportional to the 
activation of the promoter. This measure therefore acts as an indicator of activation or 
inhibition of expression of human KPNA2 gene expression.
2.2.6.1 Secretory alkaline phophatase (SEAP) assay
Secretoiy alkaline phosphatase activity was measured using the Tropix® Phospha- 
Light^*^ System-Chemiluminescent Reporter Gene Assay Kit (Applied Biosystems, 
Bedford, Massachusetts, USA). Endogenous alkaline phosphatase activity was firstly 
eliminated by heating 25 pi of medium with 75 pi Ix dilution buffer in 96-211 optiplates 
(polystyrene microplates) to 65°C for 30 minutes. Since SEAP is heat stable, the only 
remaining alkaline phosphatase activity is that generated by the reporter plasmid.
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Following rapid cooling on ice for 5 minutes and equilibration to room temperature for 
10 minutes, a 25 pi aliquot of diluted medium was added to 25 pi of assay buffer and 
incubated at room temperature for 5 minutes. Twenty five microlitres of reaction buffer 
(1 CSPD® substrate: 20 reaction diluent) was then added and incubated for 20 minutes at 
room temperature. Chemiluminescence was detected in a Lumicount II plate reader using 
Plate Reader Version 2.10 software (Packard Instrument Co. Inc., Ramsey, MN, USA) 
with optimal gain and photomultiplier settings automatically determined by the software.
2.2.6.2 Data analysis and statistics.
For SEAP assays, the ‘post-dose’ data was normalised using the ‘pre-dose’ data to 
control for transfection efficiency in individual wells. Results were analysed for statistical 
significance using one-way analysis of variance (ANOVA) with Bonferroni all-means 
post hoc test (GraphPad Prism Software version 4.0, San Diego, CA, USA). Values are 
expressed as the mean ± standard error of the mean (S.E.M.) derived from replicate data 
as specified for each experiment in the Results section. Readings are similar from 
experiment to experiment and any variations in basal readings are corrected for by 
normalisation.
2.2.6.3 Assessment of cell death using the lactate dehydrogenase (LDH) 
assay
The cytotoxic potential of xenobiotics was determined using the LDH Cytotoxicity 
Detection kit (Roche Diagnostics Ltd., Lewes, UK); a colorimetric assay for 
quantification of LDH release from damaged or dying cells. Briefly, medium was taken 
from cells treated with xenobiotics and the amount of LDH released was quantified in the 
medium in order to assess the level of cell death under specified conditions. Medium 
from treated cells was added to an equal volume of the reaction mixture (1:45; bottle 1 
(catalyst): bottle 2 (dye solution)) in a 96-well plate and left, protected from light, at
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room temperature for 30 minutes. The plate was then read at 490 nm in an ELISA plate 
reader (BioTEK ELxSOO). Results are expressed as percentage of cell viability and 
compared to a vehicle control group expressed as 1 0 0 % cell viability, and cells lysed in 
1% triton-XlOO as 0% cell viability.
2.2.7 Electrophoretic mobility shift assay (EMSA)
To confirm the functionality of putative NR binding sites within the human KPNA2 gene 
promoter and to begin characterising the factors that bind to these sites, specific sites 
were analysed by the electrophoretic mobility shift assay (EMSA). This technique, also 
known as the gel retardation assay, band or gel shift assay, is a common technique used 
to investigate and characterise protein: nucleic acid interactions (Figure 2.4). Therefore, 
this method was used as an investigative tool to examine the functionality of the putative 
transcription factor binding sites. Briefly, biotin end-labelled oligomers containing the 
binding site of interest were incubated with a nuclear extract or purified factors. This 
reaction mixture was then subjected to gel electrophoresis on a native polyacrylamide gel 
and transferred to a positively-charged nylon membrane. The complex was detected using 
a streptavidin-horseradish peroxidase conjugate and a chemiluminescent substrate. 
Retardation of the migration of DNA through the gel indicates that a protein has bound.
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Figure 2.4: Schematic representation of electrophoretic mobility shift assay
EMSA is a method to examine protein:DNA interactions; complexes of protein and nucleic acids migrate 
through a native (non-denaturing) polyacrylamide gel more slowly than free nucleic acid fragments thus 
resulting in a band shift.
2.2.7.1 Biotin-labelled probe preparation
High purity and salt-free single stranded 3’-biotin labelled and unlabelled DNA 
oligomers along with exact complementary sequence were purchased from Eurofins 
MWG Opérons (Ebersberg, Germany; Table 2.8). Oligomer length was kept to a 
minimum in order to avoid non-specific binding or binding of adjacent transcription 
factors. Single stranded oligomers were annealed in complementary pairs by mixing 1 
nmol of both forward and reverse strand in Ix annealing buffer (lOmM Tris HCl pH7.5, 
O.IM NaCl, ImM EDTA, 50pl total volume) followed by heating to 100°C for 5 minutes 
and cooling at the rate of 0.1 °C per second down to 22°C (room temperature). Negative 
controls containing only a single strand of either forward or reverse oligonucleotide were 
also performed. One micro litre of annealed product along with the control was run on a 
3% (w/v) agarose;sodium borate (lOmM Na2B4 0 ? and H3BO3) gel to ensure that the 
oligomers were annealed (Goedhart and Gadella Jr 2005).
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Oligomer Fom ard/Reverse Sequence (5’ to 3 ’)
PXR Forward CAACCTTTATGAACTCTGGCTTTAC-biotinReverse GTAAAGCCAGAGTTCATAAAGGGTTG
GR Forward AATTTTTTTGTGTTCTAAAAGATTAC-biotinReverse GTAATCTTTTAGAACACAAAAAAATT
PPARl Foiward CATCGTAAAGCCAGAGTTCATAAAGG-biotinReverse CCTTTATGAACTCTGGCTTTACGATG
PPAR2 Foiward GAAACAGAGGAAAAAGGACATGATTC-biotinReverse GAATCATGTCCTTTTTCCTCTGTTTC
ARE Foiivard TTCCCGGTGACTCCGCATTCCGA-biotinReverse TCGGAATGCGGAGTCACCGGGAA
SDMGR Forward AATTTTTTTGCTCGAGAAAAGATTAC-biotinReverse GTAATCTTTTCTCGAGCAAAAAAATT
SDM PPARl Foiward CATCGTAAAGCCAGCTCGAGTAAAGG-biotinReverse CCTTTACTCGAGCTGGCTTACGATG
SDM ARE Forward TTCCCACCGGTTCCGCATTCCGA-biotinReverse TCGGAATGCGGAACCGGTGGGAA
Positive control oligomers
CYP3A4-ER6
(PXR)
Forward TAGAATATGAACTCAAAGGAGGTCAGTGAGT-biotin
Reverse ACTCACTGACCTCCTTTGAGTTCATATTCTA
TAT-GRE Forward GACCCTAGAGGATCTGTACAGGATGTTCTAGAT-biotinReverse ATCTAGAACATCCTGTACAGATCCTCTAGGGTC
ACO-PPRE Forward CTTAGAACTAGAAGGTCACTGGTCAAGCAGCCATTTG-biotinReverse CAAATGGCTGCTTGACCAGTGACCTTCTAGTTCTAAG
hNQOl-ARE Forward CAGTCACAGTGACTCAGCAGAATCT-biotinReverse AGATTCTGCTGAGTCACTGTGACTG
Table 2.8: Oligomer sequences for the EMSA studies
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2.2.7.2 Nuclear protein extract preparation
Two types of nuclear protein extracts were used for this study: Nuclear proteins were 
extracted from naïve {i.e. untransfected) Huh7 cells and from cells transfected with PXR, 
GRa or PPARa expression plasmids. The method used for nuclear extraction was 
obtained from (Dignam et al. 1983). Huh7 cells that were 90% confluent were washed 
three times with PBS (10ml for a T75 flask), trypsinised to obtain a cell suspension and 
transferred to a 50ml tube. Cell pellets were obtained by centrifugation at 1300 xg for 5 
minutes and washed twice with PBS. The cell pellet was resuspended in 5 packed cell 
volumes (PCV, the volume of the cell pellet) of PBS, transferred to a 1.5ml eppendorf 
tube and spun at 1300 xg for 5 minutes. The supernatant was aspirated and the pellet was 
resuspended in 2xPCV of cold buffer A (10 mM Hepes-KOH, pH 7.9, 1.5 niM MgCl^, 10
mM KCl and 0.5 mM DTT) and left to swell for 10 minutes.
After swelling, the cells were disrupted using a sterile small Dounce homogeniser to 
obtain a homogenate. Another centrifugation at 2000 xg for 15 minutes was carried out. 
The pellet was resuspended in 0.5 volumes of ice cold buffer C (25 % glycerol, 20 mM 
Hepes-KOH, pH 7.9, 1.5 mM M gCy 0.2 mM EDTA, 20 mM NaCl, 0.5 mM DTT, 0.5
mM PMSF) and 0.5 packed nuclear volume (PNV; the difference between the initial 
volume and the volume of the supernatant) of high salt buffer C (buffer C containing 1.2 
M NaCl) was added dropwise and with swirling. The suspension was further 
homogenised using 10 strokes of sterile small Dounce homogeniser. The suspension was 
then centrifuged at 4°C for 30 minutes at 16,000 xg. The supernatant (nuclear proteins) 
was aliquoted and stored at -80°C and protein quantification was carried out.
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2.2.7.3 Preparation of PXR, GRa, PPARa proteins using a TNT® Quick 
Coupled Transcription and Translation System
In order to obtain individual NRs for EMSA studies, PXR, GRa and PPARa expression 
plasmids containing a T7 promoter were used in an in vitro coupled transcription and 
translation system (TNT® Quick Coupled Transcription and Translation System, 
Promega, Southampton, UK) according to the manufacturer’s protocol. Briefly, a 50pl 
reaction mixture (Table 2.9) was prepared in a 0.5ml micro centrifuge tube and gently 
mixed. The reaction mixture was incubated at 30°C for 90 minutes. The products of 
translation were analysed by SDS-PAGE and Coomassie staining (Section 2.2.7.5).
Components Volume (pi)
TNT® Quick master mix 40
ImM Methionine 1
Plasmid DNA template (0.5pg/pl) 0.5
TranscendBiotin-Lysyl-tRNA 1
Nuclease free water 7.5
Total volume 50
Table 2.9: TNT® Quick reaction components using Transcend^^ tRNA
2.2.7.4 Nuclear extract protein quantification
The quantity of protein in the nuclear extracts was measured using a modified Lowry 
assay (Lowry et al. 1951; Peterson 1977). Nuclear extracts were diluted in 0.5M NaOH to 
ratios of 1:20, 1:50, 1:100 and 1:200, and bovine serum albumin (BSA) standard 
solutions of 50, 100, 150, 200 and 250 pg/ml in 0.5 M sodium hydroxide were prepared. 
In a 96-well plate, 30 pl/well of diluted nuclear extract or each BSA standard was 
pipetted in triplicate and 150 pl/well of freshly prepared copper solution (0.61 mM 
C112SO45H2O, 0.7 niM potassium sodium tartrate, 185 mM Na2C0 3 ) was added, mixed
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and left at room temperature for 10 minutes. Fifteen microlitres per well of IX Folin- 
Ciocalteau reagent (diluted 1:1 in deionised water) was added to each sample and 
standard, and mixed thoroughly. The plate was incubated at room temperature for 2 hours 
before the absorbance was read at 490 nm in a Bio-Tek ElxSOO spectrophotometer. The 
protein concentration of the nuclear extract was determined by the software by comparing 
to the BSA standards. The acceptable range of the BSA standard curve is ~ >0.9.
2.2.7.S Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and Coomassie staining
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Coomassie staining were carried out to assess the integiity of the extracted nuclear 
proteins. A 12.5% resolving gel (12.5% acrylamide, 0.328% bisacrylamide, 0.375 M Tris 
HCl pH 8 .8 , 0.1% SDS, 0.1% ammonium persulphate, 0.01% TEMED) and a 6 % 
stacking gel (6 % acrylamide, 0.16% bisaciylamide, 0.125 M Tris-HCl pH 6 .8 , 0.1% SDS, 
0.1% ammonium persulphate, 0.02% TEMED) were used to separate nuclear protein 
samples. Before loading onto the gel, 20 pg of samples, as determined by Lowry, or 1 pi 
of the TNT reaction were mixed with an equal volume of loading dye (0.5 M Tris HCl 
pH 6 .8 , 10% SDS, 12% glycerol, 0.7 M (3-mecaptoethanol, 0.05% pyronin Y) and 
denatured by heating to 98°C for 5 minutes and placed on ice for 2 minutes. After being 
loaded onto the stacking gel the samples were separated at 300 niA, 200V for 
approximately 1 hour, until the dye front reached the end of the glass plates. After gel 
electrophoresis, the stacking gel was carefully removed and the gel was stained with 
Coomassie blue (0.25% Coomassie Blue R-250 in 40% methanol, 10% acetic acid) for 90 
minutes at room temperature with gentle rocking. The gel was destained overnight with 
gentle rocking using a destaining solution made of 40% methanol and 10% acetic acid in 
distilled water.
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2.2.T.6 Electrophoretic mobility shift assay (EMSA) binding reactions
For the EMSA binding reaction, a set of three reactions per binding site / protein 
combination was performed (biotinylated DNA only, biotinylated DNA plus protein 
(nuclear extract or TNT reaction), biotinylated DNA plus protein and unlabelled 
competitor DNA). A 20 pi binding reaction was prepared along with a positive control (a 
known target gene for each respective NR) according to Table 2.10 and the reactions 
were incubated at room temperature for 20 minutes. After incubation, 5 pi of 5X loading 
buffer (0 .0 2 % bromophenol blue) was added to each 2 0  pi binding reaction and mixed 
thoroughly.
Component
Reaction (pi)
#1 #2 #3 Positivecontrol
lOX Binding buffer 2 2 2 2
1 gg/gl Poly (dl.dC) 1 1 1 1
50% Glycerol 1 1 1 1
l% N P-40 1 I 1 1
100 mM MgCh 1 I 1 1
Unlabelled target DNA 
(20 pmol/ pi) - - 2 -
Nuclear protein extract (20 pg) or 
TNT reaction -
Volume containing 20 pg of nuclear protein 
or 1 pi of TNT reaction
Biotin end-labelled target DNA 
(100 fmol/ pi) 2 2 2 -
Biotin end-labelled positive 
control target DNA 
(100 fmol/ pi)
- - - 2
Nuclease free water To a final volume of 20 pi
Total Volume 20 20 20 20
Table 2.10: Sample of EMSA binding reactions
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2.2.7.7 Electrophoretic mobility shift assay (EMSA) native gel 
electrophoresis
A 6 % native (non-denaturing) polyacrylamide gel (Table 2.11) was prepared in 0.5X 
TBE (450 mM Tris, 450 mM Boric acid, 10 mM EDTA, pH8.3). The gel wells were 
flushed and pre-electrophoresed in 0.5X TBE for 45 minutes at lOOV. The gel wells 
were once again flushed and 25 pi of each EMSA binding reaction was loaded onto the 
gel. The samples were electrophoresed at 100 V until the bromophenol blue dye had 
migrated % of the length of gel.
Reagent (Stock concentration) Volume for 6% native gel (ml) Final concentration
5XTBE 1 0.5X
40% acrylamide 1.5 6%
2% bis-acrylamide 0.8 0.16%
100% Glycerol 0.25 2.5%
10% Ammonium persulphate 0.15 -
TEMED 0.01 -
MilliQ water 6.29 -
Total volume 10 ml -
Table 2.11: 6% Native polyacrylamide gel composition
2.2.7.8 Electrophoretic transfer of binding reaction to nylon membrane
Following gel electrophoresis, DNA and proteins were transferred to a nylon membrane. 
Biodyne® B positively charged nylon membrane (Pierce, Rockford, IE, USA), 6  blotting 
papers and 2 scotchbrite pads were cut to the size of the gel and soaked in 0.5X TBE for 
15 minutes. The gel and membrane was careMly sandwiched (Figure 2.5) in a clean 
electrophoretic transfer tank filled with cold 0.5X TBE. Transfer was carried out at 380 
niA (~100V) for 1 hour on ice. After transfer, the membrane was carefully removed and 
care was taken to make sure that the membrane did not dry. The membrane was then 
immediately cross-linked at 120 mJ.cm^ using a commercial UV-light cross-linker 
instrument with auto cross-link function. The instrument was equipped with 254 nm
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bulbs and exposure was for 1 minute. Care was taken to keep the membrane dry after 
cross-linking.
Red (positive)
Black (negative)
■> Clear top of cassette
-► Scotchbrite pad
-> 3 X blotting paper
-► Nylon membrane 
-► Gel
-> 3 X blotting paper
-► Scotchbrite pad
Black side of 
cassette
Figure 2.5: Assembly for electrophoretic transfer of binding reactions to nylon membrane
2.2.7.9 Detection of biotin-labelled DNA by chemiluminescence
After cross-linking the membrane, biotin-labelled DNA was detected using the 
Chemiluminescent nucleic acid detection module (Pierce, Rockford, IL, USA) according 
to manufacturer’s instructions. Briefly, blocking buffer and 4X wash buffer (supplied) 
were warmed to 37-50°C in a water bath to dissolve any precipitated particulates. To 
block the membrane, 10  ml/membrane of blocking buffer was added and incubated for 15 
minutes with gentle shaking. Blocking buffer was decanted and replaced with 10 
ml/membrane of conjugate/blocking solution (33.35 pi of stabilised streptavidin- 
horseradish peroxidase conjugate and 1 0ml blocking buffer) and incubated for 15 
minutes with gentle shaking. The membrane was then transferred to a new container and 
rinsed briefly with 20 ml/membrane of IX wash buffer. Washing was repeated 4 times 
for 5 minutes each time in 20 ml of IX wash buffer with gentle shaking.
The membrane was transferred to a new container and 20 ml/membrane of substrate 
equilibration buffer was added and incubated for 5 minutes with gentle shaking. The 
membrane was removed and carefully blotted from the edge on a paper towel to remove 
excess buffer. The membrane was transferred to a new container and 3ml/membrane of 
substrate working solution (1.5 ml Luminol/Enhancer solution and 1.5ml stable peroxide 
solution) was poured onto the membrane so that it completely covered the membrane 
surface. The membrane was removed from the working solution and the edge was blotted 
on a paper towel for 5 seconds. The moist membrane was carefully wrapped in a plastic 
wrap, avoiding bubbles and wrinkles. Finally, the membrane was exposed by placing it in 
an autoradiography cassette with X-ray film for between 10 seconds and 1 minute, 
depending on the intensity of desired signals.
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3.0 In silico analysis and initial in vitro characterisation of the human 
karyopherin «2 gene promoter
3.1 Introduction
Although it is clear that kaiyopherins play a central role in nuclear-cytoplasmic shuttling, 
and hence the transmission of NR-mediated signals, little work has been undertaken to 
study the transcriptional regulation of karyopherin genes themselves. Such regulation 
could be important as it may alter the capacity of cells to complete nuclear-cytoplasmic 
shuttling, and may therefore be a limiting factor for signal transduction. To date, the main 
studies in this area have been carried out by Plant et al., 2006, who demonstrated that 
certain xenobiotics increase the expression of Kpna in primary rat hepatocytes, and 
Kohler et al. (2003) who showed alterations in the levels of a specific human KPNA in 
response to a variety of stimuli. In the latter study, these stimuli, including phorbol esters 
and dexamethasone induced differentiation however, the significance of these alterations 
is not yet known.
Karyopherin a2 (KPNA2) is the most highly and broadly expressed member of the 
karyopherin a  family of nuclear transport adapter proteins and is thus of particular 
interest. The first step in investigating the regulation of human KPNA2 gene was to 
undertake an in silico analysis, identifying the putative human KPNA2 promoter and 
thereafter potential transcription factor binding sites within this region. A particular 
emphasis was made on the NR binding sites that may mediate the response to hormones 
and exogenous compounds. Whereas it is important to acknowledge that in silico analysis 
does not necessarily equate to biological function, it does provide a foundation for the 
planning of subsequent in vitro experimentations.
The complete sequencing of the human genome and its annotation within the GenBank 
database located at the NCBI (http://www.ncbi.nlm.nih.sovA provided the foundation for 
any sequence analysis. For regulatoiy region analysis, specific programme suites, such as
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VISTA and Matlnspector are of utility. The VISTA suite is a complete set of 
programmes and databases used for comparative analysis of genomic sequences (Frazer 
et al. 2004; Dubchak and Ryaboy 2006). The VISTA tools have been used in genetic 
studies (Taylor et al. 2003; Del Mastro et al. 2007); alternative splicing and gene families 
(Martinez and Amemiya 2002; Kleino et al. 2007); non-coding conservation; and 
regulatory sequences studies (Goode et al. 2003; Cleynen et al. 2007). Matlnspector uses 
a complementary approach to detect putative transcription factor binding sites, using a 
database of known binding sequences to form weight matrices for consensus binding sites 
(Quandt et al. 1995; Cartharius et al. 2005).
It is important to note that as with any in silico software, Matlnspector can only infer the 
binding potential and not the functionality of a site (Cartharius et al. 2005). Therefore, 
following in silico analysis, cloning of the human KPNA2 promoter into a reporter gene 
plasmid was undertaken to assess functionality in the presence of ligands for the 
predicted binding sites. This initial analysis was designed to identify potential leads for 
further investigations, which will be presented in subsequent chapters.
3.2 Determination of the human KPNA2 promoter position
The first step in determining the position of the human KPNA2 promoter is obtaining the 
karyopherin a2 gene from NCBI GenBank database from several different species, 
including human. The founding logic for this is that important regulatory regions such as 
promoters would be predicted to be conserved across species and therefore the 
identification of the promoter would be easier (Gumucio et al. 1996; Hardison et al.
1997). In order to select a suitable species, several factors were taken into consideration; 
firstly, the complete karyopherin a 2  gene sequence at the genomic level needed to be 
available in the NCBI database, along with at least 20 kb of 5’ flanking DNA. The 
species selected needed to be sufficiently close to humans that the functional sites might 
reasonably be expected to be conserved. However, if too closely related, insufficient 
evolutionary time will have elapsed to allow non-functional sites to diverge. For this 
reason, non-primate mammals were chosen, and of these, the rat and cattle/cow
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sequences, with estimated divergence of 40.7 MYa and 19.6 MYa respectively (Kumar 
and Hedges 1998), were available.
The human {Homo sapiens', NM 002266), rat (Rattus norvégiens', NM 053483) and 
cattle/cow {Bos taiirus; NM 001034449) karyopherin a2 gene sequences were obtained, 
including a sequence of 2 0 kb immediately upstream of and including the first exon (all 
first exons are non-coding; estimated at 109 nt in human and 103 nt in cow, incomplete 
cDNA sequence available in rat) were determined for each species. The 20kb sequence 
was aligned and sequence identity calculated between these three species using the 
mVISTA tool (http://genome.lbl.gov/vista/mvista/submit/shtmn. mVISTA is designed 
for comparison of orthologous sequences of different species, and provides rapid 
identification of conserved sequence in long alignments based on global alignment 
strategies and curve based visualisation (Dubchak et al. 2000; Mayor et al. 2000; Frazer 
et al. 2004; Dubchak and Ryaboy 2006). This programme aligns multiple sequences and 
plots sequence identity over a sliding window of predefined length. The programme also 
automatically identifies sequence motifs that will lead to overestimation of identity, 
namely repeat sequences such as short interspersed nuclear elements (SINE), long 
interspersed nuclear elements (LINE), long terminal repeats (LTR) and RNA repeats, and 
discards them from the analysis.
The 20kb sequence immediately upstream of and including the first exon of the human 
KPNA2 gene was selected as the reference sequence and aligned against the equivalent 
region in rat and cow. This VISTA plot obtained is shown in Figure 3.1; the x-axis of the 
plot represents the base sequence and the y-axis represents the percentage identity over a 
sliding 100 bp window. Locations of repeat sequences are identified above the plot; see 
figure legend for details. Within the 20kb region examined, two distinct regions of 
conservation were identified. The first region was approximately 15-16kb from the 
transcription start site of KPNA2, and corresponds to the location of the next upstream 
gene, identified as a transfer RNA (tRNA) gene by GeiiBank. The second region of 
significant identity covers the first 2 .6 kb of the examined sequence, which corresponds to 
exon 1 of KPNA2 plus approximately 2.5kb of upstream sequence. This region showed
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greater than 50% sequence identity between at least two of these three species. Notably, 
the human-cow alignment showed higher overall identity within the conserved region, 
which is to be expected given the differences in the evolutionary distance between human 
and cow, and human and rat. Since the proximal 2.6kb contains the region of highest 
identity, and is therefore likely to contain the majority of regulatory sequences. Tthese 
results suggest that the putative human KPNA2 promoter is located within this proximal 
region.
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Figure 3.1; VISTA plot showing the peaks of identity between the human sequence compared to 
the rat and cow sequences in the painvise sequence alignments.
Twenty kilobases immediately upstream of and including the first exon were aligned and percentage 
identity over a sliding window of 100 bp was plotted. Sequence position (horizontal axis) is relative to 
the splice site at the 3’ end of exon 1 whereas percentage identity (50%-100%) is indicated on the 
vertical axis; the higher tlie peak, the higher the percentage similarity. Peaks representing non-coding 
sequences (rose) fitting the criteria for conserved elements are indicated. Repeat sequences are shown 
directly above the plot (green; short interspersed nuclear element (SINE); red: long interspersed 
nuclear element (LINE); orange: DNA repeats; pink: long terminal repeats (LTR); purple: RNA 
repeats and yellow: other repeats.
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3.3 Determination of transcription factor binding sites in the human 
KPNA2 promoter
Once the most likely region of the human KPNA2 promoter had been identified, m silico 
analysis was carried out using Matlnspector (www.genomatix.de) to determine putative 
transcription binding sites within this region. The Matlnspector matrix search was first 
suggested by Quandt et al., and updated with new features in 2005 by Cartharius et al., so 
that the identification of putative transcription factor binding sites relies on the matrix 
similarities, which consider the frequency of each single nucleotide at each position 
within the response element (Quandt et al. 1995; Cartharius et al. 2005).
Putative transcription factor binding sites were identified using a high match setting with 
the core similarity at >0.85 and a matrix score at >0.75 in order to minimise the omittance 
of true positive sites or the identification of false positives sites. The core similarity is 
defined as the four consecutive highest conserved positions of the matrix, with a score of 
1.0 representing the maximum core similarity. Therefore, it describes the quality of 
match between the core sequence of a matrix and a part of the input sequence. Matrix 
similarity is the similarity over an expanded region, relating to the highest conserved 
nucleotide at that position in the match matrix, with a perfect match indicated as 1.0 
(Quandt et al. 1995; Cartharius et al. 2005). It should be noted that the matrix similarity is 
calculated only if the core similarity reaches the pre-defined threshold; 0.85 in this case.
In silico analysis of the putative 2.6kb human KPNA2 proximal promoter sequence 
obtained from mVISTA using the Matlnspector revealed 454 putative transcription factor 
binding sites; these were manually sorted and reviewed critically. Within the region 
immediately proximal to the putative transcription start site of human KPNA2 (based on 
the extent of the reported cDNA) there was a binding site for TBP (-25 relative to the 
TSS) as well as a number of GC-boxes (which bind to transcription factor SPl) within 
the region 100-400 bp upstream of the transcription start site (TSS). In order to identify 
sites important in liver regulation in response to xenobiotics, these sites were further 
sorted based upon two criteria. First, sites were of particular interest if they were known
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to belong to the NR (ligand-activated transcription factors) super-family. Second, sites 
were further refined by those with cognate transcription factors Icnown to be expressed in 
the liver. Following the screening procedure, nine putative NR binding sites were 
identified within the human KPNA2 promoter. These sites are presented in figure 3.2; 
numbering is relative to the 3’ end of exon 1 because from the information available in 
the database it was not clear where the TSS was situated. NR binding sites identified 
were for the vitamin D receptor (VDR), which is located at -1795 to -1819; the 
progesterone receptor (PR) situated at -1548 to -1566; the retinoid related orphan receptor 
a (RORa) at -1483 to -1501; a half-site of thr pregnane X receptor (PXR) at -1348 to - 
1358; two binding sites of the peroxisome proliferated activated receptor a (PPARa), - 
945 to -965 and -1337 to -1359 respectively; the glucocorticoid receptor a  (GRa) located 
at -1217 to -1235; and finally two binding sites for thr hepatic nuclear factor 4 (HNF4), - 
25 to -45 and -947 to -961. Each of these seven NRs, their ligands and known target 
genes are discussed in detail below.
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Nuclear Receptor
Core
Similarit}
Matrix
Similarity Consensus binding sites
VDR/RXR 1.00 0.863 AGGTCAnnnAGGTCA
PR 1.00 0.910 AGAACAnnnTGTTCT
ROR alpha 1.00 0.976 T/AA/TT/ACA/TA/GGGTCA
HNF4 0.952 0.856 DRl OF AGGTCA
PFARtt/RXR 0.807 0.717 AGGTCAnAGGTCA
Half site of PXR 1.00 0.984 AGTTCAnnnAGTTCA
GR 1.00 0.867 AGAACAnnnTGTTCT
PPARo/RXR 1.00 0.759 AGGTCAnAGGTCA
HNF4 0.7501.00
0.842
0.850 DRl OF AGGTCA
Figure 3.2: Putative transcription factor binding sites identified in the 2.6kb human KPNA2 
promoter. A) The human KPNA2 promoter showing tlie putative transcription factor binding sites 
determined by using tlie Matlnspector Software. Among the transcription factors are vitamin D 
receptor (VDR), progesterone receptor (PR), retinoid related orphan receptor a (RORa), pregnane X 
receptor (PXR), peroxisome proliferated activated receptor a (PPARa), glucocorticoid receptor 
(GR) and hepatic nuclear factor 4 (HNF4). Numberings are relative to -1 which is at the 3’ end of 
exon 1. B) The nuclear receptors core similarity and the matrix similarity of the 2.6kb human 
KPNA2 promoter predicted by Matlnspector. Core similarity defined as the four consecutive highest 
conserved positions of the matrix, where 1.0 is the maximum core similarity. Matrix similarity is the 
similarity of each sequence position corresponds to the highest conserved nucleotide at that position 
in the matrix, where perfect match is indicated as 1.0. A good match has a similarity of ^ .7 5  and 
their consensus binding sites are summarized in the table
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3.3.1 Vitamin D receptor (VDR; NR 111)
The Vitamin D receptor was first isolated from two receptor-specific monoclonal 
antibodies raised against a purified protein from a chicken intestinal lambda gtl 1 cDNA 
expression library (McDonnell et al. 1987). Subsequently, human VDR was isolated by 
Baker and collègues (Baker et al. 1988) from human intestine and T47D cell cDNA 
libraries. VDR belongs to the NR group II, it is closely related to the PXR and CAR NRs, 
forming a second group of steroid receptors distinct from the classic group (GR, ER, PR 
etc). Human VDR is encoded by 427 amino acids, forming a protein with a very short 
A/B domain of only 21 amino acids long (Laudet and Gronemeyer 2002). The DBD of 
VDR shows 56% similarity with human PXR and CAR, and indeed there is evidence that 
these receptors can share binding sites on DNA (Xie et al. 2000).
The Vitamin D receptor preferentially binds to a direct repeat spaced by 3 nucleotides 
(Umesono and Evans 1989) and can bind either as a homodimer (Freedman et al. 1994) 
or a heterodimer with RXR (Kliewer et al. 1992; Zhang et al. 1992). The VDR-RXR 
heterodimer can bind to both the DR3 element of a GGTTCA core motif and AGGTCA 
(classical NR motif) whereas, the homodimer can only recognise the former motif 
(Freedman et al. 1994).
In the absence of ligand, VDR resides predominantly in the nucleus, although a 
significant amount of VDR is also present in the cytoplasmic compartment (Michigami et 
al. 1999). When a ligand (e.g. l,25(OH)2-D3) is bound to the VDR, nuclear translocation 
of VDR occurs, resulting in a steady-state localisation that is mainly nuclear. This 
translocation has been shown to be mediated by short segment of the hinge region, 
further suggesting that this segment has a functional NLS (Michigami et al. 1999). The 
major heterodimerisation partners of VDR are the RXRs, with interaction shown to both 
increase affinity for DNA binding, and the specificity towards the correctly spaced DR 
elements (Zhang et al. 1992).
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The endogenous ligand of VDR is 1,25-dihydroxy vitamin D3, the hormonally active form 
of vitamin D, which is involved in calcium homeostasis (Bouillon et al. 1995). Apart 
from calcium homeostasis, 1,25-dihydroxyvitamin D3 is also able to inhibit cellular 
proliferation, induction of differentiation and immunosupression (Bouillon et al. 1995; 
Christakos et al. 1996). Studies have shown that 1,25-dihydroxy vitamin D3 binds with a 
high affinity to VDR, with a Kd=5.2 x lO'^^M (Baker et al. 1988). More than 3000 
synthetic analogues of 1,25-dihydroxyvitamin D3 are presently known; the majority of 
them carry a modification in their aliphatic side chain (Carlberg et al. 1994) and most of 
these analogues show agonistic potential albeit with various efficiency (Bouillon et al. 
1995). Within the liver, the toxic bile acid lithocholic acid (LCA) induce their own 
metabolism via VDR-mediated induction of CYP3A4 (Adachi et al. 2005).
Mutations in VDR are associated with a number of important disease states. For example, 
patients with hypocalcaemic rickets exhibit mutations of the VDR gene that cause target 
organ resistance to the action of 1,25-dihydroxyvitamin D3 (Hughes et al. 1988; Malloy et 
al. 2004). In this case, the receptor displays a reduced DNA interaction without affecting 
the binding to 1,25-dihydroxyvitamin D3 due to a mutation within the DBD, in the tip of 
the first and second zinc fingers (Hughes et al. 1988). An excess of VDR allele b that 
causes impaired VDR function may induce excess production that leads to 
hyperparathyroidism (Carling et al. 1995). Vitamin D receptor dysfunction has also been 
associated with a number of other disease states and pathologies. It has been linked 
tovarious cancers, including breast cancer, colorectal cancer, renal cell carcinoma, and 
prostate cancer; has been associated with cardiovascular pathologies such as 
arthrosclerosis, hypertension, myocardial infarction, and immune- metabolic- and 
inflammatory diseases. Furthermore, vitamin D dysfunction increases susceptibility to 
infection (AIDS, Q fever, leprosy, tuberculosis); renal conditions (kidney stone disease); 
and neurological disorders (amyotrophic lateral sclerosis, Alzheimer’s disease) (Kamel et 
al. 2003; Nieto et al. 2004; Shioi et al. 2004; Gezen-Ak et al. 2007; Thadhani and Wolf 
2007; Wu-Wong 2009; Greenwood et al. 2010).
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3.3.2 Progesterone receptor (PR; NR3C3)
The progesterone receptor is a member of the steroid receptor sub-family that includes 
the glucocorticoid receptor (GR), mineralcorticoid receptor (MR) and the androgen 
receptor (AR), and was initially cloned simultaneously in 1986 by several labs (Conneely 
et al. 1986; Jeltsch et al. 1986; Loosfelt et al. 1986). In humans, at least nine different PR 
transcripts have been characterised ranging from 2.5kb to 11 kb (Wei et al. 1990); these 
result in two isoforms, PR-A and PR-B. However, a third isoform was recently identified 
in humans, with PR-C being an N-terminally truncated receptor that contains only a 
single zinc finger, the hinge and the LBD, and functions as an enhancer of PR-A and PR- 
B transcriptional activity (Wei et al. 1990; Wei et al. 1996). The difference between PR- 
A and PR-B isoforms is in their N-terminal A/B region (Jeltsch et al. 1986), with this 
region in humans being 164 amino acid shorter in PR-A than PR-B (Laudet and 
Gronemeyer 2002). Due to the presence of a specific activation function called AF-3, in 
the unique N-terminal region of PR-B, this isoform is a stronger transactivator than PR-A 
(Sartorius et al. 1994), and both of isoforms show different promoter specificities (Tora et 
al. 1988; Bocquel et al. 1989). PR is mainly expressed in the uterus, ovaries (in the theca 
and surrounding stroma of growing follicles), vagina, fallopian tubes, breast, thymus and 
the ventral medial nucleus and the pre-optic area of hypothalamus (Baulieu 1989; Lydon 
et al. 1995; Zelinski-Wooten and Stouffer 1996; Peluso 1997). It is not however 
expressed in oocytes and the granulosa cells of the ovaries (Zelinski-Wooten and Stouffer 
1996; Peluso 1997).
The progesterone receptor binds to DNA as a homodimer with each monomer 
cooperatively recognising a half-site sequence that contains the imperfect palindromic 
sequence GGTACAmiiiTGTTCT (Tsai and O'Malley 1994). This sequence is also 
recognised by other steroid receptors (Laudet and Gronemeyer 2002). As with the 
oestrogen receptor (OR), RXR and thyroid hormone receptor (TR), PR is also able to 
bind the DNA molecule but the presence ligand, either agonist or antagonist, does not 
affect this binding property (Prendergast et al. 1994).
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Studies have revealed that three signals work together to allow efficient 
nucleocytoplasmic shuttling of PR. Mutational analysis has identified an NLS similar to 
the SV40 T antigen NLS in the D-domain of PR (Guiochon-Mantel et al. 1994), with the 
other two signals localised in the LBD and the DBD, respectively (Laudet and 
Gronemeyer 2002). Interestingly, a mutant PR, where the classical NLS has been deleted, 
is still able to translocate into the nucleus following hormone treatment, due to its ability 
to dimerise and co-translocate with wild-type receptor (Tyagi et al. 1998; Laudet and 
Gronemeyer 2002; Li et al. 2005). In addition, the PR is unusual in that the NLS, and not 
and NES, is responsible for nuclear export (Li et al. 2005). The intracellular distributions 
of both PR isoforms are distinct, where PR-A is more nuclear than PR-B, especially in 
the absence of ligand (Lim et al. 1999).
Apart from interacting with HSPs, in the nucleus the PR also collaborates with other 
partners. For example, PR interacts with the high mobility group protein HMG-1 that 
enhances its binding to DNA (Prendergast et al. 1994). These interactions result in the 
enhancement of PR transcriptional activity (Boonyaratanakornkit et al. 1998). PR is also 
able to bind to transcription factors such as Stat5 (Signal transducer and activator of 
transcription 5), TAFul 10 (a subunit of the TFIID complex) and p65 (Richer et al. 1998). 
Stat5 transduces the signal induced by cell surface growth factors and cytokines and its 
interaction with PR results in an increased nuclear accumulation of Stat5 (Richer et al. 
1998; Laudet and Gronemeyer 2002). The interaction between PR and p65, a subunit of 
the NFicB complex has also been demonstrated. This complex causes a transrepression 
effect, an effect that is also observed for the GR (Kalkhoven et al. 1996; Laudet and 
Gronemeyer 2002). Studies on the PR-TAFnllO have postulated that this interaction 
plays a role in the transcriptional activation by the liganded PR. Progesterone receptor is 
also able to interact with corepressors, where antagonist-bound PR has a conformation 
that is different from agonist-bound receptor and interacts with NCoR (NR corepressor) 
and SMRT (silencing mediator for retinoid or thyroid-hormone receptors) (Wagner et al.
1998).
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PR is able to bind to many ligands. The most well documented ligand for PR is 
progesterone, which is an agonist with a Kd of 1.0-1.5 nM. One of the most famous 
antagonists of PR is the abortifacient RU486 (Mifepristone), which inhibits the action of 
progestin and glucocorticoids in humans (Baulieu 1989). Although RU486 binds to both 
GR and PR, it exerts its antagonistic action by different mechanisms through these two 
receptors (Baulieu 1989; Beck et al. 1993). It is interesting to note that several studies 
have shown that the antagonistic action of this compound is mainly at the post-DNA 
binding step, as RU486 bound-PR can still bind to DNA but the complex is unable to 
enhance transcription (Beck et al. 1993).
Mutational analysis has shown the importance of the C-terminal region of PR for 
differential recognition of ligands, whether they are agonists or antagonists (Vegeto et al. 
1992). Progestins (and other agonists) bind to the C-terminal part of the receptor, while 
antagonists bind to a site closer to the N-terminus. This N-terminal region contains a 
twelve amino acid domain that acts as a transcription repressor domain, inhibiting the 
transcriptional activity of the PR-RU486 complex (Xu et al. 2005). The failure of PR 
bound to an antagonist to activate transcription is a consequence of its inability to interact 
with coactivators (Onate et al. 1995), and the association of this receptor-agonist complex 
with corepressors (Vegeto et al. 1992; Xu et al. 1996). This, therefore, suggests that the 
antagonistic action of PR is due to the recruitment of the corepressors and the repressor 
domain (Xu et al. 1996; Jackson et al. 1997). The transcriptional activities of any type of 
PR ligands (agonist, antagonist or mixed agonist) may be due to the differential 
interaction with NCoR and SMRT as a direct result of the unique receptor conformational 
changes that these ligands induce on binding (Wagner et al. 1996; Wagner et al. 1998).
Among the most well characterised PR target gene is the tyrosine aminotransferase 
(TAT) gene and the mouse mammary tumor virus long terminal repeat (MMTV LTR) 
(Strahle et al. 1989; Beato et al. 1995). Even the PR gene itself was studied as a 
progesterone responsive gene that down regulates its own expression (Turgeon et al.
1999). PR target genes can be categorised into two overlapping groups; first, those which 
are regulated by progesterone in reproductive tissues such as the vitellogenein II gene in
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chickens (Cato et al. 1988); matrix metalloproteinases such as collagenase and gelatinase 
A and B in the human endometrium and cathespin L and proteinase ADAMTS-1 during 
ovulation (Robker et al. 2000). Second, those genes that are regulated in the mammary 
gland and breast cancer cells, such as the progesterone upregulation of TGFa, EGF 
receptor, c-fos and c-myc genes (Musgrove et al. 1991).
3.3.3 Retinoic acid receptor-related orphan receptor a (RORa; NRIFI)
Retinoic acid receptor-related orphan receptor is a member of the steroid/thyroid 
hormone receptor subfamily of the NR superfamily of transcriptional factors. There are 
three ROR paralogues expressed in higher mammals, namely RORa, RORp and RORy. 
All these receptors have similar structural features; a veiy long D domain and a highly 
conserved C-terminal extension to the C domain, which is involved in their monomeric 
DNA binding. They bind to the DNA as monomers on half-site elements with a 5’ A/T 
rich extensions with a response element sequence of T/AA/TT/ACA/TA/GGGTCA 
(Carlberg et al. 1994). The DBD of ROR is made up of three integrated parts, the first 
being the two classic zinc fingers that recognise the AGGTCA motif in the major groove 
of the DNA double helix. Secondly, a conserved C-terminal extension interacts with the 
neighbouring minor groove and with the 5’ A/T rich sequence. Thirdly, an region N 
terminal to the zinc finger is unique to RORa (Laudet and Gronemeyer 2002). Herein, 
RORa is discussed in greater detail.
The RORa is expressed in many organs/tissues such as liver, lung, muscle, brain, spleen, 
ovaries, testis, Purkinje cells, cartilage and many others (Beckerandre et al. 1993; 
Hamilton et al. 1996). There are four isoforms of RORa, (RORal-a4; (Laudet and 
Gronemeyer 2002), which are generated by a combination of alternative promoter use 
and exon splicing of the RORA gene (Jetten 2004). These isoforms have different N 
terminal domains to the DBD, resulting in altered DNA binding site specificity (Giguere 
et al. 1994). The RORa is able to activate transcription by interacting with coactivators 
such as TIF2, which is able to enhance the transactivating properties of RORa via helix 3 
and 12 (Harding et al. 1997), and the PPAR-binding protein (PBP also known as
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TRAP220 or DROP205) (Atkins et al. 1999). The RORa is also able to interact with the 
coactivator p300 and MyoDl, a muscle specific transcription factor, which is important 
in determining muscle-specific target gene activation (Harding et al. 1997). As well as 
established interactions with coactivators, RORa has been shown to contain a repressive 
domain in its LBD, which is consistent with experiments that show the relationship 
between RORa and corepressors such as NCoR and SMRT (Harding et al. 1997).
Human CYP2C8, belonging to the cytochrome P450 2C subfamily of enzymes that 
metabolise many clinically important drugs and endogenous compounds, (e.g. the 
anticancer drug paclitaxel and arachidonic acid), and is highly expressed in liver, is a 
classic target gene for RORa (Chen et al. 2009). Other target genes for ROR include Apo 
A-V, Apo A-I, Apo C-III, human fibrinogen p, PPARy and Rev-erba, suggesting a role of 
RORa in cardiovascular physiology and lipid metabolism (Sundvold and Lien 2001; 
Raspe et al. 2002; Chauvet et al. 2005; Genoux et al. 2005; Lind et al. 2005). Consistent 
with this, RORa has also been implicated in the aetiology of vascular disorders such as 
atherosclerosis, with RORa expression levels significantly decreased in human 
atherosclerotic plaques. These levels can be increased by treatment with PR agonists, 
which suggests a potential therapeutic strategy (Besnard et al. 2002). Recently, a study 
was performed to reveal the role of RORa in hypoxia signalling, and the possibility that 
RORa ligands could be used in the treatment of hypoxia-associated vascular diseases 
(Kim et al. 2008).
3.3.4 Pregnane X receptor (PXR; NR1I2)
The pregnane X receptor was originally cloned from mice (Kliewer et al. 1998), and then 
simultaneously by three groups from humans, leading to the alternate names pregnane 
activated receptor (PAR) or steroid X receptor (SXR) (Bertilsson et al. 1998; Blumberg et 
al. 1998; Lehmann et al. 1998). The NR is expressed mainly in the liver and intestines 
and to a lesser extent, the stomach and kidneys (Laudet and Gronemeyer 2002). In the 
DBD, PXR exhibits 6 6 % amino acid similarity with the constitutive androstane receptor 
(CAR); another xenosensing NR, and 63% with VDR (Willson and Kliewer 2002), as
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well as 51 and 55% similarity with the endosensing NRs farsenoid X receptor (FXR) and 
liver X receptor (LXR) respectively. This high degree of similarity suggests that some 
sharing of response elements might occur, and indeed this is the case, with PXR, CAR 
and VDR all being able to share DNA binding elements (Xie et al. 2000). In comparison, 
there is only 45-50% identity in the LBD between PXR and CAR, 41% with VDR and 
24-29% with FXR and LXR, resulting in significantly different ligand binding profiles 
(Laudet and Gronemeyer 2002).
The human PXR can be activated by a vast array of compounds and steroid derivatives, 
with classical agonists including rifampicin, clotrimazole, lovastatin, dexamethasone and 
cyproterone acetate (Bertilsson, 1998; Blumberg, 1998; Lehmann, 1998). PXR is a 
transcriptional activator that binds to DNA as a heterodimer with RXRa, which must also 
be bound to its endogenous agonist 9-cis retinoic acid (Bertilsson et al. 1998; Blumberg 
et al. 1998; Lehmann et al. 1998). Following dimérisation, the heterodimer binds to DNA 
on a DR3 element (Smith et al. 1994). The target genes of PXR are mainly genes that 
belong to the detoxifying enzymes of the cytochrome P450 family. In humans, these 
target genes are CYP2A1, CYP2A2, CYP2C1, CYP2C6, CYP3A1, CYP3A2, CYP3A4, 
P450oxydoreductase and UDP-glucuronosyltransferase (Blumberg et al. 1998).
3.3.5 Peroxisome proliferated activated receptor a (PPAR a; NRICI)
Three paralogues of PPAR have been identified; PPARa, PPARp/5 and PPARy. PPARa 
is mainly expressed in liver, kidney, heart, muscle, and adipose tissue, whereas PPARp/5 
is expressed in many tissues but most predominantly in the brain, adipose tissue, and 
skin. Lastly, PPARy can be further classified into three forms through alternative 
splicing; yl which is expressed in virtually all tissues, including heart, muscle, colon, 
kidney, pancreas, and spleen, y2, which is expressed in adipose tissue; and y3, which is 
expressed in macrophages, the large intestine and white adipose tissue (Berger and 
Moller 2002).
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PPAR a forms a heterodimer with RXRa and binds to an imperfect DRl motif 
(AGGTCAnAGGTCA) in the regulatory regions of its target genes, (Johnson et al. 
2002). Many ligands for PPARs have been identified, including the fibrates and 
unsaturated long-chaing fatty acids (Issemann and Green 1990; Dreyer et al. 1992; 
Gottlicher et al. 1992). Fatty acids were the first natural agonists identified for PPARs, 
with PPARa showing the highest affinity towards unsaturated fatty acids such as 
linolenic and linoleic acids (Gottlicher et al. 1992).
Numerous PPARa target genes have been reported, with the classical target being acyl- 
CoA oxidase and CYP4A6, both of which are regulated by PPARa and are involved in 
fatty acid metabolism (Dreyer et al. 1992; Muerhoff et al. 1992; Tugwood et al. 1992). 
The PPARa target genes have also been implicated in lipid and cholesterol homeostasis 
in the liver, including apolipoprotein Al, All and CHI (Yu-Dac et al. 1994; Vu-Dac et al. 
1995). The gene encoding the mitochondrial ketogenic enzyme, hydroxymethylglutaryl- 
CoA synthase (mHMG-CoAS), which is responsible for the formation of ketone bodies 
from acetoacetate, is also a target of PPARa (Meertens et al, 1998). PPARs have also 
been implicated in the progression of a range of diseases, including atherosclerosis, 
inflammatory responses and carcinogenesis (Wahli et al. 1995; Desvergne and Wahli 
1999).
3.3.6 Glucocorticoid receptor (GR; NR3C1)
The glucocorticoid receptor is a steroid receptor that is a comparatively large protein for 
NRs, being 777 amino acids in humans (Laudet and Gronemeyer 2002). In the DBD, the 
GR exhibits 78%, 89% and 92% sequence identity with other members of the classical 
steroid hormone group, the androgen receptor (AR), progesterone receptor (PR) and 
mineralcorticoid receptor (MR) respectively, explaining the known overlap in their target 
genes. In contrast, they share only 49%, 54% and 56% identity in the LBD, reflecting 
their high specificity for their cognate ligands (Laudet and Gronemeyer 2002). The GR is 
expressed in many organs and systems with high levels in the cerebrum, corpus striatum, 
duodenum, jejunum, ileum, colon, kidney, brown adipose tissue, white adipose tissue.
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thymus, preputial gland, aorta, heart, lung, skeletal muscle and skin 
(WWW. nursa. or g/10.1621/datasets.02001).
GR is perhaps the best understood NR with regard to its nuclear import. There are two 
NLSs within the protein, the first mapping to a 28 amino acid region just C terminal to 
the C domain, which contains basic amino acids similar to those seen in the SV40 T 
antigen NLS. This signal mediates the interaction of GR with karyopherin a (Savory et 
al. 1999). The second NLS is located in the LBD, and by itself is sufficient to promote 
hormone-dependent nuclear localisation but at a slower rate and without the association 
of karyopherin a, thus suggesting an alternative pathway (Savory et al. 1999).
Human GR is able to bind to human cortisol as well as dexamethasone, which act as 
agonists (Hollenberg, 1985). The most famous GR antagonist is RU486 (Baulieu, 1989) 
this stabilises the non-DNA-binding hsp90-complexed form of the GR but can also bind 
to the free receptor (Groyer et al. 1987; Sackey et al. 1996). Once activated, the GR binds 
to DNA molecules as a homodimer (Umesono and Evans 1989), recognising a core 
hexamer sequence of AGAG/ACA that is often present in two palindromic copies (Karin 
et al. 1980; Karin et al. 1984; Strahle et al. 1987). Classic target genes of GR include 
enzymes implicated in gluconeogenesis such as PEPCK, TAT and serine dehydratase 
(Simons et al. 1992). Other target genes include tyrosine hydroxylase (Lewis et al. 1987), 
sytosolic aspartate aminotransferase (Garlatti et al. 1994), carbamoylphosphate 
synthetase (Christoffels et al. 1998), glutamate synthetase (Richardson et al. 1999), (3- 
casein (Doppler et al. 1989), and thyrotropin-releasing hormone (TRH) (Tavianini et al. 
1989).
Interestingly, GR positively regulates the multidrug resistance gene, MDR (Altuvia et al. 
1993) as well as p57^'^^ and the insulin-like growth factor binding protein-1 (IGFBP-1) 
(Suh et al. 1996). In contrast, GR inhibits the transcription of several genes such as c-myc 
(Ma et al. 1992), human glycoprotein hormone a subunit (Akerblom et al. 1988) and the 
osteocalcin gene (Meyer et al. 1997). The GR, or its malfunction, has been implicated 
with various diseases, most notably metabolic disorders (glucocorticoid resistance, type II
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diabetes, obesity) (Lin et al. 2003; Liu et al. 2005; Schmidt et al. 2006), cardiovascular 
diseases (Kuningas et al. 2006), immune disorders (asthma and lupus erythematosus) 
(Gagliardo et al. 2000; Li et al. 2010), psychiatric disorders (depression, stress) (Pariante 
2006; Molteni et al. 2010) and renal conditions (nephrotic syndrome) (Haack et al. 1999).
3.3.7 Hepatic nuclear factor 4 (HNF4; NR2A)
The human hepatic nuclear factors have three main subfamilies; HNFl, HNF3 and 
FINF4. Within the HNF4 subfamily there are two isoforms; HNF4a (NR2A1) and HNF4y 
(NR2A3), which are mainly expressed in the liver, but also in other organs, including the 
kidney, pancreatic islet cells and insulinoma cells (Miquerol et al. 1994; Laudet and 
Gronemeyer 2002). Both HNF4 isoforms bind to DNA exclusively as a homodimer 
(Jiang et al. 1995), although they also interact physically and functionally with numerous 
coactivators, including SRCl, P300, GBP and GRIPl in the absence of any exogenous 
ligands (Sladek et al. 1999). Although several ligands have been suggested to interact 
with HNF4a, these have yet to be shown to interact in vivo (Hertz et al. 1998), making a 
detailed study of the (liganded) effects of this NR on transcription difficult. HNF4 has 
been shown to regulate the expression of various genes that are expressed in the liver, 
including apolipoproteins; clotting factors (factor IX, factor VII); genes involved in fatty 
acid metabolism such as medium-chain acyl-CoA dehydrogenase (MCAD); cytochrome 
P450s, including CYP3A4; TAT; glucose metabolism genes such as L-pyruvate kinase; 
the aldolase gene and phosphoenolpyruvate carboxykinase, amongst others (Hall et al. 
1995; Gregori et al. 1998; Hong et al. 2003). Of particular note in the context of this 
thesis is the identification of a functional binding site for HNF4a within the XREM of the 
CYP3A4 gene, which enhanced both PXR- and CAR-mediated basal and drug induced 
CYP3A4 gene expression (Tirona et al. 2003). Alterations in HNF4-mediated gene 
expression have been linked with hemophilia B Leyden, due to its transcriptional 
regulation of the blood coagulation factor IX gene (Reijnen et al. 1992). In addition, 
HNF4 dysfunction is associated with type 2 diabetes (MODYl) (Yamagata et al. 1996).
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3.4 Transcriptional regulation of the human karyopherin a2 promoter 
by nuclear receptors
The in silico data described in the first half of this chapter showed that the human 
KPNA2 promoter contains putative binding sites for seven NRs. This opened an avenue 
to further explore the role of some of these NRs in altering KPNA2 expression. The 
initial investigation involved the generation of a reporter gene construct containing the 
human KPNA2 promoter and characterisation of its activity in the human Huh? hepatoma 
cell line. Following this, the effect of xenobiotics on the human KPNA2 promoter was 
determined.
3.4.1 Generation of a reporter gene clone containing the human KPNA2 
promoter
In order to generate a reporter clone containing the human ICPNA2 proximal promoter, 
nested PCR was first carried out to isolate the DNA fragment of interest. Nested PCR is 
an alteration of basic PCR with the aim of reducing contamination and non-specific 
amplification in the main product of PCR. In this instance two sets of primers, -2686F 
plus +162R and -2549F plus -77R (Table 2.2), were used in two successive rounds of 
amplification. The latter set of primers amplified the target of interest (the human 
KPNA2 promoter) using the material derived from the first amplification as template; this 
enrichment process greatly increases the chances of a strong amplification of the target 
sequence. For the outer (-2686F and +162R) set of primers, a band of 2.85 kb was 
observed under all PCR conditions but with the best conditions being 60°C annealing at 5 
seconds annealing (Figure 3.3; lane 5).
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Figure 3.3: First round PCR amplification of the human KPNA2 promoter using different 
annealing temperatures. PCR was carried out using human genomic DNA as a template, primers - 
2686F and +162R, and PrimeSTAR® polymerase. Annealing tenqieratures ranging from 52®C to 60°C 
(5 seconds) were tested and amplification products are shown in lanes 1-5 (L1-L5) (temperatures as 
shown at the bottom of the gel). DNA markers (L6) are in kilobases (kb).
For the internal set of primers (2549F and -77R), initial attempts at amplification using 
the PCR product shown in figure 3.3 as a template were unsuccessful. However, with 
addition of the PCR enhancer betaine (Rees, 1993; Henke, 1997), all conditions tested 
showed good amplification of the target amplicon (Figure 3.4), and 60°C (Figure 3.4, 
Lane 5) was chosen as being optimal to generate sufficient PCR product for cloning as it 
showed fewer contaminating bands.
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Figure 3.4: Second round PCR of the human KPNA2 promoter at different annealing 
temperatures. PCR was carried out using the first round cleaned PCR product as template, primers - 
2549F and -77R, PrimeSTAR® polymerase and betaine. Amiealing temperatures ranging from 52°C to 
60°C (5 seconds) were tested and amplification products are shown in lanes 1-5 (L1-L5). Annealing 
tenqieratures were as shown at the bottom of the gel. Markers (L6) are in kilobases (kb).
Following amplification the 2.6 kb DNA fragment corresponding to the KPNA2 
promoter, the DNA was isolated by gel extraction. Restriction sites designed into the 
PCR primers (Acc65 1 and Hind III) were used to insert this DNA fragment into the 
pSEAP2-Basic reporter vector as shown in figure 3.5B. Transformants were screened by 
restriction digestion using EcoK I, which confirmed the orientation of the inserted DNA. 
Two clones were chosen for the generation of endotoxin-free plasmid DNA to be used in 
subsequent experiments. From these DNA preparations, 250ng of DNA from each clone 
was digested with 5 different sets of restriction enzymes- Bgl I, Eco Rl, Pst I, Sac 1 and 
Stii I (Figure 3.5A) to assess the insert integrity. All of these diagnostic digests gave the 
expected fragment pattern except Stu 1, where the DNA was not digested due to DCM 
méthylation, which blocks digestion by overlapping the AGGCCT sequence (Figure 
3.5A; Lane 5 and 11). By comparing the plasmid map in figure 3.5B with the band size 
obtained in figure 3.5A, both samples were confirmed to be the right clone. Finally, both 
clones were confirmed to be correct by sequencing.
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Figure 3.5: Restriction analysis of pSEAP-human KPNA2 clones. A) Plasmid map of pSEAP2- 
Basic reporter vector containing the human KPNA2 insert with restriction sites marked on it B) DNA 
was prepared from two successful transformants using the midi-preparation method and was digested 
with Bgl I (lane 1 and 7), Eco RI (lane 2 and 8), Pst I (lane 3 and 9), Sac I (lane 4 and 10), and Stu I 
(lane 5 and 11). Digests were separated on a 1% agarose gel and showed the expected fragments; note 
however that the enzyme StuI is sensitive to DCM méthylation and thus does not cut at site 537. 
Markers are in kilobases (kb).
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3.4.2 Secretory alkaline phosphatase (SEAP) reporter gene assay
To determine the optimum conditions for the reporter gene assay and to ensure robust, 
reproducible experiments, previous work undertaken in our lab measured the optimum 
time for secretory alkaline phosphatase (SEAP) production. The effect of culture passage 
and the amount of NR in Huh? cells on SEAP production has also been determined 
(Phillips et al. 2005; Aouabdi et al. 2006). These experiments showed that significant 
SEAP production was observed after 48 hours and that this time point yielded the most 
reproducible effects (Aouabdi et al. 2006). Extensively passaged Huh? cells lost their 
ability to respond to drugs due to the loss of cell phenotype, therefore Huh? cells were 
only used until passage 20 (Aouabdi et al. 2006). In addition, expression of endogenous 
NRs in Huh? cells differs. Most notably, expression of PXR in Huh? cells is so low that 
PXR ligand will elicit no effect without the co-transfection of PXR expression plasmid 
(El-Sankary et al. 2001). On the other hand, expression of NRs such as GR is relatively 
high; therefore addition of a GR expression plasmid is not required to observe a response 
to GR ligands. In order to produce consistent and reproducible results, the following 
experiments all included co-transfection of respective NR expression plasmids regardless 
of their endogenous level.
Finally, before embarking on studying the transcriptional regulation of the human 
KPNA2 by xenobiotics, it was important to ensure that the region cloned was indeed a 
functional promoter. A number of genes (for example the mouse arylamine N- 
acetyltransferase type 2 gene; (Cornish et al. 2003)) have upstream untranslated exons, 
the presence of which can lead to the mis-identification of the likely promoter region. 
Each of the two plasmid clones identified in Figure 3.5 were transfected into Huh? cells 
and the strength of the human KPNA2 promoter was compared with the human 
cytomegalovirus immediate-early promoter (CMV) and the simian virus 40 (SV40) 
promoters. These promoters are extensively used in mammalian expression vectors 
because they generally have a very strong activity in a wide variety of cells of differing 
tissues and species (Najjar and Lewis 1999; Chung et al. 2002; Fitzsimons et al. 2002; 
Harms et al. 2004). Figure 3.6 shows that both of the human KPNA2 promoter clones
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exhibited intermediate expression when compared to other the CMV and SV40 
promoters. Other vectors such as the CYP3A4 promoter and the pSEAP2-basic promoter 
showed very low or no SEAP expression. As expected, in the absence of a PXR ligand, 
expression from the CYP3A4 promoter was very low, and since the pSEAP2-basic vector 
lacks any type or form of promoter, no SEAP expression was observed. These results 
confirmed that the human KPNA2 promoter had been successfully identified and cloned, 
and that its expression is high enough to ease detection of SEAP expression in future 
experiments.
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Figure 3.6: Comparison of human KPNA2 promoter-driven reporter gene expression when 
compared to human cytomegalovirus immediate-early (CMV) promoter, simian virus 40 (SV40) 
promoter, CYP3A4 promoter and pSEAP2-basic vector. Huli7 cells were transfected with 
50ng/well of each respective reporter gene plasmid togellier with the pEGFP-C2 plasmid as a co­
transfection control. SEAP expression was measured 48 hours post transfection as well as green 
fluorescence, which was read at an excitation wavelength of 472 nm and emission of 512 mil. SEAP 
data was normalised to GFP, and is expressed as relative lummescence units. Data are shown as SEM 
where n=5. The data shown are representative of at least two independent experiments.
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3.4.3 The effect of nuclear receptor ligands on human KPNA2 promoter 
activity
The in silico analysis identified potentially functional NR binding sites within the human 
KPNA2 promoter. To delineate the functionality of these binding sites, it was important 
to investigate the role of NR ligands on human KPNA2 promoter expression. The cloned 
human KPNA2 proximal promoter was co-transfected into the Huh? cells along with an 
expression plasmid for the NR that binds the site under investigation. These cultures were 
then dosed with the cognate ligands for the co-transfected NRs along with an appropriate 
vehicle control. Ligands were determined using the Nuclear Receptor Signalling Atlas 
website (NURSA; http://www.nursa.org/) and through literature searching and an initial 
screen at a a single dose at 50 pM was examined. Full dose response curves were 
generated for ligands selected from this preliminary study and are presented in the 
following chapters. In the SEAP assay, post-dose medium was removed from cells and 
SEAP expression was measured using the Phospha Light SEAP Assay kit (Applied 
Bioscience). Post-dose readings were normalised to pre-dose levels and expressed as 
percentage vehicle (% vehicle) prior to one-way ANOVA analysis and Bonferroni post- 
hoc test. The level of lactate dehydrogenase (LDH) was assessed as a measure of cell 
death in order to ensure that any changes in SEAP levels were the result of interactions 
with the human KPNA2 proximal promoter and not as a result of significant change in 
cell viability. The LDH assay is expressed as percentage of cell viability (% cell 
viability).
3.4.3.1 Activity of the human KPNA2 promoter in the presence of VDR 
ligands phenobarbitone and lithocholic acid
Treatment with phenobarbitone (PB) caused a significant (five-fold) inhibition of 
expression (p<0.001) compared to vehicle control (0.1% MilliQ water). No effect was 
observed with lithocholic acid (LCA; Figure 3.?A). The LDH assay to determine the
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amount of cell death showed a small but significant cytotoxic effect (Figure 3.7B), 
although it is not a major contributing factor to the observed inhibition of expression.
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Figure 3.7: Human KPNA2 prom oter activity ant! evaiuation of cytotoxic effect in H uh? cells in 
the presence of phenobarbitone or lithocholic acid. Human KPNA2 promoter (25ng/well) was 
transfected into Huh? cells along with a VDR expression plasmid (pEF6A^5-VDR; 25ng/well). Cells 
were treated with 50|.iM phenobarbitone (PB) or 50pM lithocholic acid along with vehicle controls of 
0.1% MilliQ and 0.1% ethanol respectively. A) The level o f expression from the human KPNA2 
promoter was indhectly assessed by measuring generation of a luminescent product by secretory 
alkaline phosphatase. Post-dose values were normalised to pre-dose reading as a transfection control 
and results are expressed as luminescence units relative to the vehicle control. B) The cytotoxic 
effects o f phenobarbitone on Hull? cells were evaluated using the LDH Assay. The level of LDH 
released into the media was quantified using the LDH Cytotoxicity Detection kit (Roche) and read on 
an ELISA plate reader (BioTEK ELxSOO) at 490nm. Results are expressed as percentage cell 
viability compared to vehicle control (100% cell viability) and cells lysed in 1% triton-X 100 (0% cell 
viability). Error bars represent the SEM where n = 5. Data was analysed by one-way ANOVA witli 
Bonferroni post-hoc analysis; *=p<0.05, *'^=p<0.01, ***= p<0.001. The data shown are 
representative o f at least two independent experiments.
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3.4.3.2 Activity of human KPNA2 promoter in the presence of 
progesterone
When transfected Huh? cells were treated with 50 jiM progesterone, a significant three­
fold decrease in expression (p<0 .0 1 ) was observed compared to the vehicle control (0 .1% 
MilliQ water) (Figure 3.8A). The LDH assay showed a small but significant cytotoxic 
effect (Figure 3.8B), although it is unlikely that this explains the large inhibition of 
expression in transcription observed for the KPNA2 reporter gene.
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Figure 3.8: Expression of hum an KPNA2 prom oter activity and evaluation of cytotoxicity effect 
in H uh? cells in the presence of progesterone. Huh? cells were transfected with tire human KPNA2 
reporter plasmid (25ng/well) and after 24 h were treated with 50pM progesterone (Prog) or with 0.1% 
MilliQ water as a vehicle control. A) Post-dose SEAP levels were normalised to pre-dose reading and 
are expressed relative to the vehicle control. B) Cytotoxicity was evaluated by LDH assay and 
expressed as percentage cell viability compared to vehicle control (100% cell viability) and cells lysed 
in 1% triton-X 100 (0% cell viability). Error bars represent the SEM where n = 5. Data was analysed 
by one-way ANOVA with Bonferroni post-hoc analysis; *=p<0.05, **=p<0.01, ***= p<0.001. The 
data shown are representative of at least two independent experiments.
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3.4.3 3 Activity of human KPNA2 with co transfected human PPARa in
the presence of clofibrate or Wy-14,643
Wy-14,643 elicited a significant two-fold inhibition of expression (p<0.01) compared to 
the vehicle control (0.1% DMSO), whereas no effect was observed with clofibrate 
(Figure 3.9A). Since Wy-14,643 appeared to inhibit the KPNA2 promoter, the LDH 
assay was carried out to ensure that the apparent decrease in expression was not due to 
cytotocicity. There was no significant difference in the amount of LDH released 
following treatment with Wy-14,643, versus 0.1% DMSO (Figure 3.9B) suggesting that 
the inhibition of expression observed is not due to high levels of cell death.
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Figure 3.9: Expression of human KPNA2 prom oter activity and evaluation of cytotoxicity effect 
in H uh? cells in the presence of clofibrate or Wy-14,643. A) Human KPNA2 promoter (25ng/well) 
was transfected into Huh? cells along with a PPARa expression plasmid (pCR3- PPARa). Cells were 
treated with 50pM clofibrate (Clo) or Wy-14,643 along witli 0.1% Ethanol or 0.1% DMSO 
respectively (vehicle control). The level o f inliibition of expression was assessed by measuring tlie 
luminescence from the reporter gene product. Results expressed as luminescence units relative to 
vehicle control. Data are shown as SEM where n = 5. B) Evaluation of cytotoxicity effect of 50pM 
Wy-14,643 on Huh? cells using the LDH Assay. Level of LDH release was quantified using an 
ELISA plate reader (BioTEK ELxSOO) at 490nm. Results expressed as percentage of cell viability 
and compared to a vehicle control group expressed at 100% cell viability and cells lysed in 1% triton- 
X 100 as 0% cell viability. Data are shown as SEM where n = 5. *= p<0.05, **= p<0.01, 
***= p<0.001 (one-way ANOVA witli Bonferroni post-hoc analysis). The data shown are 
representative of at least two independent experiments.
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3.4.3.4 Activity of human KPNA2 with co transfected human GRa in
the presence of dexamethasone or hydrocortisone
A significant 2.3-fold activation (p<0,05) in the reporter gene activity was observed with 
dexamethasone compared to vehicle (0.1% ethanol). Treatment with hydrocortisone 
caused a 2.5 fold significant activation (p<0.01) when compared to the vehicle (0.1% 
ethanol; Figure 3.10).
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Figure 3.10: Expression of human ICPNA2 prom oter activity Huh? cells in the presence of 
dexamethasone or hydrocortisone. Human KPNA2 promoter (25ng/\vell) was transfected into 
Huh? cells in the presence of a GR expression plasmid (pSG5-GR; 25ng/well). Cells were treated 
with 50pM dexamethasone (DEX) or 50pM hydrocortisone (HC) along witli 0.1% ethanol (vehicle 
control). The level of activation was assessed by measuring tlie luminescence from the reporter gene 
product. Results expressed as luminescence units relative to vehicle control. Data are shown as SEM 
where n = 5 *= p<0.05, **= p<0.01 (one-way ANOVA with Bonferroni post-hoc analysis). The data 
shown are representative of at least two independent experiments.
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3.4.3.S Activity of Human KPNA2 with co transfect human PXR in the
presence of cyproterone acetate or rifampicin
A significant 3-fold inhibition of expression (p<0.001) was observed with CPA compared 
to the vehicle (0 .1% methanol), whereas with rifampicin, a small but not significant 
increase in expression was seen (Figure 3.11). The LDH assay revealed no significant 
increase in cell death compared to the control (data not shown, however cytotoxicity 
across a full range of CPA doses was assessed as separate experiment and are presented 
in chapter 4).
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Figure 3.11: Expression of human KPNA2 prom oter activity in H uh? cells in the presence of 
cyproterone acetate. A) Human KPNA2 promoter (25ng/well) was transfected into Huh? cells with 
a PXR expression plasmid (pSG5-PXR; 25ng/well). Cells were dosed with 50pM cyproterone acetate 
(CPA) or 50pM rifampicin (RIF) along with 0.1% metlianol (vehicle control). The level of inliibition 
of expression was assessed by measuring tlie luminescence from the reporter gene product. Results 
expressed as luminescence units relative to vehicle contiol. Data are shown as SEM where n = 5. *= 
p<0.05, **= p<0.01, ***= p<0.001 (one-way ANOVA with Bonferroni post-hoc analysis). The data 
shown are representative o f at least two independent experiments.
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3.5 Discussion
Karyopherins (importins) are nuclear import factors that mteract with cargo proteins 
containing NLSs and mediate their import into the nucleus. The karyopherin a family of 
adapter proteins form a molecular bridge between nuclear cargoes and the nuclear import 
machinery. Six karyopherin a encoding genes have been identified in humans (Kohler et 
al. 1997) and evidence suggests that these proteins show cargo specificity (Kohler et al. 
1999). To date, no experimental data are available to define the mechanism of 
transcriptional regulation of karyopherins a genes by xenobiotics. Furthermore, there is 
no transcriptional analysis of this family of genes, which would identify any putative 
binding sites of NRs within their promoters and/or enhancers. Interestingly, previous 
work in our lab proposed that the NRs are likely to be central to rat Kpna gene regulation 
(Plant et al. 2006). Therefore, this research is aimed at investigating this area with the aim 
of understanding the transcriptional regulation of the KPNA genes, particularly the 
human KPNA2 gene.
3.5.1 Initial characterisation of the human KPNA2 promoter
Literature suggests that the karyopherin a genes are evolutionarily conserved 
(Mosammaparast and Pemberton 2004). Consequently, determination of the human 
KPNA2 promoter position could be performed by comparing DNA sequences between 
species. Important regions of DNA such as coding regions or regulatory regions tend to 
be conserved between species, although in the case of the latter this conservation is less 
stringent. In this experiment, the position of the human KPNA2 promoter was determined 
by comparing a 20kb sequence upstream of, and including the first exon between the 
human, rat and cattle genomes. In summary, the proximal 2.6 kb showed 50% or more 
similarity in sequence to at least two of these three species. Further more, a search for 
transcription factor binding sites within this region revealed a number of elements found 
in basal promoters. For example, a TATA binding protein (TBP) binding site within 50
1 2 0
bp of the estimated transcription start site and several GC-boxes (binding sites for SPl) 
within the first 0.4 kb were identified. This supports the conclusion that this 2.6 kb region 
includes the proximal promoter and transcription start site of the human KPNA2 gene.
In order to confirm this finding, cloning the 2.6 kb KPNA2 promoter into the pSEAP2 
reporter plasmid, some initial experiments were carried out to characterise its activity. 
The most widely used promoter in mammalian expression systems is the human 
cytomegalovirus immediate-early gene (CMV) promoter. The CMV promoter induces 
high-level constitutive expression in a variety of mammalian cell lines (Fitzsimons et al. 
2002). From figure 3.6, the CMV promoter has the highest SEAP expression followed by 
the human KPNA2 promoter, which was even higher that the SV40 that is reported to 
have an intermediate level of expression. Conversely, an extremely low-level of SEAP 
expression was detected with the CYP3A4 promoter. This is typical of what has 
previously been reported, since the CYP3A4 promoter normally has low levels of activity 
unless induced by xenobiotics (Phillips, 2004). The low endogenous level of PXR in 
Huh7 cells may also help to explain the low-level expression of CYP3A4 in Huh7 cell 
lines, as a major role of constitutive PXR expression is to maintain the basal expression 
of drug metabolising enzymes, including members of the CYP3A family (Phillips et al. 
2005). The pSEAP2-basic vector was used as a negative control as it lacks any promoter 
upstream of the SEAP gene, and it was confirmed that when this vector was used, little or 
no SEAP expression was observed.
The results of the initial transfection experiments not only confirmed the in silico 
analysis, but also identified the human KPNA2 promoter as being of moderate to high 
activity in human liver cells. This analysis gave confidence in the integrity and 
functionality of the promoter and the endorsement to move forward and study the effects 
of xenobiotics on modulating expression of this promoter.
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3.5.2 Regulation of human KPNA2 promoter activity by nuclear 
receptor ligands
In the conserved 2.6 kb proximal region, putative binding sites of seven NRs were 
identified within the human KPNA2 proximal promoter, supporting the suggestion by 
Plant et al. (2006), that karyopherin a  genes are specifically regulated in response to 
xenobiotics. The expression of various NRs in Huh7 cells varies greatly among NRs. As 
discussed previously, studies carried out by Phillips et al., have demonstrated the 
relatively high level of GR and very low level of PXR in Huh7 cells. PXR ligands will 
not take effect without the co-transfection of a PXR expression plasmid whereas, GR 
ligands will still produce a response even without any additional GR expression plasmid 
(Phillips et al. 2005). Moreover, the passage number and the optimum SEAP production 
time points were also optimised by our lab (Aouabdi et al. 2006). Using the conditions 
previously discussed, the role of those NRs for which specific ligands have been robustly 
identified has been systematically analysed.
3.5.2.1 Role of the vitamin D receptor in the human KPNA2 promoter 
activity
In order to study the role of VDR in regulating human KPNA2 gene expression, two 
VDR ligands were used; PB and EGA. PB is a barbiturate that is used as a sedative and 
an anticonvulsant, whereas LCA has been implicated in human and experimental animal 
carcinogenesis (Kozoni, 2000). Despite LCA being a more potent agonist of VDR, 
(Adachi et al. 2005; Ishizawa et al. 2008)when compared to PB, no significant changes 
were seen, whereas a significant inhibition expression was seen with PB.
The fact that a known, potent VDR agonist did not alter KPNA2 activity may suggest that 
the in silico analysis revealed a false VDR binding site within the KPNA2 promoter. It is
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possible that the inhibition of expression seen with PB may be mediated via the CAR and 
not the VDR, since PB is also known to activate CAR resulting in the induction of 
cytochrome P450 genes (Kawamoto et al. 1999; Czekaj 2000; Zelko and Negishi 2000). 
In response to PB exposure, CAR in the cytoplasm translocates into the nucleus, forms a 
heterodimer with the RXR, and activates the PB response enhancer element leading to the 
concerted induction of numerous genes (Zelko and Negishi 2000). Interestingly, a 
putative CAR binding site was detected within the KPNA2 promoter, thus adding weight 
to the possibility of CAR-mediated inhibition of KPNA2 expression by PB. In addition, 
the inhibition seen may be due to a safety-net mechanism in which the cell controls the 
expression of KPNA2 in an ordered manner. Such a control mechanism would directly 
affect the nuclear translocation of CAR and/or other NRs that will eventually reduce the 
expression of various target genes.
3.S.2.2 Inhibition of human KPNA2 expression by progesterone
In order to identify the validity of the PR binding site within the human KPNA2 
promoter, progesterone, a PR agonist was used. Progesterone is steroid hormone that is 
involved in maintaining pregnancy, the female menstrual cycle and embiyogenesis. 
Using the purified LBD of PR fused to the fygal enzyme, it has been shown that the PR 
has a Kd of 1.0-1.5 iiM to progesterone (Bui et al. 1989). From figure 3.8, significant 
inhibition of human KPNA2 activity with minimal cytotoxicity was detected. This 
strongly suggests that the putative PR binding site that was detected by in silico analysis 
is functional. The inhibition of expression may also be due to the safety-net mechanism 
explained previously. Alternatively, the inhibition of expression by progesterone may 
also be mediated by GR, as both PR and GR bind to an inverted repeat as a homodimer, 
separated by three nucleotides AGAACAnnnTGTTCT (Lucas and Grainier 1992). 
Further experiments are required to elucidate the potential role of either the PR or GR on 
the inhibition of KPNA2 expression by progesterone.
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3.S.2.3 Role of PPARa in regulating the human KPNA2
The functionality of PPARa binding sites within the human KPNA2 promoter was tested 
by using its cognate ligands; clofibrate and Wy-14,643. Clofibrate is a lipid lowering 
drug used for controlling high cholesterol and triglycerides levels in the blood. It 
increases lipoprotein lipase activity to promote the conversion of very low-density 
lipoprotein (VLDL) to low-density lipoprotein (LDL), and hence reduces the level of 
VLDL, which is biologically benificial. Studies have shown that clofibrate causes the up- 
regulation of PPARa target genes such as Acyl-CoA (ACO), Carnitine 
palmitoyltransferase 1 (CPT-1) and Stearoyl-CoA desaturase-1 (SCD) (Luci et al. 2007). 
Wy-14,643 is an agonist of PPARa and its potency is species dependent; with receptor 
activation occurring at concentrations as low as 0.1 pM in the mouse compared to 10 pM 
in Xenopiis. The effect of these agents on the human KPNA2 promoter differed greatly in 
this research. No effect was observed with clofibrate, whereas a significant inhibition of 
expression was observed with Wy-14,643. This result was somewhat surprising as both 
agents are well documented agonists of PPARa but neither elicited an induction of 
KPNA2 expression. This finding lead to the conclusion that the putative PPARa binding 
sites within the human KPNA2 promoter are unlikely to be functional.
The inhibition by Wy-14,643 may be explained by the fact that Wy-14,643 causes 
oxidative stress that could lead to the down-regulation of KPNA2 expression. A study has 
reported that Wy-14,643 causes a 16-fold increase in peroxisomal (3-oxidation, which 
generates hydrogen peroxide as a by-product and hence causes oxidative stress to the cell 
(Soliman et al. 1997). Furthermore there is a report that shows that Wy-14,643 induces 
oxidative stress in mouse liver (Woods et al. 2007). It is important to acloiowledge that 
the effects observed herein may be as a result of the differing potencies of these agents 
against PPARa. It should also be noted that only a single dose was examined for 
clofibrate and hence it is difficult to conclude if the lack of repression is due to an 
absence of repressive potential, or the position on the dose response curve studied. 
However, this initial data suggested that the inhibition of KPNA2 expression by Wy-
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14,643 is most probably associated with oxidative stress and this hypothesis is 
investigated in more detail in chapter 5.
3.5.2.4 The glucocorticoid receptor a regulates human KPNA2 gene 
expression
The GR binds as a homodimer to the consensus sequence AGGTCA as an inverted repeat 
(Lee et al. 1993). The GR is widely expressed and is involved in various functions such 
as the regulation of protein and lipid metabolism as well as inflammation (Dahia et al. 
1997). The anti-inflammatory drugs, dexamethasone and hydrocortisone were used to 
examine the functionality of the putative GR binding site within the human KPNA2 
promoter. Both dexamethasone and hydrocortisone are well known and documented 
agonists of GRa, with KdS in the low nanomolar range; 2.7-4.4nM for dexamethasone 
and 1.9nM for hydrocortisone (Honer et al. 2003). A study has shown that 
dexamethasone permits the sugar-induced trafficking of GR in rat intestine via the 
KPNA2 (Douard et al. 2008). Both dexamethasone and hydrocortisone activate KPNA2 
promoter activity showing that the GR binding site is functional and that it may therefore 
play a role in the transcriptional regulation of the KPNA2 gene. Therefore, the postulated 
mechanism of regulation is that upon exposure to GR ligands, the receptor is activated 
and translocated into the nucleus via KPNA2 and the nuclear import machinery. Once in 
the nucleus, GR activates its target genes, including KPNA2 thus potentially resulting in 
an increase in KPNA2-mediated trafficking and as such up-regulating its own nuclear 
import.
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3.S.2.5 Regulation of the human KPNA2 by PXR
The PXR is regarded as a central factor in the body’s response to alterations in chemical 
levels. It is activated by a wide variety of endogenous and exogenous compounds that 
will eventually regulate genes that are involved in the compound’s uptake, metabolism 
and excretion (Kliewer et al. 2002). The presence of a putative PXR binding site within 
the human KPNA2 promoter initially suggested that it may play a role in regulating 
KPNA2 expression upon xenobiotic exposure. To confirm the fiinctionality of this site, 
two PXR ligands, rifampicin and CPA were selected and their effects on KPNA2 
expression determined (Jones et al. 2000; Moore and Kliewer 2000; Kliewer et al. 2002). 
The data gathered from these experiments showed that a significant inhibition of KPNA2 
expression was observed with CPA, whereas the well documented agonist of PXR, 
rifampicin had no significant effect.
The lack of effect with rifampicin was not entirely unexpected since the in silico analysis 
identified only a half-site for PXR binding, meaning that this site is most likely non­
functional. In comparison, CPA elicited a significant inhibition of KPNA2 expression, 
although this may be due to its interaction with different NRs. In addition to being a PXR 
agonist, CPA is also a GR antagonist (Honer et al. 2003). Such an action would be 
supported by the observation that cyproterone acetate has the opposite effect to the two 
GR ligands, both of which significantly induced the human KPNA2 proximal promoter. 
Thus, taken together, the in silico and initial in vitro analysis would suggest that the 
putative PXR binding site within the human KPNA2 promoter is not functional and that 
CPA effects are in fact mediated via GR. This interpretation was tested by further 
analysis, presented in Chapter 4.
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3.6 Summary
The karyopherins a are a family of adaptor proteins that link specific cargos to the 
nuclear import machinery and thereby help to mediate their transport from cytoplasm to 
nucleus. Since many toxicological responses involve gene expression changes mediated 
by the ligand activated transcription factors, which require translocation into the nucleus 
either before or following ligand binding, we have an interest in understanding this gene 
family as part of a coordinated response to xenobiotic exposure. To date there is no 
existing data detailing the transcriptional analysis of the KPNA2 genes, which would 
identify any putative transcription factor binding sites within the promoter of this gene.
In silico analysis has detected seven putative NR binding sites within the KPNA2 
promoter. In order to study the effect of the cognate ligands of these NRs on human 
KPNA2 gene regulation, a reporter clone containing the KPNA2 promoter was generated 
and was thereafter exposed to the cognate ligands of selected NRs. This study provided 
preliminary results with the aim of depicting a framework for the regulation of the human 
KPNA2 promoter by xenobiotics. This initial phase strongly shows that regulation of the 
human KPNA2 gene is dependent on xenobiotics and that these effects are mediated via 
the NRs.
To better understand the human KPNA2 transcriptional regulation mechanism in detail, 
some of the NRs mentioned above were selected for more thorough investigation. The 
NRs of interest, PXR or GR were chosen to elucidate their role in mediating the response 
elicited by CPA. Finally, the role of PPAR agonists and oxidative stress in regulating the 
expression of the human KPNA2 was explored. The experiments performed and the 
results obtained regarding these two mechanisms are described in detail in subsequent 
chapters.
127
4.0 Transcriptional regulation of the human karyopherin a2 (KPNA2) 
gene by cyproterone acetate
4.1 Introduction
The in silico analysis of the human KPNA2 promoter described in the previous chapter 
identified putative binding sites for a number of NRs. This finding is very interesting as it 
provides the first indication that NRs maybe able to regulate human KPNA2 gene 
expression upon xenobiotic exposure. Moreover, the results obtained from the initial 
investigation of the affect of xenobiotics on KPNA2 in a reporter gene assay, suggested 
that upon xenobiotic exposure, some of these NRs were able to regulate the expression of 
KPNA2, This may have an effect on the nuclear import of these NRs since the 
predominant pathway for the nuclear import of other proteins and NRs originates from 
the interaction with the karyopherin superfamily (Gorlich et al. 1996; Nigg 1997; Ohno et 
al. 1998). This may affect the overall biological consequences via the expression of 
respective NR target genes.
One of the xenobiotics that has been shown to affect the human KPNA2 promoter 
(chapter 3), as well as transcript levels of the rat KPNA2 (Plant et al. 2006), is 
cyproterone acetate (CPA). This antiandrogen is interesting because apart from being a 
human and mouse PXR agonist (Lehmann et al. 1998), CPA is also known to be a GR 
antagonist (Honer et al. 2003). As described in section 3.3, putative binding sites for both 
PXR and GRa were identified in the human KPNA2 promoter (regions -1348 to -1358 
and -1217 to -1235 base pairs respectively from upstream and including the first exon), 
and the identification of putative binding sites of both NRs could provide a molecular 
rationale for the observed inhibition of expression of the human ICPNA2 gene.
To further explore the effect of CPA on the expression of the human KPNA2 gene and to 
determine whether this effect is mediated via the PXR or GRa, a number of approaches 
including promoter deletion, site-directed mutagenesis and an electrophoretic mobility 
shift assay were used.
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4.2 Inhibition of the human KPNA2 promoter in the presence of 
cyproterone acetate
Before undertaking these experiments it was first important to establish under which 
conditions CPA inhibits the wild-type human KPNA2 promoter. As well as generating a 
dose response curve, the degree of repression in the presence and absence of exogenous 
NR, principally PXR was also determined.
4.2.1 Dose-dependent inhibition of the human ICPNA2 promoter in the 
presence of cyproterone acetate
The previous analysis of the effect of CPA on the activity of the human KPNA2 promoter 
was carried out at only a single high dose; 50pM. To further examine the inhibition of 
expression from the human KPNA2 promoter by CPA and to ensure that the inhibition 
observed was dose-related, a dose response curve for CPA was generated. Huh? cells co­
transfected with the human KPNA2 promoter cloned into a SEAP reporter vector along 
with a human PXR expression plasmid were dosed with a range of CPA concentrations 
from lOpM to lOOpM. Huh? cells are known to express very low levels of endogenous 
PXR, and hence in order to see responses mediated by this NR, co-transfection with a 
PXR expression plasmid is required (El-Sankary et al. 2001; Phillips et al. 2005). A CPA 
dose-dependent inhibition of the human KPNA2 promoter was observed and strong 
significant inhibition was indicated from 50pM concentrations onwards. An EC50 of 
46pM ±1.15 was calculated from the dose-response curve shown in Figure 4.1.
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Figure 4.1; Inhibition of human KPNA2 promoter by increasing the doses of CPA. Huh? cells 
were co-transfected with the pSEAP2-human KPNA2 (25ng/well) along with an expression plasmid 
for human PXR (pSG5-PXR; 25ng/well) before being exposed to CPA over a dose range of lOpM to 
lOOpM. The level of inhibition of expression was assessed by measuring the luminescence generated 
by the reporter gene product. The points were fitted with non-linear regression to give an EC50 46pM 
±1.15. Results expressed as luminescence units relative to vehicle control. Data are shown as SEM 
where n = 5 and R2 =0.9204. *= p<0.05, **= p<0.01, ***= p<0.001 (one-way ANOVA with 
Bonferroni post-hoc analysis).
In addition, the lactate dehydrogenase (LDH) assay was undertaken to determine if the 
inhibition of KPAN2 expression observed was due to high amount of cell death, as 
opposed to a true inhibitory effect. As shown in figure 4.2, no significant cytotoxicity 
was observed across the entire dose range. This suggests that the inhibition of the human 
KPNA2 promoter is not due the increase amount of cell death, but rather occurs in a 
dose-responsive manner to CPA treatment. Inhibition by CPA is a specific effect and not 
an artefact caused by increased cell death.
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Figure 4.2: Evaluation of cytotoxicity of cyproterone acetate on HuH7 cells using the lactate 
dehydrogenase (LDH) Assay. The level of LDH release was quantified using an ELISA plate reader 
(BioTEK ELxSOO) at 490mn. Results are expressed as percentage of cell viability and compared to a 
vehicle control group expressed at 100% cell viability and cells lysed in 1% triton-X 100 as 0% cell 
viability. Data are shown as SEM where n = 5. *= p<0.05, pO.Ol, ***= p<0.001 (One-way 
ANOVA with BonfeiToni post-hoc analysis). The data shown are representative of at least two 
independent experiments.
4.2.2 No alteration in the level of inhibition of the human KPNA2 
promoter expression in the presence or absence of exogenous 
human PXR
To further examine whether PXR does indeed play a role in the inhibition of KPNA2 
expression seen upon exposure of Huh? cells to CPA, whether there is any difference in 
the level of inhibition in the presence or absence of exogenous human PXR was 
examined. As described above, the rationale behind the supplementation of Huh? cells 
with exogenous PXR (by co-transfection of its expression plasmid) is the very low levels 
of this NR in hepatoma cell lines (Phillips et al. 2005). It is therefore assumed that PXR 
ligands will not affect gene expression without the co-transfection of a PXR expression 
plasmid. By contrast, GR levels in hepatoma cells are much closer to their in vivo levels
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in human liver (Phillips et al. 2005) and as a consequence GR ligands will still produce a 
response in Huh? cells without any additional of GR expression plasmid. Therefore, to 
investigate this theoiy, the Huh? cells transfected with pSEAP-human KPNA2 were 
dosed with 50pM CPA in the presence or absence of the human PXR expression plasmid. 
Figure 4.3 clearly shows that there is no change in the level of inhibition of the human 
KPNA2 promoter, regardless of the presence of exogenous human PXR expression 
plasmid.
Methanol CPA Methanol CPA
No PXR With PXR
Figure 4.3: Alteration in the inhibition of the human KPNA2 promoter in the presence or 
absence of exogenous human PXR. The Huh? cells were transfected with the pSEAP2-lniman 
KPNA2 (25ng/well) along witli expression plasmid for human PXR (25ng/well) before being exposed 
to 50pM CPA along with 0.1% methanol (vehicle control). The level of inhibition o f expression was 
assessed by measuring the luminescence from the reporter gene product. Results expressed as 
luminescence units relative to vehicle control. Data are shown as SEM where n = 5. *= p<0.05, 
>!>«= p<0.01, ***= p<0.001 (one-way ANOVA witli Bonferroni post-hoc analysis). The data shown 
are representative of at least two independent experiments. N.S.= not signiticant.
Taken together with the failure of the PXR ligand rifampicin to alter KPNA2 promoter 
activity (section 3.4.3.5), and the ability of two GR agonists to induce this promoter 
(section 3.4.3.4), this data suggests that it is GR and not PXR that mediates the repression 
of the human KPNA2 promoter by CPA.
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4.2.3 Loss of inhibition of expression of the human KPNA2 promoter by 
glucocorticoid receptor a  following ablation or mutation of its 
putative binding site
To clarify the potential roles of PXR and GRa in regulating human KPNA2 expression, 
further investigations were undertaken to examine the functionality of their putative 
binding sites. These experiments were performed on the premise that if either site is 
involved in the regulation of human KPNA2 by CPA, then upon its deletion and/or 
mutation, the inhibition of expression of the human KPNA2 promoter should be lost.
4.2.3.1 Ablation of the GRa binding site within the human KPNA2 
promoter leads to the loss of inhibition by CPA
In order to demonstrate the role of either PXR or GRa in eliciting the inhibition effect, 
promoter deletion was carried out to produce daughter constructs that either lack the PXR 
binding site, or both PXR and GR binding sites (see Figure 2.2 for the full deletion series 
and figure 4.4 for clones used in this study). Two daughter constructs; ftagment 4/APXR 
and Fragment 5/AGR were generated and were transfected mto the Huh? cells and dosed 
with 50pM CPA. As can been seen from figure 4.4, APXR still retained the ability to 
inhibit the human KPNA2 promoter to the same extent as the whole 2.6kb promoter. 
Interestingly, the AGR construct containing the sequentially deleted GR binding site 
showed a significant loss of GRa mediated inhibition of the human KPNA2 promoter. 
Together these data demonstrate that complete deletion of the GRa binding site results in 
a significant reduction in the inhibition seen previously. This result suggests that the 
identified putative GRa binding site is functional and adds weight to the theory that GRa 
and not PXR is responsible for the inhibition of the human ICPNA2 promoter by CPA.
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A) PXR/PPARa
RORa AREGRVDR PR HNF4
-2.6kb
Fiagineiit 4: APXR -1.32kb
Fragment 5: AGR -0.98kb
SEAP
SEAP
SEAP
B)
***
2.6kbKPNA2 APXR
Methanol
i : î  CPA
AGR
Figure 4.4: Effect of 50 jiM CPA on the sequentially deleted PXR and GR binding sites within the 
human KPNA2 promoter. A) The human KPNA2 promoter or deletion constructs 4 (removing PXR 
half site) and 5 (additionally removing GRE) (25ng/\vell) were transfected into Huh? cells along with 
human PXR or GRa expression plasmid (25ng/well). Cells were dosed with 50pM cyproterone acetate 
(grey bars) or 0.1% methanol (vehicle control; black bars). The level of inhibition of expression was 
assessed by measuring the luminescence from the reporter gene product. B) Results expressed as 
luminescence units relative to vehicle control. Data are shown as SEM where n = 5. *=p<0.05, 
**=p<0.01 ***= p<0.001 (one-way ANOVA with Bonferroni post-hoc analysis) as compared to 
vehicle control. The data shown are representative of at least two independent experiments.
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4 2.3.2 Loss of human KPNA2 promoter inhibition by CPA following 
mutation of GRa binding site
The data above suggest that while the GR site within the human KPNA2 promoter is 
functional, the PXR site is probably not. However, whilst it is a rapid and convenient way 
of studying multiple putative regulatory elements, promoter deletion is a relatively crude 
approach to understanding individual sites, since each deletion removes several hundred 
base pairs from the promoter. In the case of the human KPNA2 promoter deletions 
described above, there is a 340 bp difference in the size of fragments 4 (APXR) and 5 
(AGR), which may include other un-identified transcription factor binding sites. For this 
reason, site-directed mutagenesis (SDM) was undertaken on the putative PXR and GRa 
binding sites within the human KPNA2 promoter; The underlying principle being that 
with SDM, mutations are only introduced at specific sequences within the putative 
binding site of interest, without altering the rest of the promoter. SDM therefore provides 
a more precise evaluation of promoter function than does promoter deletion by ensuring 
that any changes observed are due to the mutation of the predicted NR recognition 
sequence and not any other region within the promoter.
Two mutant plasmids were generated: in SDM of PXR, the PXR half site was mutated by 
the introduction of an Xho I restriction site at the most highly conserved bases within the 
putative binding site, whereas for SDM of GR, a similar strategy was used to mutate the 
putative GRE (see figure 4.5A). In silico analysis was carried out to confirm that the 
mutations introduced should ablate NR binding. The effects of these mutations were then 
examined by transfecting the mutated plasmids (pSEAP human KPNA2 SDM PXR and 
pSEAP human KPNA2 SDM GR) into Huh? cells and dosing with 50pM CPA or vehicle 
control. As can be seen in figure 4.5, when compared to its vehicle control, SDM PXR 
still elicited a significant inhibition of expression, the same in magnitude as the wild type 
construct (2.6kb human KPNA2 promoter). Conversely, inhibition of expression is totally 
lost when the GRa binding site is mutated. This strongly suggests that the inhibition of 
the human KPNA2 promoter by CPA is likely to be mediated via GRa.
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A) PXR wildtype C C T T T A TG A A CTCTG G CTTTRCG A TG A A TG
PXR mutant C CTTTA CTCG A G CTG G CTTTA CG A TG A A TG
B)
GRE wildtype 
GRE mutant
G TAATCTTTTAG A ACACA A AA A AA TTG C
G TA A TCTTTTCTCG A G CA A A A A A A TTG C
Methanol
CPA
2.6kbhKPNA2 + PXR SDM PXR + PXR 2.6kb hKPNA2 + GR SDMGR+GR
Figure 4.5: Effect of 50fiM CPA on the wild type construct, mutated PXR and GR binding sites 
within the human KPNA2 promoter. The human 2.6kb KPNA2 promoter representing tlie wild 
type constract and A) site-directed mutants (SDM) o f PXR and GRa (25ng/well) were transfected 
into Hull? cells along with either human PXR or GRa expression plasmid (25ng/well) respectively. 
Cells were dosed with 50pM cyproterone acetate along with 0.1% methanol (vehicle control). The 
level of inliibition of expression was assessed by measuring the luminescence generated by the 
reporter gene product. B) Results expressed as luminescence units relative to vehicle control. Data 
are shown as SEM where n =  5. *=p<0.05, *^'=p<0.01 ’■'^‘*=p<O.OGl relative to vehicle control (one­
way ANOVA with Bonferroni post-hoc analysis). The data shown are representative of at least two 
independent experiments. SDM= site-directed mutant; predicted half sites are underlined, mutated 
bases are in red. For the GRE two bases that deviate from tlie consensus sequence are shown in 
italics.
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4.3 Functionality of the PXR and GRa binding sites
To confirm the results obtained above, it was finally necessary to show that the human 
KPNA2 GRE is able to bind to its NR, whereas the there is no such binding by PXR to its 
putative site. Further analysis by electrophoretic mobility shift assay (EMSA) was 
carried out using oligonucleotides representing wild type DNA for both PXR and GRa 
binding sites and both of the mutations described above. The EMSA is based on the 
observation that if a particular DNA sequence interacts with a protein, it will form a 
complex, and this complex, being larger migrates more slowly than free DNA during 
electrophoresis in a non-denaturing polyacrylamide gel thus resulting in a band shift. 
Therefore, if either the PXR or GRa binding site is functional, it will form a complex 
with the protein and result in such a band shift. On the other hand, successful mutation of 
the NR binding site would prevent this protein interaction and therefore no alteration in 
DNA migration would be observed. These experiments with therefore confirm the 
validity of the putative NR binding sites and will also demonstrate the effectiveness of 
site directed mutagenesis.
4.3.1 Electrophoretic mobility shift assay binding reactions
In order to detect the functionality of the PXR or GRa binding sites, two short 
complementary DNA oligonucleiotides corresponding to the sequence of each putative 
NR binding site from human KPNA2 were generated; one of these oligonucleotide 
strands was biotin-labelled. The oligonucleotides were hybridised to one another before 
being mixed with proteins from naïve Huh? nuclear extract, nuclear extract from 
transfected Huh? cells over-expressing either PXR or GRa as appropriate, or a 
transcription and translation (TNT) reaction for either PXR or GRa. If the DNA interacts 
with any protein within these extracts it will form a complex and a shift will be detected 
(lane 2 in the following figures). To show the specificity of binding, an incubation was 
also performed in the presence of a 200-fold molar excess of unlabelled DNA (lane 3). A 
negative control was performed in the absence of protein extract (lane 1), while a positive 
control consisting of a well documented PXRE (taken from CYP3A4: ER6) or GRE
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(taken from the GRa target gene tyrosine aminotransferase; TAT) was also carried out 
(lane 4). If the putative NR sites from human KPNA2 bind to PXR or GRa then any 
bands observed in lane 2 should therefore correspond with the positive control bands in 
lane 4.
In figure 4.6, it can be seen that there is no retarded band observed for PXR (figure 4.6, 
lane 2) that corresponds in size to that of a positive control (CYP3A4-ER6; lane 4) under 
any of the conditions (naive or transfected cells or using PXR generated in vitro). This 
strongly suggests that the PXR binding site within the human KPNA2 promoter is non­
functional. This result agrees with the SEAP reporter gene studies that showed no 
response when cells were dosed with the potent PXR ligand, rifampicin (chapter 3, figure 
3,11). Taken together with the promoter deletion and mutagenesis analysis described 
above (section 4.2.3.1 and 4.2.3,2 respectively), these results indicate that the response of 
the human KPNA2 promoter to CPA is not mediated via the pregnane X receptor.
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A) Naïve Huh? B) Transfected Huh? C) TNT reaction
Tanc 1 2  3 4 1 2  3 4 1 2  3 4
Huh? extract (20ng) _ + + +  + + +
PXR TNT reaction (20^1) + + +
hKPNA2-PXRE (200fmol) + + + - + + + . + + + .
Competitor (40pmol) + +
CYP3A4-ER6 (200fmol) . . .  +
Free DNA
Figure 4.6: Analysis of hKPNA2-PXR response element binding to protein extract by 
electrophoretic mobility shift assay. The 3’ biotin labelled oligonucleotides (200fmol) were incubated 
in the absence (lane I)  or presence (lanes 2, 3 and 4) of A) naive Huh? nuclear extract B) nuclear 
extract from Huh? cells transfected with pSG5-PXR for 48 h or C) a coupled in vitro transcription and 
translation (TNT) reaction performed using pSG5*PXR. In parallel experiments, incubation was 
performed in presence of 200 fold molar excess of unlabelled DNA (lane 3) to show specificity of 
binding. A positive control was performed (lane 4) by incubating 3' biotinylated-oligonucleotides 
containing the everted repeat ER6 from CYP3A4, with appropriate extract. Samples were separated on a 
6% non-denaturing PAGE gel and labelled oligonucleotides detected by chemilurainescence. S“ DNA:protein 
complex.
In comparison, retarded bands corresponding in size to those generated using a control 
DNA fragment containing the well-characterised GR from the TAT GR response element 
were detected using oligonucleotides containing the human KPNA2 GRE. Although the 
intensity of human KPNA2-GR binding site is not as strong as the positive control, this 
band retardation suggests that the GRa binding site within the KPNA2 promoter is fully 
functional. Thus, the dexamethasone and hydrocortisone results presented in chapter 3, 
where activation of the human KPNA2 promoter was detected (chapter 3, figure 3.10), 
correspond to this finding. This might also suggest that the inhibition observed from CPA 
may also be mediated via GRa.
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Figure 4.7: Analysis of hKPNA2-GR response element binding to protein extract by 
electrophoretic mobilit) shift assay. The V  biotin labelled oligonucleotides (200fmol) were incubated 
in tlie absence (lane I)  or presence {lanes 2, 3 and 4) of A) naive Huh? nuclear extract B) nuclear 
extract from Huh? cells transfected with pSG5-GR for 48 h or C) a coupled in vitro transcription and 
translation (TNT) reaction performed using pSG5-GR. In parallel experiments, incubation was 
performed in presence of 200 fold molar excess of unlabelled DNA {lane 3) to show specificity of 
binding. A positive control was performed {lane 4) by incubating 3’ biotinylated-oligonuc leotides 
containing the tyrosine aminotransferase glucocorticoid response element (TAT-GRE), with appropriate 
extract. Samples were separated on a 6% non-denaturing PAGE gel and labelled oligonucleotides detected by 
chemiluminescence. S=DNA;protein complex.
Finally, the same experiment was repeated but with the wild type GRa binding site sequences 
replaced by the SDM GRa binding site sequences. As seen in figure 4.8, the SDM GRa band 
was very much weaker than observed with the wild type, suggesting that the mutated GRa 
binding sites has significantly lower affinity for GR. This is consistent with the transfection 
data, which demonstrated that the SDM of GRa completely ablated the GRa mediated 
inhibition of human KPNA2 promoter expression.
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Huh? extract (20pg) + +
hKPNA2-GRE (200fmol) + + +
Competitor (40pmol) +
TAT-GRE (200fmol)
Free DNA
Figure 4.8: Analysis of SDM KPNA2-DNA binding to naïve Huh? nuclear extract by 
electrophoretic mobility shift assay. Oligonucleotides containing mutated KPNA2 GRE were 3’ 
biotinylated and incubated in the absence {hne  7) or presence (lanes 2, 3 and 4) of Huh? nuclear 
extract. To show the specificity of binding, incubation was also performed in presence of 200 fold molar 
excess of unlabelled DNA {lane 3). Die positive control {lane 4) was the tyrosine aminotransferase 
glucocorticoid response element (TAT-GRE), as previously described. Samples were separated on a 6% 
non-denaturing PAGE gel and labelled oligonucleotides detected by chemiluminescence. S=DNA protein 
complex.
4.4 Discussion
The work described in chapter 3 used in silico analysis to identify putative NR binding 
sites, including those for PXR and GRa, within the human KPNA2 promoter. This 
provided the insight that the human KPNA2 gene may be regulated by NRs, and was 
supported by preliminary experiments in which cells transfected with a reporter gene 
under the control of the human KPNA2 promoter were treated with a single dose of a 
variety of NR ligands. From the reporter gene data, the effect elicited by CPA was of 
particular interest because apart from being a human PXR agonist (Lehmann et al. 1998), 
it is also a GR antagonist (Honer et al. 2003). Since both NR binding sites were identified 
within the human KPNA2 promoter, the aim was to further understand whether the effect 
of CPA on the human KPNA2 promoter was elicited via PXR or GRa. In order to do this, 
a number of experiments were derived to elucidate the potential mechanism.
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Since inhibition of the human KPNA2 promoter expression at 50pM CPA was observed, 
the next logical step was to investigate whether the inhibition seen occurs in a dose- 
dependent manner. The result generated, shows that the CPA inhibition does indeed 
occur in a dose-dependent manner, where significant inhibition was observed from 50pM 
onwards (figure 4.1) and with no significant cytotoxic effect (figure 4.2). This indicates 
that the inhibition seen is due to the effect of CPA on the human KPNA2 promoter and 
not because of high amounts of cell death. For consistency and comparability, the dose 
50pM dose was selected for all future experiments as as it was close to the observed IC50 
(46 pM).
The in silico analysis described in chapter 3 showed that the putative transcription factor 
binding site for GRa was much more likely to be factional than the PXR binding site, 
where only a half-site was identified. Therefore it was hypothesised that the effect of 
CPA on the human KPNA2 promoter was more likely to be mediated via GRa. CPA was 
also noted to be a GR antagonist, an opposite effect to the two other GR ligands used, 
both of which significantly induce the human KPNA2 promoter (Figure 3.10). Evidence 
to support this mechanism was gathered from a number of experiments.
Firstly, it is important to acknowledge the relative levels of endogenous NRs in Huh? 
cells. Levels of GR in this cell line is comparable to human liver but much lower levels of 
PXR are expressed (Phillips et al. 2005). PXR ligands will not affect gene expression in 
Huh? cells without exogenously supplied PXR (by the transfection of PXR expression 
plasmid) whereas, GRa ligands will still respond even without any additional of 
exogenous GRa. Taking advantage of this varying expression level of both NRs it was 
possible to examine whether any difference in level of CPA inhibition existed with or 
without addition of exogenous PXR expression plasmid. If CPA action on human 
ICPNA2 is mediated by PXR, no, or little, response should be observed in wild type Huh? 
cells when dosed with CPA. It was demonstrated that there was no significant difference 
between the levels of CPA inhibition regardless of PXR expression status (figure 4.3) 
thus further signifying that the response seen is unlikely to be mediated via PXR but via 
another NR, which is most likely the GRa.
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The next step was to see whether there would be any difference the in inhibition by CPA 
upon removal of either the PXR or GRa binding sites from within the human KPNA2 
promoter. This was initially carried out by the analysis of a sequential deletion series. 
From the data obtained, it can be seen that inhibition by CPA was still apparent when the 
PXR binding site was ablated and that, this inhibition was lost when the GRa binding site 
was deleted (figure 4.4). This evidently shows the potential role of GRa in eliciting the 
CPA effect. However, one important drawback to this experiment is that it does not only 
ablate the binding site of interest but also a large portion of the promoter. It could 
therefore be argued that the loss of inhibition may not be due specifically to the ablated 
binding site. To overcome this issue, site-directed mutagenesis, which specifically 
mutates the sequence of interest, (i.e. the PXR or GRa binding site) without altering the 
remainder of the human KPNA2 promoter was carried out. The sequence within the 
binding sites that was mutated was founded on the bases that are the most highly 
conserved.
Prior to examining the effect of these mutations in vitro, the new mutated binding site 
was re-analysed using the in silico method employed previously. The in silico analysis 
did not detect any putative PXR and/or GR binding site(s) remaining following 
mutagenesis, suggesting that the important binding region had been successfully mutated. 
Consequently, in vitro experiments were carried out whereby the Huh? cells were 
transfected with the SDM PXR and SDM GRa plasmids along with co-transfection with 
PXR and GRa expression plasmids, and were dosed with CPA. The results clearly show 
that the inhibition was still present despite the PXR binding site being mutated, while the 
inhibition was completely lost when the GRa binding site was mutated (figure 4.5). 
Together, the promoter deletion and SDM consolidated the opinion developed herein that 
GRa may play an important role in regulating the human KPNA2 gene upon CPA 
exposure.
Finally, to confirm that GRa is the key regulator in controlling the response of the human 
KPNA2 promoter to CPA exposure, and that the binding site for PXR is truly non 
functional, EMSA was carried out. From the results obtained it clearly shows that there is
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no band shift observed for the putative PXR binding site (figure 4.6), thus suggesting that 
this site is non-functional. This is consistent with the in silico analysis showing only the 
presence of a half-site, and the reporter gene assays (including deletions and SDM) that 
suggested that this site was probably not functional. By contrast, the GRa binding site 
within the human ICPNA2 promoter was shown to be functional as evidenced by the band 
shifts observed in figure 4.7. To confirm that binding to SDM GRa was totally ablated, 
EMSA was also carried out on the mutated GRE. From the result in figure 4.8, it is clear 
that binding to the mutated receptor is much weaker than to the wild type. This reduced 
affinity could account for the observed lack of inhibition. Overall, the EMSA 
experiments support the hypothesis that the PXR binding site is not functional whereas 
the GRa is fully functional.
In combination, the data gathered strongly suggests that CPA may be able to regulate 
human KPNA2 expression via GRa, although these experiments do not define the 
mechanism inhibition by CPA. Interestingly, studies carried out by Honer and colleagues, 
clearly demonstrate that CPA causes GR antagonism in vitro and in vivo and further 
explained its mechanism of antagonism (Honer et al. 2003). They clearly demonstrated 
that CPA competitively antagonised dexamethasone-induced GR transactivation and that 
CPA does not possess intrinsic transactivatiiig properties (Honer et al. 2003). Building on 
this information, the following model is proposed for the mechanism of down-regulation 
of human KPNA2 gene expression by CPA.
A number of endogenous GR ligands, such as cortisol that is important in regulating a 
variety of important cardiovascular, metabolic, immunologic, and homeostatic functions, 
are constitutively present both in vivo and in in vitro cell culture systems (being a 
component of the serum which is added to medium). Cortisol or any other GR cognate 
ligand, may bind to the ligand binding domain of GR, forming a complex. This complex 
is then translocated into the nucleus via the nuclear pore complex where it binds to the 
GR response element of the human KPNA2 gene, causing the transactivation/up- 
regulation of KPNA2. KPNA2 protein then in turn regulates the nuclear import of 
proteins that are involved in various biological processes (Figure 4.9A). When CPA is
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present, it passively diffuses into the nucleus and causes competitive displacement of 
cortisol from the GR ligand binding pocket to reach a new stability equilibrium. Since 
CPA lacks intrinsic transactivation properties, this will result in the down-regulation of 
human KPNA2 gene expression (Figure 4.9B).
Since CPA lacks bulky side chain as other antagonist as described previously in section 
1.2.3.2, the functional effect may occur by a different mode of receptor antagonism as 
suggested by (Shiau et al. 2002) with ERp antagonist compound, THC (R,R enantiomer 
of 5,1 l-cis-diethyl-5,6,1 l,12-tetrahydrochrysene-2,8-diol). The THC also lacks the bulky 
side chain and no steric hindrance of the AF-2 helix was revealed in the crystal structure 
of the ER|3 /THC complex (Shiau et al. 2002). Therefore, THC antagonised ERj3 by 
stabilising non-productive conformation of key residues in the ligand binding pocket thus 
disfavouring agonist binding to the helix 12 and favour inactive confirmation of helix 12. 
They referred to this mode as ‘passive antagonism’ (Shiau et al. 2002). In detail, Shiau 
and colleagues showed that the Leu 476, which form only non-polar contacts with the A’ 
ring region of the binding pocket, was positioned 2.3Â away as compared to normal 
antagonist position and this causes the Met 479 to adopt a random coil conformation. The 
failure of both Leu 476 and Met 479 to be positioned appropriately destabilise active 
conformation of helix 12 by positioning certain binding pocket residues in non­
productive confirmation as described above (Shiau et al. 2002).
Theoretically, since CPA is lacking the bulking side chain, it may induce a similar 
‘passive antagonism’ mode that alters the stability equilibrium towards an inactive 
receptor conformation and this theory idea was also shared by (Honer et al. 2003).
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Figure 4.9: Mechanism of CPA dependent regulation of the human KPNA2 gene by GR 
antagonism. A). Cortisol, an endogenous GR ligand, associates with GR (1) and the resulting complex 
is translocated into the nucleus tlirough the nuclear pore complex (2). Once in the nucleus, this complex 
then binds to the response element on the human KPNA2 promoter (3) and up-regulates the human 
KPNA2 gene expression (4). B) Upon exposure CPA passively diffiises into the nucleus (5) and 
competitively displaces the cortisol from GR (6) to form a GR-CPA complex (7) which has no 
transactivating properties therefore resulting in the downregulation of the cortisol induced KPNA2 
expression (8). C=cortisol; CPA=cyproterone acetate, GR=glucocorticoid receptor, NPC=nuclear pore 
complex, GRE=glucocorticoid response element.
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4.5 Summary
In summary, it has been proven that the down-regulation of the human KPNA2 gene by 
CPA is mediated via the GRa. This was achieved by showing that CPA inhibits the 
human KPNA2 promoter in a dose-dependent manner. Through deletion and mutation 
analysis it has been elucidated that the inhibition seen was mediated via GRa and not 
PXR. In addition, it has been demonstrated that the putative PXR binding site is not 
functional, whereas the GRa binding site is fully functional. Based on these findings, a 
model explaining the possible mechanism of the down-regulation of the KPNA2 by CPA 
via passive antagonism of GRa has been proposed. The biological impact of this 
mechanism forms part of a wider discussion on the affect of altering levels of KPNA, and 
are addressed in chapter 6 .
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5.0 Transcriptional regulation of the human karyopherin «2 (ICPNA2) 
gene by oxidative stress inducers
5.1 Introduction
From the data presented in previous chapters it was shown that some NRs were able to 
regulate the expression of the human KPNA2 gene. Furthermore, it was postulated that 
this may affect biological processes by altering the expression of target genes for 
transcription factors, including the NRs, which are transported by KPNA2. Another 
interesting avenue worthy of further exploration was the role of Wy-14,643 in regulating 
the human KPNA2 gene. As seen in chapter 3, Wy-14,643 elicited a significant inhibition 
of human KPNA2 expression. This hypolipidemic drug is a potent PPARa activator 
across a wide range of species including human with receptor activation concentrations 
ranging from as low as 0.1 pM in mouse compared to 10 pM in Xenopus (Hsu et al. 
1995; Devchand et al. 1996; Forman et al. 1997; Keller et al. 1997; Tenhaken et al. 2001; 
Ip et al. 2004). As a consequence of being a PPARa activator, Wy-14,643 causes a 16- 
fold increase in peroxisomal p-oxidation, which generates hydrogen peroxide as a by­
product (Soliman et al. 1997). Excess hydrogen peroxide can cause oxidative stress to the 
cell, which has been shown to cause damage in mouse liver (Woods et al. 2007). Thus, 
while it is possible that regulation of the KPNA2 promoter by Wy-14,643 is caused by 
direct interactions between PPARa and putative binding sites identified in the KPNA2 
proximal region, it is also possible that this may be an oxidative stress response.
To further explore the mechanism of Wy-14,643 action the expression of the human 
KPNA2 gene, two well documented oxidative stress inducers, namely hydroquinone and 
hydrogen peroxide, were used to determine whether alterations in KPNA2 promoter 
activity are also directly caused by oxidants. Promoter deletion, SDM and EMSA were 
also used to determine which transcription factor(s) are responsible for mediating the 
response to Wy-14,643, in order to further distinguish direct regulation by PPARa from 
oxidative responses.
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5.2 Inhibition of the human KPNA2 promoter in the presence of Wy- 
14,643
Before embarking on further detailed promoter analysis, it was firstly important to 
determine if the inhibition seen with Wy-14,643 is dose-dependent and to determine 
whether a similar inhibition was seen in response to oxidants.
5.2.1 Dose-dependent inhibition of the human KPNA2 promoter in the 
presence of Wy-14,643
Previous analysis of the effect of Wy-14,643 on human KPNA2 promoter activity was 
carried out at only a single, high dose; 50pM. To further examine the inhibition of 
expression from the human KPNA2 promoter by Wy-14,643 and to ensure that the 
inhibition observed was dose-related, a dose response curve for Wy-14,643 was 
generated. Huh? cells were co-transfected with the human KPNA2 promoter cloned into 
a SEAP reporter vector, and a PPARa expression plasmid. Cells were then treated with 
vaiying concentrations of Wy-14,643, from 5pM to lOOpM. As can be seen in Figure 
5.1, dose-dependent inhibition of the human KPNA2 promoter was observed, which was 
significant at all doses and for which an EC50 of approximately 5 pM was determined 
(Figure 5.1). Importantly, as was previously shown at 50 pM Wy-14,643, this effect was 
not caused by excessive cell death as the LDH assay showed no significant difference 
between treated and control groups (data not shown).
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Figure 5.1: Inhibition of human KPNA2 prom oter by increasing doses of Wy-14,643. Huh? cells 
were transfected with the pSEAP2-human KPNA2 (25ng/well) along with an expression plasmid for 
human PPARa (pCR3-PPARa; 25ng/well) for 24 h before being exposed to Wy-14,643 over a dose 
range of 5|.iM to lOOpM for 48 h. The level of inhibition of expression was assessed by measuring the 
lumineseenee from the reporter gene product; post-dose reading were normalised to pre-dose levels 
and are expressed as relative lumineseenee units (RLU). Data are shown as SEM where n = 5. 
*=p<0.05, **=p<0.01, ***= p<0.001 (one-way ANOVA with Bonferroni post-hoe analysis) The 
points were fitted with non-linear regression to give an EC^^ of 5pM and an R  ^of 0.8276.
5.2.2 Dose-dependent inhibition of the human KPNA2 promoter in the 
presence of oxidative stress inducers
Since Wy-14,643 can also cause oxidative stress (Soliman et al. 1997; Woods et al. 
2007), it was important to determine whether human KPNA2 can also be inhibited under 
oxidative conditions. A dose response curve for the potent oxidative stress inducer, 
hydroquinone (HQ) was generated by dosing Huh7 cells transfected with the human 
KPNA2 promoter reporter clone with varying concentration of HQ, from IpM to lOOpM. 
Dose-dependent inhibition of the human KPNA2 promoter was observed, and strong 
significant inhibition was indicated from 20pM onwards with an E C 5 0  of 15pM ±1.23 
(Figure 5.2). As with Wy-14,643, there was no significant increase in cell death at any of
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these doses used, suggesting that the effect is specific to the KPNA2 promoter (data not 
shown).
EC6o=15hM±1.23 
Ef = 0.91
P SO-
=? 2&
40 SO 60 70
[fVdroqulnone] pM
90 100 110
Figure 5.2: Inhibition of human KPNA2 prom oter by increasing the doses of HQ. Hull? cells 
were transfected with the pSEAP2-human KPNA2 (25ngAveIl) along with co-transfection of 
expression plasmid for human PPARa (25ng/well) before being exposed to HQ over a dose range of 
IfiM to lOOpM. After 48 h SEAP expression was measured using the Phospha-Light™ Secreted 
Alkaline Phosphatase Reporter Gene Assay System kit and post-dose readings were noiinalised to 
pre-dose SEAP expression, as a transfection control. Results are expressed as luminescence relative to 
vehicle control; data shown represent the mean and SEM where n = 5. *=p<0.()5, **=p<0.01, 
>:<>i«>s<= p<0,001 (one-way ANOVA with Bonferroni post-hoc analysis). The points were fitted with 
non-linear regression to give an EC50 of iSpM ±1.23; R^ =0.91.
As well as being an inducer of oxidative stress that activates the NF-E2-related factor 2 
(Nrf2) transcription factor (Rubio, 2011), HQ is also known to interact with the aryl 
hydrocarbon receptor (AhR; (Gharavi and El-Kadi 2005)). Interestingly, both AhR and 
Nr£2 transcription factor binding sites were detected within the human KPNA2 promoter, 
at positions -480 to -504 and -139 to -159 base pairs upstream of the first exon 
respectively. In order to determine which transcription factor could provide a molecular 
rationale for the observed inhibition of expression of the human KPNA2 gene, the 
response to HQ was firstly compared with that of a well known agonist of the AhR, (3- 
naphtoflavone (Chirulli et al. 2007; Platzer et al. 2009; Ramirez et al.). This was
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undertaken to determine if p-naphtoflavone acts via the putative AhR binding site within 
the human KPNA2 promoter. A dose response curve of P-naphtoflavone was generated 
by dosing Huh? cells transfected with the human KPNA2 reporter clone with varying 
concentration of (3-naphtoflavone, ranging from IpM to lOOpM (Figure 5.3).
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Figure 5.3: Inhibition of human KPNA2 promoter by increasing the doses of p-naphtoflavone.
Huh? cells were co-transfected with the pSEAP2-human KPNA2 and the PPAR expression plasmid 
(25ng/well each) before being exposed to p-naphtoflavone over a dose range of 1 pM to 100 pM. The 
level of inliibition of expression was assessed by normalising the luminescence from the reporter gene 
product in media taken 48 h after dosing with pre-dose levels. Results are expressed as luminescence 
units relative to the vehicle control. Data are shown represent the mean and SEM where n = 5 and 
were analysed by one-way ANOVA with Bonferroni post-hoc analysis. The data was fitted with non­
linear regression: R  ^=0.33.
No significant effect on the KPNA2 promotor was observed across the whole 
concentration range (Figure 5.3). This finding suggests that the effect elicited by HQ may 
be mediated by Nrf2 and not through AhR. To further consolidate this mechanism 
another potent ligand of Nrf2, hydrogen peroxide (H2O2), was also used (Figure 5.4). A 
dose response curve for H2O2 was generated by dosing Huh? cells transfected with the 
human KPNA2 reporter clone with varying concentrations of H2O2, from lOpM to 
lOOOpM. Significant dose-dependent inhibition of the human KPNA2 promoter was
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observed at all doses (Figure 5.4) and for which an EC50 of 62.5 |iM was determined. 
This finding suggests that the Nrf2 binding site within the human KPNA2 promoter is 
functional and the observed initial inhibition with Wy-14,643 may at least in part be an 
oxidative response mediated via Nrf2.
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Figure 5.4: Inhibition of human KPNA2 prom oter by increasing the doses of HjOj. Huh? ceils 
were co-traostectecl with tlie pSEAP2-human KPNA2 and the PPAR expression plasmid (25 ng/well 
each) before being exposed to HjOj over a dose range of lOpM to lOOOpM, The level of inhibition of 
expression was assessed by measuring the luminescence generated by the reporter gene product, 
normalising post- to pre- dose reading. Results are expressed as luminescence units relative to vehicle 
control. Data are shown as the mean and SEM where n = 5. *=p<0.05, ’='*=p<0.01, p<0.001 (one-way
ANOVA with Bonferroni post-hoc analysis). The points were fitted with non-linear regression to give an 
ECjoof62.5pM; R2=0.56.
5.3 Functionality of the predicted PPAR and Nrf2 binding sites
To further consolidate the roles of PPARa and Nrf2 in the regulation of the human 
KPNA2 expression, further investigations were undertaken to examine the functionality 
of their binding sites. If any of the binding sites were functional, upon ablation and/or 
mutation, the inhibition of expression of the human KPNA2 promoter in response to 
oxidants would be lost. Parallel experiments to determine whether the putative binding
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sites are able to interact with their predicted protein partners were also carried out. 
Together, these experiments began to clarify how the KPNA2 gene might be regulated in 
response to oxidants and the chemicals that can stimulate their production.
5.3.1 Deletion of the Nrf2 binding site, but not the PPREs, within the 
human KPNA2 promoter leads to the loss of inhibition by HQ
In order to distinguish the role of either the peroxisome proliferator response element 
(PPRE) or the Nrf2 binding site (ARE) in eliciting the inhibition effect observed, 
promoter deletion was carried out to produce daughter constructs that lack the first 
PPARa binding site, both PPARa sites, or both PPREs and the Nrf2 binding sites. For the 
PPREs, daughter constructs fragment 4 (APPARal) and fragment 6 (A both PPARa) 
were generated and were transfected into the Huh? cells and dosed with 50pM of HQ. As 
can been seen from figure 5.5, neither ablation of the single, most upstream, PPARa 
binding site nor deletion of both PPREs affected the inhibition of the human KPNA2 
promoter by HQ. In both cases, inhibition still occurred to the same degree as with the 
whole 2.6kb promoter.
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Figure 5.5: Effect of 50 pM HQ on the ablated PPARa binding sites within the human KPNA2 
promoter. A) The human KPNA2 promoter or deletion constructs 4 (removing the distal PPAR binding site) 
and 6 (removing both PPAR sites) (25ng/well) were co-transfected into Huh? cells along with human PPARa 
expression plasmid (25ng/well). Cells were dosed with 50pM hydroquinone (grey bars) or 0.1% 
milliQ water (black bars; vehicle control). The level o f  inhibition o f expression was assessed by 
measuring the luminescence from the reporter gene product. Results expressed as luminescence units 
relative to vehicle control. Data are shown as the mean and SKM where n = 5. *=p<().()5, **=p<0.01, 
***= p<0.001 (one-way ANOVA with Bonferroni post-hoc analysis). The data shown are 
representative o f at least two independent experiments.
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In contrast, when the daughter construct in which the Nrf2 binding site was deleted 
(ANrf2; fragment 7) was transfected and the cells were treated with HQ, there was a 
complete loss inhibition of the human KPNA2 promoter (Figure 5.6). This suggests that 
the Nrf2 binding site may mediate this response, however it should be noted that the 
putative Nrf2 site is close to the predicted transcription start site for human KPNA2. 
Therefore, it is possible that other vital promoter elements have also been removed in this 
case. In summary, these data demonstrate that complete deletion of the Nrf2 binding site 
results in loss of the inhibition seen previously, and suggest that the identified putative 
Nrf2 binding site is functional and that Nrf2 is responsible for the inhibition of the human 
KPNA2 promoter by HQ.
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Figure 5.6: EfTect of 50 pM HQ on the KPNA2 promoter ablated for Nrf2 (ARE) binding sites.
A) The human KPNA2 promoter or deletion constructs 7 (removing the distal Nrt2 binding site) were co­
transfected into Huh? cells along with the PPAR expression plasmid (25ng/well each). Cells were 
dosed with 50pM hydroquinone along with 0.1% milliQ (vehicle control). The level of inhibition of 
expression was assessed by measuring the luminescence from the reporter gene product. Results 
expressed as luminescence units relative to vehicle control. Data shown represent the mean and SEM 
where n = 5. *= p<0.05 (one-way ANOVA with Bonferroni post-hoc analysis). The data shown are 
representative of at least two independent experiments.
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5.3.2 Loss of human KPNA2 promoter inhibition by HQ following 
mutation of Nrf2 binding site
While promoter deletion is a crude method to study the functionality of putative 
transcription factor binding sites, it not only ablates the desired binding sites but also a 
vast chunk of other sequences as well. Therefore SDM was carried out on both putative 
PPARa sites as well as the predicted Nrf2 binding site within the human KPNA2 
promoter. As shown in figure 5.7A, mutations that simultaneously alter the most 
conserved bases within the putative binding sites and introduce restriction sites (for 
cloning and detection) were introduced into the 2.6 kb human KPNA2 promoter clone. In 
silico analysis of the mutant sequences confirmed that they would no longer be expected 
to bind to PPARa or Nrf2. The effects of these mutations were then examined by 
transfecting Huh7 cells and dosing with 50pM HQ.
As shown in Figure 5.7B, all three of the mutant report clones were still able to respond 
to HQ, showing similar levels of repression to the wild-type sequence of the KPNA2 
promoter. This was perhaps not surprising for the two PPRE mutants, since the role of 
PPARa is that of an oxidative stress generating transcription factor rather than one that 
responds to it. Further experiments would determine whether these mutations also 
prevent the human KPNA2 response to Wy-14,643 and would therefore clarify how this 
repression is mediated.
It was somewhat surprising that mutation of the predicted ARE did not prevent the 
human KPNA2 promoter from responding to HQ, particularly in view of the very 
pronounced effect of complete ARE deletion (Figure 5.6). However as mentioned 
previously, deletion of the ARE removes over 2 kb of promoter DNA in addition to the 
predicted Nrf2 binding site. It is possible that the response to oxidants is mediated by 
other, as yet unidentified sites within this region that may act either independently or in 
concert with the putative Nrf2 site identified herein. Again, further experiments, 
including the generation of additional SDM clones, are required to clarify this result.
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Figure 5.7: Effect of 50pM HQ on the wild type construct, mutated PPARa and Nrf2 (ARE) binding sites 
within the human KPNA2 promoter. A) The human 2.6kb KPNA2 promoter representing the wild type 
construct and site-directed mutants (SDM) of both PPARa sites and the Nrl2 binding site was cloned into the 
pSEAP2 reporter plasmid. Huh? cells were transfected with 25ng/wcll of reporter plasmids for 24 h, before 
being dosed with 50[jM hydroquinone along with 0.1% MilliQ (vehicle control). The level of inhibition of 
expression was assessed by measuring the luminescence from the reporter gene product. Results expressed as 
luminescence units relative to vehicle control. Data shown represent the mean and SEM where n = 5. *=p<0.05, 
*<’=p<0.01 p<0.001 (one-way ANOVA with Bonferroni post-hoc analysis). The data shown are
representative of at least two independent experiments.
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5.3.3 Protein interactions with the human KFNA2 ARE and PPREs
In order to determine which, if any, of these three putative transcription factor binding 
sites are able to bind to proteins, a series of (EMSAs were undertaken. Using double 
stranded oligonucleotides corresponding to each predicted site, labelled with biotin for 
detection purposes, each sequence was incubated with nuclear extract and 
electrophoresed on a native polyacrylamide gel to reveal any DNA retardation indicative 
of protein binding. The results of these experiments are shown in figures 5.8 and 5.9 
(PPARa and Nrf2 binding sites respectively). In each case, a positive control; an 
oligonucleotide corresponding to a previously characterised binding site for the 
transcription factor in question, was included {lane 4). For PPARa this was the PPRE of 
acetyl CoA oxidase (AGO), whereas for Nrf2 the ARE from NAD(P)H:quinone 
oxidoreductase 1 was used. As in the previous EMSA experiments, a negative control (no 
protein extract; lane 1) was also included, along with a control for binding specificity 
(excess unlabelled competitor DNA; lane 3).
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Figure 5.8: Analysis of hKPNA2-PPAR response elements binding to protein extract by 
electrophoretic mobility shift assay. The 3’ biotin labelled oligonucleotides (200fmol) were incubated 
in the absence {latw J) or presence {lanes 2, 3 and 4) of A) naive Huh? nuclear extract B) nuclear 
extract from Huh? cells transfected with pCR3-PPARa for 48 h or C) a coupled in vitro transcription 
and translation (TNT) reaction performed using pCR3-PPARa. In parallel experiments, incubation was 
performed in presence of 200 fold molar excess of unlabelled DNA {lane 3) to show specificity of 
binding. A positive control was performed {lane 4) by incubating 3’ biotinylated-oligonucleotides 
containing the acetyl CoA oxidase (AGO) PPRE, with appropriate extract. Samples were separated on a 
6% non-denaturing PAGE gel and labelled oligonucleotides detected by chemilurainescence. S=DNA:protein 
complex.
As seen in figure 5.8, the most distal PPRE within the human KPNA2 promoter 
(PPARal) was found to bind to a protein present in nuclear extract (from untransfected 
cells and from cells over-expressing PPARa; figure 5.8 A and B, top panels). The likely 
identity of the protein binding to this PPRE was suggested by comparing the degree of 
retardation with that seen with the PPARa positive control oligonuicleotide (compare 
lanes 2 and 4). Protein identity was then confirmed by using PPARa produced in vitro
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using a coupled transcription / translation system (Figure 5.8C). In contrast, when the 
more downstream putative PPRE was examined, no such retardation was seen, strongly 
suggesting that this predicted site is not functional.
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Figure 5.9: Analysis of hKPNA2-AR£ binding to protein extract by electrophoretic mobility shift 
assay. The 3’ biotin labelled oligonucleotides (200tinol) were incubated in the absence {Jane 1) or 
presence {lanes 2, J and 4) of Huh? nuclear extract In parallel experiments, incubation was performed 
in presence of 200 fold molar excess of unlabelled DNA {lane i )  to show specificity of binding. A 
positive control was performed {lane 4) by incubating 3’ biotinylated-oligonucleotides containing the 
NAD(P)H:quinone oxidoreductase 1 (NQOl)-ARE, with appropriate extract. Samples were separated 
on a 6% non-denaturing PAGE gel and labelled oligonucleotides detected by chemiluminescence. 
S=DNA;protein complex.
The results of EMSA using the putative ARE within the human KPNA2 promoter are 
shown in figure 5.9. The presence of a retarded band when the hKPNA2-ARE was 
incubated with nuclear extract (lane 2) shows that a protein is able to recognise this DNA 
sequence. The similarity in band position and intensity to the control suggests that the 
hKPNA2-ARE is able to bind to Nrf2 to a similar degree as the ARE within the NQOl 
promoter (lane 4). Unfortunately, in the absence of a suitable Nrf2 expression plasmid 
this finding could not be definitively confirmed using an in vitro translation system.
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In addition to the EMSAs using wild-type oligonucleotides shown above, EMSAs were 
also carried using oligonucleotides equivalent to the mutant clones generated by SDM, 
for the PPARal and ARE sites (note: the mutated version of PPARa2 was not analysed 
since the wild-type did not bind to proteins). In both cases, the mutations rendered the 
oligonucleotides completely unable to bind to protein extract (data not shown).
5.4 Discussion
During the initial in silico analysis of the human KPNA2 promoter, two putative PPARa 
binding sites were identified, at positions -950 and -1340 upstream of the first exon. 
However, data from the preliminary experimental studies was somewhat conflicting; 
whilst the PPARa agonist Wy-14,643 was a potent inhibitor of the KPNA2 promoter in a 
reporter gene assay, another PPARa agonist, clofibrate, was unable to elicit such a 
response. While both of these compounds are known to be PPARa ligands capable of 
regulating PPARa responsive genes (Forman et al. 1997; Luci et al. 2007), several 
reports suggest that with Wy-14,643. up-regulation of peroxisomal proteins causes an 
increase in the level of peroxisomal ^-oxidation, which can place an oxidative burden on 
the cell (Soliman et al. 1997; Woods et al. 2007). The possibility that regulation of the 
KPNA2 promoter may reflect an oxidative stress response, rather than representing direct 
interactions between the KPNA2 promoter and PPARa was thefore considered.
The results of this investigation that showed the effects of two oxidants, namely 
hydroquinone (HQ) and hydrogen peroxide (H2O2), certainly support such a model. Both 
caused significant inhibition of the KPNA2 promoter and while at high doses of H2O2 
cell death is seen (Supaporn Yimthaing, communication)^ at low doses and with
HQ cell death was minimal, suggesting that this decrease in KPNA2 expression cannot be 
accounted for by viable cell number alone. The presence of a putative Nrf2 binding site 
within the proximal regions of the human KPNA2 promoter provided a potential 
mechanism for such regulation, which was explored using a number of approaches.
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The promoter deletion and SDM experiments provided what initially appeared to be 
conflicting data. While promoter deletion strongly suggested that the response to the 
KPNA2 promoter to oxidants is mediated via the predicted Nrf2 binding site (AARE; 
Figure 5.6), mutagenesis of this site had no effect on the inhibition seen with HQ (SDM- 
ARE; Figure 5.7). However, these results do not rule out a regulatory role for the Nrf2, 
but rather suggest that other, as yet unidentified regions of the promoter may play an 
equally important role. Indeed, such a mechanism would make sense as responses to 
stress need to be robust in order to enable the cell to respond to changing conditions 
effectively. Inevitably, this leads to both redundancy and cooperativity in the response 
pathways. The results of the EMSA experiments showed that the predicted Nrf2 site does 
have the capacity to bind to a protein present in nuclear extract of Huh7 cells. 
Furthermore, the co-migration of this complex with one formed on a well characterised 
Nrf2 binding site (NQOl-ARE) suggests that the protein binding to the KPNA2 promoter 
region is indeed Nrf2. However, further experiments such as TNT-production of Nr£2 or 
super-shift assays would be needed to definitively prove this hypothesis.
The analysis of the two putative PPARa binding sites showed that neither of these sites 
was involved in the response to oxidants such as HQ. This was not a surprising finding, 
as PPARa is not known to be involved in oxidative stress responses, despite often playing 
a role in causing it. In addition, the more downstream of the two PPREs probably 
represents a false positive obtained by the initial in silico screen, since it was unable to 
bind to bind to PPARa in vitro. The site located at position -1340 on the other hand, gave 
a band shift when incubated with either nuclear extract or PPARa produced in vitro 
(Figure 5.8). It is therefore still possible that PPARa has a direct effect on the KPNA2 
promoter, and further experiments to compare the response of the deletion and mutant 
clones to Wy-14,643 and other PPARa agonists are needed to fully understand its 
regulation.
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5.5 Summary
In summary, the experiments presented suggest that the human KPNA2 promoter is able 
to respond to oxidative stress; becoming transcriptionally down-regulated at moderate to 
high levels of oxidants. Further experiments are needed to fully reveal the mechanism 
involved, however it is likely that an ARE, which is able to bind the transcription factor 
Nrf2, is one element involved. It is also not yet clear how the regulation of KPNA2 in 
response to oxidative stress might impact upon the cell, although previous studies have 
shown that nuclear import is affected by such conditions. In particular, kaiyopherins 
become sequestered in the nucleus in oxidative states (Miyamoto et al. 2004); this area is 
discussed more deeply in chapter 6.
While it is possible that an Nrf2-mediated response to increased oxidative pressure fully 
explains the affect of the PPARa ligand Wy-14,643 on the ICPNA2 promoter, the 
identification of a PPRE that is able to form a complex with PPARa may suggest that the 
response to Wyl4,643 is somewhat more complex, involving both direct and indirect 
regulation. However, further investigations are required to fully elucidate the biological 
role of the PPRE, as other PPARa ligands do not appear to alter KPNA2 expression.
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6.0 Discussion
6.1 General Introduction
Karyopherins are nuclear import factors that interact with cargo proteins containing 
nuclear localisation signals and mediate their import into the nucleus. The karyopherin a 
family of adapter proteins form a molecular bridge between nuclear cargoes and the 
nuclear import machinery. There now exists an increasing amount of data to suggest that 
nuclear-cytoplasmic shuttling is an important regulatory step in signal transduction 
pathways, as is discussed in detail below. However, the majority of this data is at the 
level of protein localisation and post-translational modification, with no experimental 
data available to define the mechanism of transcriptional regulation of karyopherins a 
genes by xenobiotics. Moreover, no transcriptional analysis of this family of genes has 
been undertaken, which would identify any putative binding sites of NRs within its 
promoter and/or enhancers. Therefore, this research aimed to rectify the situation in the 
hope of understanding the transcriptional regulation of the karyopherin a  genes, 
particularly the human karyopherin a2 gene.
6.2 Specificity and regulation of nuclear transport as a potential control 
point
As stated in the general introduction, increasing evidence suggests that nucelo- 
cytoplasmic shuttling in general, and nuclear transport specifically, may represent a novel 
regulatory point in signal transduction pathways. This regulation is facilitated through 
both the specificity of karyopherin as for their cargoes, and the modification of importin 
function by cellular stimuli; these two points are examined in turn in the following 
sections.
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6.2.1 Specificity of karyopherin a-cargo interactions
Karyopherin as are responsible the transport of a wide range of proteins through the 
NPC, and despite their limited number (six karyopherin a proteins in human), there is 
specificity in this transport. For example, HIF-1 (hypoxia-inducible factor), a 
transcription factor that mediates adaptive mechanisms to maintain cellular and tissue 
function in hypoxic conditions, is translocated into the nucleus by importins 4 and 7 
(Chachami et al. 2009). Similarly, the nuclear translocations of SMADs especially 
SMAD4 are under the influence of importiii7/8 (Yao et al. 2008). It is interesting to note 
that many cargoes are capable of being transported by more than one karyopherin a, with 
molecules such as Notch 1, which is important in regulating the development and self­
renewal of various cells, being transported by three karyopherin as; Importin a3 
(kaiyopherin a4), importin a4 (karyopherin a3) and importin a7 (karyopherin a6) 
(Huenniger et al. 2010). The reason that the majority of cargoes can be transported by 
more than one karyopherin a is unclear, but may reflect a physiological safety net, 
minimising the potential biological impact of loss-of-function mutations in individual 
karyopherin as. Such redundancy is viewed as a common feature in biology, contributing 
to an organisms robustness (Hai 2008; Chou and Voit 2009; D'Elia et al. 2009; Reichheld 
et al. 2009). However, it should be noted that this view of universal redundancy is not 
accepted by all, with recent work by Mendorca and colleagues suggesting that evolution 
may actually be driven towards the loss of such redundancy, due to the predictable 
environments that organisms are exposed to (Mendonca et al. 2011).
6.2.2 Modulation of karyopherin «-mediated transport capacity
Whereas specificity for individual cargoes hi a sub-set of karyopherin as provides a 
potential distinction that may optimise the regulation of transport of target proteins, it will 
not mediate this regulation precisely. To achieve this, there must be some alteration in the 
relationship between karyopherin a  and cargo. This can be envisaged to occur in three
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ways: First, the activation of a cargo is known to increase its affinity for kaiyopherin as 
through the unmasking of the NLS; second, post-translational effects on karyopherin as 
could alter their ability to mediate nuclear translocation; third, alteration in the expression 
of karyopherin as may alter their capacity for nuclear transport.
The first scenario is well established, with NLS unmasking following protein activation 
being a common phenomenon (Sorokin et al. 2007). In addition to the unmasking of 
NLS’, other modifications to the cargo may increase the interaction with karyopherin as. 
For example, Harreman and colleagues demonstrated that phosphorylation near to the 
NLS increased interaction of cargo and karyopherin a (Harreman et al. 2004). 
Interestingly, not all karyopherin a-cargo interactions may be beneficial. Work by 
Kolodkin and colleagues used systems modelling to demonstrate that, under certain 
biological conditions, enhanced levels of karyopherin a could lead to futile cargo 
sequestration, diminishing signal transduction (Kolodkin et al. 2010). This work is 
consistent with the recent finding that Snail signalling, which downregulates the 
expression of ectodermal genes in the mesoderm, can be reduced through such futile 
couplings with karyopherin a, which prevent Snail interacting directly with KPNB and 
being translocated into the nucleus (Sekimoto et al. 2011).
The second scenario, post-translational modification is becoming increasingly accepted, 
with more examples of this phenomenon being identified. Recent work by Kodiha and 
colleagues demonstrated that MEK and ERK pathways are able to mediate 
phosphorylation of a number of components of the nucleo-cytoplasmic shuttling 
pathway, including karyopherin as (Kodiha et al. 2009). It should be noted that 
phosphorylation is not the only potential post-translational modification of karyopherin 
as, with ubiquitination of karyopherin a l by RAGl ubiquitin ligase being previously 
demonstrated (Simlais et al. 2009). Interestingly, the work of Kodiha and colleagues has 
demonstrated that oxidative stress results in the activation of both MEK and ERK and the 
subsequent phosphorylation of karyopherin a, leading to a decrease in import capacity 
(Kodiha et al. 2009). Such work is consistent with the findings of this study, where
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oxidative stress resulted in a decrease in karyopherin a2 gene expression. It can be 
forseen that these two pathways could interact to synergistically decrease nuclear import 
capacity under conditions of oxidative stress. This would, of course, raise the question of 
‘why’ such synergism would occur, and while no definitive answers exist, some 
suppositions can be made. We now know that cellular response to stimuli is highly 
complex, and involves the interaction of many response networks. It is important that the 
response produced is both sufficient to allow a return to homeostasis, while not being so 
strong as to cause pathology. To achieve this fine balance, a large number of feed­
forward and feed-back loops are exploited (Zhang et al. 2008; Zhang et al. 2009). It is 
thus not unreasonable to suggest that the down regulation of nuclear import activity in 
response to oxidative stress is a result of such regulatory loops, and aids in the attenuation 
of the biological response, limiting the possibility of adverse effects.
Finally, the third scenario, transcriptional regulation of karyopherin a gene expression, is 
the area in which least work has been done, and the focus of this thesis. Initial work by 
Kohler and colleagues demonstrated that transdifferentiation of AR42J cells (insulin 
producing cells from pancreatic acinar) by dexamethasone or activin A was associated 
with an up-regulation of importin a3 (karyopherin a4) and importin a4 (karyopherin a3) 
expression respectively (Kohler et al. 2002). Conversely, the differentiation of human 
leukemia (HL60) cells by DMSO treatment resulted in the down-regulation of importin 
a l (karyopherin a2) and importin a4 (karyopherin a3) expression (Kohler et al. 2002). 
Moreover, the expression of both of these karyopherins was also down-regulated when 
the HL60 cells differentiated towards a macrophage phenotype upon phorbol-ester 
exposure (Kohler et al. 2002). The research presented herein has added significantly to 
this area. For instance, the initial work compliments that of Kohler and colleagues, 
demonstrating that glucocorticoids may increase karyopherin a expression, whereas 
oxidative stress reduces karyopherin a expression levels. This work was then extended by 
demonstrating some of the underlying molecular mechanisms for these regulations.
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6.2.3 Nuclear import of nuclear receptor family members
Several studies have shown the association of NRs and karyopherins, and the 
involvement of this complex in nuclear translocation of these receptors. The nuclear 
import of RXR is mediated by kaiyopherin p alone, whereas many other NRs require 
karyopherin a to act as a molecular bridge to kaiyopherin p. For example, imaging 
analysis of the mineralcorticoid receptor using GFP colour variants has shown that 
karyopherin a is vital in its nuclear transport (Tanaka et al. 2005). VDR nuclear 
translocation has also been shown to be mediated by karyopherin a (Yasmin et al. 2005), 
and more specifically kaiyopherin ct3 (Supaporn Yimthaing, personal communication). 
Importin 7 and the karyopherin a/p complex have been demonstrated to act as the 
translocation machinery for the nuclear import of the GR (Freedman and Yamamoto 
2004). Whereas it is likely that many other NRs also interact with karyopherins in a 
specific manner to mediate their nuclear translocation, at present this area of research is 
under investigated, with little literature available.
Given the fact that NRs act as transcriptional regulators to allow the coordination of 
cellular responses to chemical challenge, both endogenous and xenobiotic (Plant and 
Aouabdi 2009), and that nuclear import appears to be a regulatory step in signal 
transduction, it seemed sensible to hypothesis that NRs may be able to control the 
expression of karyopherins. Initial in silico analysis of the human karyopherin a l  
promoter identified several putative NR binding sites, including the VDR, PR, GR and 
PPARa. Beyond this initial identification, this research has shown that GR agonists and 
antagonists are able to regulate karyopherin a2 transcription through the direct alteration 
of GR binding to the proximal promoter. These interesting findings add weight to the 
argument that karyopherin as do indeed act as an important regulatory step in signal 
transduction, and that the efficiency of this step can be altered by not only NRs but also 
other transcription factors.
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As with the regulation of karyopherin a  levels by oxidative stress, it is possible to 
speculate upon the reasons behind the regulation of karyopherin a  level by 
glucocorticoids. One possible reason is suggested by recent work from our laboratory 
using systems biology to examine the design principles underlying NR nucleo- 
cytoplasmic shuttling (Kolodkin et al. 2010). In this work, the efficiency of signal 
transduction was simulated under conditions where NRs rapidly shuttled between the 
nucleus and cytoplasm and under conditions where stationary pools existed in both 
compartments. For high affinity NRs, such as the GR, rapid shuttling produced a much 
more efficient response, increasing the strength of the transcriptional response and 
decreasing the time to this response. This was achieved because the shuttling acted to 
concentrate ligand within the nucleus, where it may interact with both the NRs and target 
response elements on DNA, eliciting the transcriptional response. Given such a scenario, 
it can be hypothesised that increasing the levels of karyopherin a would further facilitate 
this concentration step, by increasing the rate of formation of GR-karyopherin a 
complexes. Thus, whereas in the case of cellular response to oxidative stress (section 6.2) 
a reduction in transport capacity may be important to attenuate cellular responses, in the 
response to glucocorticoids the opposite is true; increasing karyopherin a levels may act 
to increase the sensitivity of the signalling pathway.
6.2.4 The potential for a general mechanism of karyopherin-mediated 
control of signalling pathways
From the current literature, and the work presented in this thesis, it can be clearly stated 
that karyopherin a acts as an important regulatory step in signal transduction within 
eukaryotic cells. Regulation at several different levels can alter the transport capacity of 
the cell, and is therefore likely to be important for tailoring cell responses to stimuli.
In the present work it has been shown that NR agonists lead to karyopherin a up- 
regulation, whereas oxidative stress results in karyopherin a level decreases. It is
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tempting to speculate that this may represent a differential response between homeostatic 
(e.g. glucocorticoid) and pathological (e.g. ROS) signalling, but more examples would 
need to be studied before such a statement can be made. Indeed, work in this laboratory 
by Supaporn Yimthaing has recently demonstrated that 2 5 OH-D3, the active metabolite 
of Vitamin D, causes a down-regulation of kaiyopherin a3 expression levels; such a 
finding would argue against such a general theory of nuclear transport. Instead, it must be 
concluded that while nuclear transport will undoubtedly be confirmed as an important 
regulatory step for a large number of signalling pathways, the reasoning behind these 
regulations is still far from understood in general terms. Nevertheless, the work contained 
in this thesis adds substantially to our understanding of the role of nuclear import in 
oxidative stress and glucocorticoid-mediated signalling pathways.
6.3 Future work
In this thesis, the focus has been on the regulation of the human KPNA2 gene at the 
transcriptional level. One possible avenue worthy of exploration is to determine whether 
the rate of transcription correlates with mRNA and protein levels. This is vital as 
biological function is generated at the protein and not the transcript level. This could be 
achieved by using real-time polymerase chain reaction (RT-PCR) to determine mRNA 
levels and Western blotting to assess protein levels. Such correlation will prove vital to 
further the understanding of the importance of KPNA2 regulation by xenobiotics, and the 
level at which this regulation occurs.
Since this work has shown that KPNA2 is regulated by GRa, it is important to 
acknowledge and to confirm that GRa interacts/binds to KPNA2 and whether this 
binding occurs in the cytoplasm or in the nucleus. This could be achieved by using a V2 
GFP recombinant assay or pull-down assay such as the GST pull-down assay or even 
immunoprécipitation. With the elucidation of this interaction, it will add weight to the 
CPA/GRa/KPNA2 interaction model discussed previously.
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It is also important to determine the impact of altered human KPNA2 expression on the 
disposition/functionality of its cargo proteins. This could be done through over­
expression and knock-out studies to provide vital understanding of the level of impact 
ICPNA2 has on its downstream cargo proteins in biological terms.
Another potential future direction is to determine whether the Huh? cell line used in this 
study is a valid model. By using alternative cell lines such as Hep G2 (human liver 
carcinoma cell line) or primary hepatocytes, this will give some indication as to whether 
KPNA2 regulation is cell-type dependent. This could validate the Huh? cell line as an in 
vitro screening tool.
The functionality of the remaining putative transcription factor binding sites for VDR, 
RORa, PR, and HNF4 could be verified using the same approach employed herein, 
which includes reporter gene assays, promoter deletion, SDM and EMSA as well as 
mRNA and protein studies. These experiments would help to complete the story of how 
and which type of NRs actually bind and interact with KPNA2 and how these NRs 
regulate KPNA2 and the cellular effects.
Lastly, the study of individual proteins and/or pathways may be insufficient to fully 
understand the implication of KPN A regulation, as they may mediate multiple effects on 
the cell. Hence, systems approaches may represent a valid alternative. In these 
approaches, the entire response network, with nuclear import at its core, is reproduced m 
silico and its behavior studied. A whole network approach will allow the identification of 
so-called emergent properties; properties that cannot be envisaged by looking at the 
components in isolation.
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6.4 Summary
In summary, the position of the human KPNA2 proximal promoter has been identified 
and an attempt has been made to identify the putative transcription factor binding sites 
within the promoter. Furthermore, the human KPNA2 proximal promoter has been 
amplified and the manipulated/isolated DNA was inserted into plasmid DNA. The 
resulting human KPNA2 proximal promoter plasmid construct was transfected into Huh? 
cells where the influence of several xenobiotics on promoter expression was examined. 
The data gathered demonstrates that GRa may regulate the expression of the human 
KPNA2 gene, with agonists of GRa (e.g. dexamethasone) increasing expression, and 
antagonists (e.g. cyproterone acetate) decreasing expression. A model explaining this 
interaction was then proposed. In addition, it was elucidated that oxidative stress stimuli 
down-regulate human KPNA2 expression, and that this response is most likely mediated 
by Nrf2. Overall, this enhances our understanding of the role of nuclear import in 
oxidative stress and glucocorticoid-mediated signalling pathways, and specifically the 
role of transcriptional regulation in this process. This further expands the weight of 
evidence that emphasises the important role of nuclear import in coordinating intricate 
cellular responses.
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